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Multiple Sclerosis (MS), a neuronal demyelination disease of the central nervous system, is the 
most common neurological disease in young adults worldwide, with an unknown cause. It 
affects over 23,000 people in Australia, and despite effective immune-based treatments, clinical 
deterioration and disability still occur. Epstein-Barr Virus (EBV), a human herpesvirus, which 
infects early in life and remains dormant within immune cells, is common in the unaffected 
population but almost universal in MS patients. Studies have found that MS patients maintain 
elevated EBV-specific antibody levels, most notably against latent Epstein-Barr Nuclear 
Antigen-1 (EBNA-1) proteins. The aims of this research were to investigate the significance of 
EBV immune responses, including those targeting the novel epitope EBNA-1(398-413), 
previously associated with MS risk in disease-discordant identical twins, and to understand the 
relationship between EBV-specific serological responses and genetic risk factors in an 
established MS cohort (n=426) and healthy controls (n=186). This study also investigated the 
influence of arginine modification (citrullination) on EBNA-1(398-413)-specific antibody 
responses, as well as the role of EBNA-1-specific IgG subclass bias. Novel in-house assays 
were compared with commercial ELISAs for EBV viral capsid antigen (VCA) and EBNA-1. 
MS patients had significantly higher antibodies against all EBV targets. Inclusion of EBNA-
1(398-413)-specific antibody levels further discriminated cases and controls in risk analysis, in 
addition to genetic risk factors. Citrullinated and IgG1-specific EBNA-1 antibody levels were 
also elevated in MS cases compared to controls, although they did not improve case-control 
classification in combined statistical models. EBNA-1(398-413)-specific IgG from acute patients 
showed different protein reactivity from whole serum, as well as differences between 
progressive MS serum and healthy control plasma. This project contributes to the importance 
of EBV in the pathogenesis of the complex disease MS, and has identified novel and statistically 
powerful relationships between environmental and genetic MS risk factors. 
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1.1. General Introduction 
Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous 
system (CNS). Demyelination is the continual destruction of myelin, the insulating component 
surrounding neurons. This destruction, and associated inflammation, reduces the ability of 
neurons to conduct impulses and thus can reduce the ability of motor skills, muscle strength, 
coordination, speech and vision. MS affects 1 in 1,000 individuals, making it the most common 
neurological disorder in young adults. In the period before modern brain-imaging techniques 
were developed, diagnosis was based on clinical symptomatic criteria but could only be 
formally ascertained during autopsy, where lesions or plaques (‘scleroses’) were found in the 
brain and spinal cord. With the introduction of magnetic resonance imaging (MRI) in the 1980s 
(1), a diagnosis of MS which was initially only prompted by the recognition of clinical 
neurological symptoms, could now be confirmed with demonstrated dissemination of 
inflammatory brain and/or spinal cord lesions in space (DIS) and time (DIT) (2). Currently, 
most treatments target suppression of the inflammatory environment within a patient, but 
studies are continuing to understand what combination of factors are necessary and/or sufficient 
to cause MS. Genetics and environmental factors are the two largest confirmed contributors to 
MS risk, with continued investigation into potential biomarkers aiming to elucidate the 
mechanisms that underpin epidemiological risk factors of MS development and progression. A 
key challenge for investigating this debilitating disease is that research is trying to find the cure 
and cause of the disease simultaneously, so that the success of treatment interventions can 
inform research into MS pathogenesis, which can in turn inform new therapeutic strategies. 
Decades of research have shown that the disease does not have a single causal factor and that 
risk factors for MS disease onset may not necessarily influence subsequent disease progression, 
so treatments must be established to target all stages of the disease spectrum in order to aid 
patient quality of life.  
3 
1.2. Impact of MS on global health 
1.2.1. Global prevalence of MS 
According to the MS International Federation in 2013 (3), MS affects 2.3 million people 
worldwide, with over 23,000 diagnosed people living in Australia. The number of diagnosed 
individuals has increased over the past decades (4), although this could potentially be attributed 
to increased expertise in diagnostics rather than legitimate increase of disease prevalence. For 
a study by the World Health Organization (WHO), worldwide prevalence was reviewed from 
data collected between the 1970s to mid-1990s (5), although prevalence has increased since this 
publication. The WHO report showed that comparison of different studies needs to address 
population variability (such as age and ethnic composition (6)), determination of benign/early 
cases (7), medical and diagnostic access and knowledge (7, 8), and different diagnostic criteria 
as well as inter-observer variability (6). A more recent collaboration organized by the MSIF 
estimated the world-wide prevalence at 33/100,000 (3) and provided data for differences 
between countries, summarized in Figure 1-1. Regionally, median estimated prevalence of MS 
is greatest in Europe and North America (108 and 140 per 100,000 respectively) and the lowest 
in East Asia and Sub-Saharan Africa (2.2 and 2.1 per 100,000 respectively). The MSIF reported 
average onset at 30 years old and a global 2:1 female to male ratio, while other publications 
report a higher ratio of 3.5:1 (9). The 2013 MSIF study did not report global incidence (new 
diagnoses), due to limited data contribution from some countries. Estimated incidence is greater 
in high income countries, and proportionally lower for decreasing income, which could be due 
to limited access to diagnostic facilities such as MRI but may also reflect true differences in 
disease risk. A strong geographical pattern can be identified: MS is more frequent in countries 




Figure 1-1. Worldwide prevalence of Multiple Sclerosis (MS).  Higher MS prevalence can 
be seen in North America and Europe, as well as a latitudinal gradient with increased MS 
prevalence further away from the equator. Figure unedited from (3). 
 
1.2.2. Prevalence of MS in Australia 
Australia is a large continent within the southern hemisphere, and spans multiple latitudes. 
There is limited current reporting on Australian MS prevalence, but in a seminal study from 
1968, McCall et al (10) reported prevalence rates from capital cities across the country, where 
Brisbane, Queensland (27.468°S, 153.028°E) had a lower prevalence than Hobart, Tasmania 
(42.881°S, 147.325°E). Perth, Western Australia (31.952°S, 115.859°E) had a moderate rate of 
prevalence (20/100,000) and a 2.3:1 ratio of females to males. This report greatly under-
represents current prevalence, as do subsequent reports (11-13) which used data from 1981. 
Others have studied regional areas of Australia such as New South Wales and South Australia 
(14), as well as the city of Newcastle (15). Interestingly, these papers did not report MS cases 
among individuals who identified as Aboriginal or Torres Strait Islander (which was reported 
as “rare” by Miller et al (11)). The most recent publication of Australian MS prevalence is part 
5 
of the ATLAS study (a collaboration of MSIF and WHO) (3), but only at a national level, not 
separated by state or latitude. Current higher prevalence could be due to better and earlier 
diagnosis (11). The Australia Bureau of Statistics stated in a 2009 survey (16) that there was an 
estimated 23,700 Australians with MS (0.1% of the population), of whom 11,400 (48%) had 
profound or severe core-activity limitation. An estimated three quarters of these individuals 
were female. Of the 20,400 people aged 15-64 who were living with MS, 9,800 were employed, 
with 5,900 part-time, and 12,700 (62.5%) of individuals had some employment restriction 
(needing time off work, restricted in job type, restricted in hours, difficulty changing jobs and/or 
needs additional support). In addition, the survey reported that 15,800 (66.7%) needed 
assistance with at least one of the 10 everyday activities, of which the most common was 
mobility (reported by 46% of MS individuals). MS was the known cause of a “very small” 
number of deaths (56 male/106 female) in 2013 and was reported as an associated cause of a 
further 266 deaths in that year (84 male/182 female) (17).  
 
1.3. History, diagnosis, lesions and treatment of MS 
1.3.1. History of MS 
There is a range of historical personal accounts (18) of what is now thought to be MS, based on 
descriptions of clinical symptoms (Figure 1-2). Anatomically, MS was defined by Dr Jean-
Martin Charcot in 1877, from post-mortem brain lesions of a female patient who had presented 
an unusual combination of neurological symptoms. The term MS originates from the French 
‘sclerose en plaques’ meaning multiple lesions or plaques. This finding added a tangible link to 
presented symptoms, and in 1916 James Dawson identified microscopic evidence of 
inflammation and demyelination. It wasn’t until 1947 that researchers identified proteins 
(‘oligoclonal bands’, OCB) in patients’ cerebrospinal fluid (CSF), and in the 1970s genetic 
associations were identified. By this time, treatment of MS already utilized anti-inflammatory 
6 
steroid treatments. Since then, advances in technology enabled further findings of MS-specific 
pathologies, and these continuously assist in developing new targeted immunotherapies. 
 
 
Figure 1-2. Clinical symptoms common for suggested Multiple Sclerosis. Wide variation of 
symptoms can occur between individuals as well as for a patient over time. 
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1.3.2. Diagnosis of MS 
Diagnosis of MS is based upon dissemination of lesions in time and space, combining patient 
history, clinical examination and laboratory findings. These diagnostic criteria have been 
developed over the past 50 years, starting when the Schumacher Committee published the first 
official criteria in 1965 (19). This was before knowledge of OCB or MRI, and so was based 
upon fulfilment of the criteria below (i-vi), from which individuals were categorized as either 
having ‘clinical’ MS, ‘probable’ MS or ‘possible’ MS: 
i. Presentation of neurologic exam abnormalities, suggesting problem in the CNS.  
ii. Onset of symptoms in patient between 10-50 years of age 
iii. Signs and symptoms indicating CNS white matter involvement and/or damage 
iv. Evidence of two or more areas of CNS involvement, suggesting lesion dissemination in 
space (two or more separate lesions) 
v. Either two attacks/relapses lasting ≥24 hours at least one month apart or symptom 
progression (slow or stepwise), suggesting lesions are disseminated in time 
vi. No better explanation 
This has served as a template for all further development of diagnosis criteria. Poser et al. (20) 
formed a set of criteria as a guideline for research protocols which was later adopted in clinical 
practice, that included laboratory evidence in the form of OCB Immunoglobulin gamma (IgG) 





Table 1-1. Summary of Poser Criteria for Multiple Sclerosis Diagnosis. 
 Attacks Clinical 
lesions 
 Laboratory or 
paraclinical lesions 
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Table adapted from (21). 
 
Using the Poser criteria, patients were defined into two groups: ‘definite’ or ‘probable’ MS, 
both with subgroups ‘clinically supported’ and ‘laboratory supported’, with further analysis of 
evoked potentials and spinal fluid evaluations to document asymptomatic damage in the CNS, 
confirming dissemination in space and time. Clinically definite MS required occurrence of two 
separate attacks (relapses) and clinical evidence of two separate lesions, or two attacks with 
clinical evidence or one lesion and paraclinical evidence of another separate lesion. The 
McDonald criteria were published in 2001 by The International Panel on the Diagnosis of 
Multiple Sclerosis, integrating MRI assessment to identify lesions, as well as diagnosing new 
or active lesions by Gadolinium (Gd)-enhancing examinations as well as visual evoked 
potentials and CSF analysis (Figure 1-3). They also reviewed the diagnosis of primary 
progressive MS (PPMS), although this was further classified years later (22, 23). McDonald 
and Poser criteria were compared by Fangereau et al. (24), who found that inclusion of 
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laboratory evidence was beneficial in diagnosis, and that the McDonald criteria enabled 
diagnosis after a single attack or relapse (an exacerbation or presentation of new symptoms), 
allowing earlier diagnosis and initiation of treatment. In 2005, a revision of the McDonald 
criteria was released (25), demonstrating dissemination of lesions in time, clarifying the use of 
spinal cord lesions and allowing for a simplified approach to diagnosis of PPMS. However, 
these criteria were suggested to be unsuitable for paediatric cases, and are being reviewed for 
their application by the Asian Neurological Community and in Latin America (2). Difficulties 
in MS diagnosis were also reported by Confavreux et al (26), stating that only about one tenth 
of new/active lesions result in a clinical relapse, depending on location and volume (27). 
Uitdehaag et al. (28) have proposed standardizing the approach to interpretation of clinical 
symptoms and signs of the first episode of neurological symptoms, ‘Clinically Isolated 
Syndromes’ (CIS) and Swanton et al. (29) have also advocated for simplified MRI criteria for 
DIT and DIS for relapse-remitting MS (RRMS). The most recent review in 2011 by Polman et 
al (2) has again revised the McDonald criteria, and a current summary of the updated criteria 
(Table 1-2) has been made available by the International Panel for Diagnosis of MS.  
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Figure 1-3. Three laboratory techniques for MS diagnosis. Following presentation of 
clinical symptoms, MS lesions can be identified by (A) Standard Magnetic Resonance Imaging 
(MRI) with Gadolinium enhancement (30) as well as (B) T2-weighted fluid-attenuated 
inversion recovery (FLAIR; left; lesions) and T1-weighted (right; holes). Black arrows indicate 
older lesions with more damage (as matched in the scan on the right), while white arrows 
identify new lesions (31). Additionally, (C) Oligoclonal bands can be identified in CSF fluid of 





Table 1-2. Revised McDonald MS Diagnostic Criteria (2011). 
Clinical attacks Lesions Additional Criteria for Diagnosis 
Two or more Two or more None 
Two or more One DIS, demonstrated by: 
 MRI or 
 2 or more MRI lesions plus positive 
CSF 
or await further clinical attack implicating different 
CNS site 
One Two or more DIT demonstrated by 
 MRI 
 Second clinical attack 
One One DIS or await further clinical attack implicating 
different CNS site AND DIT; or await second clinical 
attack 
Zero  One year of disease progression (retrospective or 
prospective) and 
Two of the following: 
 Positive brain MRI 
 Positive spinal cord MRI 
 Positive CSF 
DIS: Dissemination in space. DIT: Dissemination in Time. MRI: Magnetic Resonance Imaging. 
CNS: central nervous system. CSF: cerebrospinal fluid.  
 
Globally, MSIF (3) reported that 96% of surveyed countries use the McDonald criteria, with 
the remaining 4% assumed Poser and/or Schumacher criteria. The discrepancy in criteria could 
be due to access to diagnostic techniques, such as MRI machines. It should be noted that this 
also doesn’t take into account individual neurologist’s diagnoses, but is currently the best means 
of diagnosis until a singular diagnostic test is developed.  
 
12 
Initial symptoms of CIS may depend on the sites of demyelination, and can vary between 
patients (Figure 1-2). The three most typical presentations are: 
i. Optic nerve (optic neuritits) e.g. Blurred vision 
ii. Spinal cord (transverse myelitis) e.g. Tingling, prickling sensation in skin 
iii. Brainstem (brainstem syndrome) e.g. Nausea, vomiting, double vision. 
Patients with CIS have a high likelihood of developing MS. Exacerbations (relapse, attack, flare 
up), are defined as episodes of clinical worsening with either new symptoms or the worsening 
of old symptoms. Following diagnosis of MS, there are different ways the disease can progress. 
 
1.3.3. Classification of MS progression 
MS has until recently been classified into four types of disease progression (32), outlined in 
Figure 1-4A. Approximately 85% of individuals develop RRMS, characterised by partial or 
total remission followed by another relapse (33). It has been estimated that up to 90% of RRMS 
patients developed secondary progressive MS (SPMS) after 25 years (34), although most 
publications conservatively estimate 50% RRMS convert to SPMS (35), where initial relapse-
remitting course is followed by increased progression with only minor or no remissions. PPMS 
occurs in 15% of patients and is defined by disease progression from onset with little or no 
recovery from symptoms. This form of the disease is usually classified after a minimum of one 
year’s disease progression with laboratory findings (lesions in brain and spinal cord identified 
by MRI and CSF abnormalities (36)), and is more commonly seen in males and older patients 
(33). The fourth and least common type is progressive relapsing MS (PRMS), with progressive 
disease from onset, with clear acute relapse, with or without full recovery (32). The most recent 
review defining MS clinical course by ‘The MS Phenotype Group’ suggested ‘dropping’ the 
term relapsing-progressive due to being vague and overlapping with other courses (37). This 
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group also commented on the re-examination of MS disease phenotypes, with focus on 
assessment of disease activity by clinical assessment of relapse occurrence or lesion activity 
detected by CNS imaging. This is important also with radiologically isolated syndrome (RIS) 
where inflammation is detected but no symptoms manifest (37). A somewhat controversial 
diagnosis is ‘benign’ MS, where a patient following initial CIS does not suffer relapse attacks, 
or progressive worsening of symptoms for prolonged periods of time. The classification of 
benign MS is still being reviewed, as some studies found that at most 55% of initially ‘benign’ 
diagnosed patients remain benign over the subsequent 10 years (38, 39). Pathologically, more 
lesions have been found in SPMS compared to PPMS (40, 41). However, MRI activity appears 
to decrease with time and age, and Ebers (32) found no significant difference between the two 
progression types. It is important to note that classification of a patient into one or the other 
category usually can only be made after several years, with tracking of worsening disability, 
which can be graded by Expanded Disability Status Scale (EDSS; Figure 1-4B). 
 
Early MS diagnosis is important for patients as immunomodulatory therapy introduced earlier 
is beneficial and has shown prolonged time to subsequent relapses, reduced MRI lesions and 
slower progression (42-44). There has not been much success with identifying risk factors in 
early MS disease that can predict how MS will progress for individual patients. However, 
Debouverie et al (45) summarized that numerous studies that identified groups with later onset 
of long-term irreversible disability: females, younger patients, patients with an initial relapse-
remitting course, those with complete recovery from first neurological episode, patients with 
symptoms reflecting one region rather than poly-regional lesions, individuals with a low 
number of relapses during the first years of the disease and patients with longer periods of time 
between the first two attacks (26, 32, 46-51). However, none of these variables remained 
predictive of the time course of disability after the point of initial assignment of irreversible 
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disability, indicating that when a detectable threshold of irreversible disability has been reached, 
the disease enters a final common pathway (26).  
 
Figure 1-4. (A) Four classifications of MS progression and (B) Kurtzke’s Expanded 
Disability Status Scale (EDSS).  (A) The four main types of MS is defined by presence of 
remission between relapses (exacerbation or new symptoms) as shown by peaks. The solid line 
shows no remission from disease progression. (B) A scale outlining progression of motor skill 






1.3.4. Current MS medications 
Disease modifying treatments were first introduced in 1993 with interferon beta-1b (53), and to 
date there are at least eight FDA-approved treatments to reduce MS symptoms and prolong time 
between relapses. Most treatments are aimed at RRMS cases, as treatment for progressive 
patients has not been shown to be as effective. However, there is no medication to date which 
is universally effective for MS patients. Treatment can be grouped into two main categories: 
treatment for easing individual symptoms, and treatment which is disease modifying with 
immunomodulatory/anti-inflammatory activity. As MS is considered an autoimmune disease, 
with inflammation seen in brain lesions, immunomodulatory and immunosuppressive drugs are 
the current standard for treatment (Table 1-3). Monitoring patient progression and 
inflammatory activity is vital, as new lesions can be identified with MRI, and change of 
treatment might be indicated. A recent review by Minagar (54) outlined the success of 
individual treatments, and the problems associated; ranging from side effects to complications 
with compromised immune systems allowing opportunistic infections. Steroids including 
methylprednisolone, dexamethasone and prednisolone are common treatments, sometimes in 
addition to other medications. Not included in Table 1-3 is Cladribine, an immunosuppressant 
which although effective in supressing DNA synthesis and repair, was withdrawn from the 
European market and is awaiting follow up in the United States due to concerns about prolonged 
suppression of the immune system and potential risk for cancer (54). Lastly, clinical trials have 
begun to identify the potential benefit of vitamin D as a treatment (55), and its analogue 
Alfacalcidol (56). Immunomodulatory therapies are currently ineffective in modifying disease 
for PPMS patients (57), and treatment strategies need to be developed. There are many therapies 
currently under trial, including ATX-MS-1467 (58). This drug was based upon the vaccination 
theory, which aims to develop T cell tolerance for myelin basic protein (MBP) peptides which 
are thought to be a major target for inflammatory myelin-specific T cells.  
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Table 1-3. Current treatments and medications for MS. 
Treatment Type Brand names Mechanism of Effect Clinical Trials 
Interferon beta-1b Betaseron, 
Extavia 
Anti-inflammatory (44, 59-65) 
Interferon beta-1a Rebif, Avonex  (66-70) 
Glatiramer acetate Copaxone Unknown, possible MHCII binding 
competitor 
(71-75) 
Mitoxantronea Novantrone Immunosuppressive, 
Immunomodulatory 
(76-81) 
Natalizumaba Tysabri Stop leukocyte adhesion to BBB (82-86) 
Fingolimoda Gilenya Modulates chemoattractive function 
of lymphoid cells 
(87-89) 
Alemtuzumab Campath-1H Depletes CD52 cells (including T 
lymphocytes) 
(90-92) 





Tecfidera Immunomodulatory (95-99) 
Laquinimod Nerventra Immunomodulatory (100) 
Daclizumab Zenapax Depletes CD25+ activated T and B 
lymphocytes 
(101-103) 




Rituximab Depletes CD20+ B lymphocytes (106) 
BBB: blood brain barrier. MHC: Major Histocompatibility Complex. CD: cluster of 




1.4. Identified risk factors of MS 
1.4.1. Gender 
Over the past decades the female to male ratio of diagnosed individuals with MS has increased, 
with publications reporting a ratio of between 2.3 to 3.5:1 (9, 107-111), and Pennell et al (112) 
reported that additionally males had later age of onset and more rapid disease progression. Some 
papers have reported that females have better prognosis than males (113) and are more likely 
to follow a benign disease course (114). There have been reviews of differences in MS disease 
associated with gender: influence on clinical course, severity prognosis, MS pathology, 
immunological and genetic findings in MS, response to immunotherapy, effects of gonadal 
hormones, the menstrual cycle and pregnancy effects on MS (112). However, the most 
comprehensive review of potential explanations for the gender discrepancy to date is by Greer 
et al (35). They suggested contributing factors including: biological differences of the immune 
system and CNS, genetic and epigenetic factors including sexual dimorphism, the effect of X 
and Y chromosomes, mitochondrial inheritance, microRNAs, different environments and 
lifestyle as well as maternal microchimerism (the mother carrying genetically distinct cells 
different from herself, such as a foetus). Additionally, it was reported that the predominant MS 
genetic risk marker human leukocyte antigen (HLA)-DRB1*1501 is more prevalent in female 
patients (115). If there is a female predisposition for MS, gender has to be taken into 
consideration when interpreting research results and for developing new therapies and clinical 
trials. Oestrogen is associated with MS risk at a genetic level (116), and has been shown to 
reduce severity and symptoms in mice models (117). The role of pregnancy in modulating MS 
risk is also a subject of extensive current research, as it is associated with fewer relapses (118), 
possibly due to a skewing of the immune system towards immunological tolerance towards the 
hemi-allogeneic foetus.     
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1.4.2. Genetics 
The influence of genetics on MS development was initially identified through studies of familial 
aggregation of diagnosed individuals, and MS prevalence in the general population has been 
estimated at 0.1%. Multiple cross-sectional studies of MS patients and their families (94, 119), 
twin studies (120-129), adoptive relatives (130), half siblings (131), conjugal pairs and their 
offspring (132, 133) determined a significant genetic contribution to MS risk. Additional 
findings included that stepchildren have the same risk as the general population (134), maternal 
half siblings had greater risk than paternal half siblings (131, 135) and that SPMS is more 
common in families with multiple affected relatives (136). Ebers et al (137) reported a 20-fold 
increase in disease risk associated with having a first degree relative with MS. A meta-analysis 
of 18 studies (138) reported risk of 18.2% for monozygotic twins and 2.7% for siblings, 
supporting genetic contribution to MS risk, of which the 57 known MS loci found in the 
genome-wide association study (GWAS), at the time of this publication, were estimated to 
contribute 18-24% of sibling relative risk. The most prominent gene association with MS risk 
is human leukocyte antigen (HLA) allele variation (139-141) (Figure 1-5). The HLA lies within 
the major histocompatibility complex (MHC), a series of highly polymorphic genes responsible 
for presenting antigenic peptides to immune cells, and is critical in developing the adaptive 
immune response to foreign pathogens (142). These genes are classified as ‘class I’ (“A, B and 
C”; present on all nucleated cells and recognised  by cluster of differentiation (CD)8+ T cells) 
and ‘class II’ (“DR, DP, DQ”; present on dendritic cells, B cells, mononuclear phagocytes, 
some endothelial cells, epithelium of thymus and recognised by CD4+ T cells). 
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Figure 1-5. Positioning of Human Leukocyte antigen (HLA) alleles (class I and class II) 
along chromosome 6.  
 
Advances in technology have enabled improved discrimination of HLA alleles which were 
initially defined by serological typing of ‘class II’ DR1-18 and DQ1-9. Current typing methods 
allow definition of at least 71 DRB alleles, 10 DQA alleles and 21 DQB alleles to four-digit 
resolution; that is, to the level of non-synonymous polymorphism at antigen-binding sites 
(exons 2 and 3) of the HLA molecule (143). For example, serotype DR15 can be sub-classified 
further to DRB1*15:01, *15:02, *15:03, *15:04, *15:05 or *15:07, thus allowing deeper 
investigation of risk alleles for MS, and understanding of their functional abilities. A genome-
wide linkage study in affected relative pairs (144) identified HLA as a MS risk factor, but 
numerous studies have identified other genetic risk factors, as summarized in Table 1-4. The 
varying frequency of HLA alleles in ethnically different populations has led to different 
prominent risk alleles within these populations, and has contributed to population-specific 
differences in MS prevalence overall. At the haplotype level, serotype DR2 is common in 
Caucasian MS populations (145-147), while DR3 and DR4 are common in Sardinians (148-
150), DR4 in Jordan (151), Canaries (152), Turkey (153) and Spain (154), while DR6 is 
prevalent in Japan (155) and Mexico (156). With four digit HLA-typing, the dominant 
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association for Caucasians (157) (Table 1-5) or ‘Europeans’ in Australia (158, 159) is HLA-
DRB1*15:01, found in over 50% of MS cases with further evidence for preferential 
transmission through the maternal line (160). This allele is less common in African-Americans 
(161) and not reported at all in Asian-type MS (162) or Israelis (163). In comparison, some 
alleles have been identified to have a protective effect on MS risk, including HLA-A*02 (164-
166), HLA-DRB1*11 (167), -DRB1*12 (150, 168, 169), -DRB*14 (170, 171), -DRB1*07 
(150), as well as -DRB1*04 and -DRB1*01, but only in combination with -DRB*15 (158). 
When comparing high risk and low risk heterogeneity, a dose-dependent effect of HLA has 
suggested multiple genetic contributions (169). Studies of linkage disequilibrium (genes 
inherited grouped together rather than completely independently) and epistasis (the effect a 
gene has on other genes, directly or indirectly) resulted in further refinement. Evidence of these 
mechanisms includes DRB1*15 high risk being abrogated by DRB1*14 (170, 171) and 
HLA-A*02 (164); DQA1*0102 only contributing to MS risk in presence of DRB1*1501, (172), 
and doubling of DRB1*08-associated risk when present with DRB1*15 (170, 173), while 
DQA1*0101 and DQB1*0501 are protective with DRB1*15, but neutral in its absence (172). 
The combination of genes DRB1*1501-DQA1*0102-DQB1*0602 (Haplotype ‘DR15’ (174-
176)) is common in Northern European MS cases (177-180), while a stronger risk is identified 
for DRB1*0301-DQA1*0501-DQB1*0301 (DR3) in Southern Europeans (152, 153, 181), 
suggesting groups of alleles have stronger risk than a single locus (177, 182, 183). This is 
supported by our own research (184) showing grouping of HLA-DRB1 alleles as “high risk” 
and “low risk” stratified MS risk in an Australian Caucasian population (Figure 1-6). In terms 
of linkage disequilibrium, DRB1*08 is preferentially and over-transmitted with DRB1*1501 
(139, 172, 173) and DRB1*1501 and DQB1*0602 are nearly always located together, making 
it difficult to determine whether only one of them is the causative risk factor (172, 185). 
Associations between HLA alleles and disease onset, severity and progression have been 
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investigated, with conflicting results (Table 1-5), including an in-depth review (186). Not 
included in the table were additional studies reporting no genetic association with clinical 





Figure 1-6. Stratifying MS risk according to combined HLA allele profiles from 498 MS 
cases and 498 controls. Boxes show odds ratio with 95% confidence intervals, and identify 
stratification of MS risk with absence of “low risk” HLA-DR alleles and presence of “high risk” 
HLA-DR alleles. Figure unedited from (184). 
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Table 1-4. Summary of HLA and non-HLA genes associated with MS risk. 
MS risk gene  Published studies 
HLA   
HLA-DR (6p21) (178, 191-195) 
DR1*15 (150, 158, 165, 166, 168, 170-172, 185, 187, 196-198) 
DR17 (168) 
DRB1*03 (158) (only with 1501) (187, 199)  
DRB1*10 (150) 
DRB1*13 (163, 165)  
DR2 (185, 200-206) 
DQB1*02 *03 *06 (147, 165, 187, 202, 206-208) 
Non HLA  
Cytokine Pathway 
IL7R/IL7Rɑ (158, 165, 191, 194, 197, 209-215) 
IL7 (165, 213) 
IL2R/IL2Rɑ (165, 182, 191, 194, 197, 214) 
IL1 cluster (216, 217) 




IL12A/ IL12B (165) 
IRF8 (165, 218) 
TNFRSF1A (165, 218) 
TNFRSF14, TNFS14 (165) 
SOCS1 (213) 
Co-stimulatory 
CD6 (218, 219) 
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CD37, 40, 80, 86 (165) 







TYK2 (165, 197, 213) 
Environmental 
CYP27B1 (vitamin D) (165) 
CYP24A1 (vitamin D) (165) 
VCAM1 (Natalizumab) (165) 
Viral 
EVI5 (194, 214) 
EVI5-RPL5 (197) 
Anti-inflammatory 
CTLA-4 (221, 222) 
Other 
T cell receptor gene (223, 224) 
Apolipoprotein E (182, 223, 225-227) 
12q13-14 (197) 
20q13 (197) 
CLEC16A (194, 197)  
KIF1B (228) 
STK11 (SNP) (229) 
ASF1B (195) 
HLA: Human Leukocyte Antigen. IL: Interleukin.  
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Table 1-5. Association of HLA alleles and disease progression and course. 
HLA haplotype Disease Association 
HLA-DR15 Lower age of onset, no influence on course or outcome (168, 230)  
No link to more severe disease progression, clinical or MRI (223) 
Increased risk (231) 
Younger onset, no link to lesion development (115) 
HLA-
DRB1*1501 
Normal Appearing White Matter, brain volume, 1501+ more woman and 
younger mean age for onset, less cognitive function (232) 
Younger onset, no link to clinical course (165) 
Multiple Sclerosis Severity Score (MSSS)  increased dose-dependently 
(169) 
Presence in both PPMS and RRMS, no clinical significance (170) 
DRB*1201 More severe MRI changes, but not lesion development (187) 
DR1 Unfavourable outcome (233) (not confirmed (168, 206)) 
Decreased risk or RRMS/SPMS compared to PPMS (187) 
Protected against PPMS vs RRMS (158)(*01/*15) 





Development from optic neuritis, especially with baseline brain MRI 
abnormalities (202)   
Increased frequency in RRMS (235) 
Worse prognosis (179, 185, 236, 237) 
More benign (217, 238) 
Long term no influence (168, 233, 239) 
Increases risk, less benign and more severe progression (185) 
No correlation to ‘type of disease’ (240) 
More brain lesions (202) 
DR4 Increased frequency in PPMS (201, 206, 235, 241)  
Protected against PPMS vs RRMS (158)  
HLA: Human Leukocyte Antigen. MRI: Magnetic Resonance Imaging. RR: Relapse remitting. 
PPMS: Primary Progressive MS. SPMS: Secondary Progressive MS.  
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Class II MHC molecules can present longer peptides, while class I are restricted to binding 
peptides 8-10 amino acids (aa) long (242). As HLA-DR presents antigens to CD4+ T cells (243, 
244), Wu et al. (169) suggested that heterozygous, co-dominant HLA-DR alleles could present 
different antigens to the immune system, such as presenting a disease-associated epitope and 
acting through cytokine networks simultaneously, contributing to disease pathogenesis. The 
HLA-DRB1*1501 receptor also contains an ideal binding region for presenting MBP peptides 
shown in vitro (245, 246) and MS lesion-associated CD4+ T-cell TCRs have been shown to 
recognize the MBP peptide (aa87-99) (247). DRB1*1501 is also linked to increased pro-
inflammatory cytokine tumour necrosis factor alpha (TNF-ɑ) secretion (248) and in response 
to MBP (249). More research is warranted, particularly into the quantitative expression of HLA 
based upon cell types as well as functionality of HLA-DR alleles in context of disease 
pathogenesis, especially with consideration of the influence of grouped alleles.  
 
1.4.3. Environment 
Genetic risk factors account for only 20-30% of MS risk (124, 191, 197, 250), suggesting a 
major role of environmental factors. The strongest evidence of this includes smoking, latitude, 
adolescent obesity (251, 252), ultraviolet radiation (UVR), vitamin D levels and infectious 
agents. These factors could be additive as well as cumulative over the lifetime of the individual, 
but appear to be vital in determining the susceptibility, triggering and outcome of MS (253). 
Thus far, there is little evidence for a prominent role of epigenetic factors such as methylation, 
histone modification and non-coding RNA (128, 140, 254-256) in predisposing for MS, 
although this research field is an emerging area of interest. The “Hygiene hypothesis” evolved 
from epidemiological associations between MS and improved sanitation (257), lower sibling 
number (258, 259) and birth order (260). In addition to more recent studies contradicting the 
correlation with lower sibling number (260, 261), this theory conflicts with evidence of an 
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infectious influence on disease risk (259), and reports of stepchildren of MS cases remaining at 
baseline population level risk also argues against the influence of a common familial 
microenvironment (253). Smoking is more prominent in MS diagnosed individuals, and 
increases the risk of MS (199, 262-270), but is an easily preventable risk. Genetics alone do not 
explain the influence of the ‘latitude gradient’ on MS risk, in which incidence (risk) is 20 times 
higher and prevalence (cases) increases from 5-10 to 200/100,000 for populations at 59⁰N 
compared to the equator (250, 271). This gradient (as depicted in Figure 1-1) is also seen in the 
Southern Hemisphere, with increased risk of MS further south of the equator (272), but inversed 
in several countries including regions of Italy and northern Scandinavia (271). In Europe, age 
and HLA-DR adjustments did not affect the association, and HLA-DR adjustment reverses the 
Italian inverse gradient so that it is the same as the rest of Europe (271). However, earlier studies 
found conflicting strength of association following adjustment for age, sex or HLA-associated 
genetic risk (110, 187, 273). These gradients can also be seen in migration studies, where it has 
been observed that migration before 15 years of age from low to high latitude can increase MS 
risk (274-276), although Hammond et al (277) found migration up to 30 years of age still 
identified this change in risk. Additional studies reported MS risk increased in the second 
generation following moving further away from the equator (13, 278, 279). 
 
The latitude gradient is strongly suggested to reflect the importance of ultraviolet radiation 
(UVR) exposure, and the role of vitamin D in disease pathogenesis (reviewed by (250, 267)). 
UVR is vital in initial steps of production of 25-hydroxyvitamin D3 [25(OH)D3], the 
measurable circulating form of vitamin D3 (280), which can locally (in kidney and other 
tissues) be converted to 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) (267, 281). This biologically 
active hormone can bind to the Vitamin D Receptor (VDR) which acts as a promoter for 
transcription (282). There have been recent studies suggesting that VDR-dependent signalling 
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could influence HLA-DR1*1501 expression and subsequent antigen presentation with deletion 
of autoreactive T cells (196). UVR is a dominant source for vitamin D (283) and during winter 
in higher latitudes UVR is absorbed by the atmosphere, reducing exposure (284). Additionally, 
vitamin D deficiency is common in higher latitudes (285-289). MS risk, prevalence and 
mortality have been associated with low UVR or “sunshine exposure” (199, 253, 290-297) and 
vitamin D deficiency (267, 295, 298-301) while high 25(OH)D3 levels are associated with 
slowed progression (302). Low vitamin D levels have been suggested to facilitate activation of 
autoreactive T cells, promoting a pro-inflammatory environment (303). Vitamin D 
supplementation increases levels of 25(OH)D3 (304), reduces MS risk (299) and has shown 
promise in clinical trials (55, 305, 306). Both UVR exposure and vitamin D have also proven 
protective in animal models (307-311), which may elucidate underlying mechanisms. The 
influence of vitamin D and UVR may explain the ‘month of birth’ effect, in which more MS 
cases have their have birthdays in spring (312-316), thereby suggesting that maternal end-of-
winter vitamin D deficiency could influence the child’s subsequent risk of MS (253) and 
highlighting the potential importance of early-life seasonal events (315, 317). 
 
Multiple pathogens have been targeted as infectious risk factors. Parasites have been postulated 
to reduce MS risk and progression (318-320), with evidence that this effect may be mediated 
by the up-regulation of interleukin (IL)-10 and regulatory B cells (321, 322). The strongest 
positively correlated infectious risk factor has been human herpesvirus (HHV) infection, which 
is common in most populations. Christensen et al (323) reviewed that HHV-2, HHV-7 and 
HHV-8 have no association with MS. Some evidence exists for MS association with HHV-1 
(324-326), HHV-3 (326-328), HHV-5 (325), and HHV-7 (329), but a majority of studies that 
looked at multiple herpesviruses found these to be non-significant. Evidence in support of a 
HHV-6 association includes DNA in plaques (324, 330-333), cellular immune responses to 
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HHV-6 (334), presence of HHV-6 DNA in serum (335-337), antibodies against HHV6 in serum 
and CSF (338-343), and increased virus-specific immune response linked to exacerbations 
(344, 345). Other studies have reported no significance in HHV-6 DNA levels or antibody 
responses (325, 346-351). The strongest evidence to date supports HHV-4 viral influence on 
MS development, commonly known as the Epstein-Barr Virus.  
 
1.5. Epstein Barr Virus 
1.5.1. History and genome of EBV 
Epstein-Barr Virus (EBV), “human herpesvirus 4”, is a human gamma herpesvirus which is 
believed to have evolved with humans for thousands of years. It has the unique ability 
(compared to alpha and beta herpesviruses) to utilise the host system to replicate itself during 
latency (352) and immortalize virus-infected cells (353) with the potential to cause B cell 
lymphomas (354). EBV infects 90-95% of the population (355), generally during childhood or 
early adolescence where it can manifest as infectious mononucleosis (IM) in 35-50% of cases 
(4). EBV is a linear, double stranded DNA virus enclosed by a nucleocapsid of icosahedral 
structure, with an outer layer envelope with multiple binding receptors (356). Genes of EBV 
are differentially expressed during viral development and through alternating phases of latent 
and lytic infection. A schematic of the EBV genome is shown in Figure 1-7. Following primary 
infection, the virus remains dormant in B cells using only latent viral genes to replicate with the 
host DNA and evade immune recognition. There are three major strains of EBV: Guangdong 
strain 1 (GD1) from Chinese nasopharyngeal carcinoma (357), B95-8 from a North American 
IM case (358) and AG876 from a case of Burkitt’s Lymphoma in West Africa (359-361). 
Understanding the mechanisms of the virus replication provides insight into its role in MS risk, 
and potential targeting therapies. 
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Figure 1-7. Epstein-Barr Virus (EBV) genome (A) and open reading frame (B). The viral 
genome contains genes to be expressed during latent and lytic stages of replication. Figure 
unedited from (362). 
 
1.5.2. Life cycle 
The life cycle of EBV, as depicted in Figure 1-8, can be divided into three main stages: initial 
infection, lytic replication with release of virions, and latency, in which the virus evades 
immune recognition and elimination through controlling gene products, thereby establishing 
lifelong persistent infection in memory B cells (363). There are five programmes controlled by 
EBV genes; one lytic and four latent cycles (364-367). Initial infection by EBV in naïve hosts 
occurs via saliva transfer (sharing food, kissing etc.), where the virus infects epithelial cells and 
naïve B lymphocytes in the oropharyngeal tissue (368, 369) and submucosa (370), through 
binding of envelope protein gp350 to the CD21 receptor on B cell surfaces (371) and second 
glycoprotein gp42 to HLA class II molecules as a co-stimulatory signal (372-375). Immediately 
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following B cell infection, EBV expresses BALF1 and BHRF1, homologues of cellular anti-
apoptotic Bcl-2 protein (376). Employing latency III or the ‘growth’ programme, in which all 
latent viral proteins are expressed: EBV nuclear antigens (EBNA)-1, 2, 3, LP and latent 
membrane protein (LMP) 1, 2a and 2b (377). EBV induces proliferation of naïve B cells into 
lymphoblasts (366), expressing proliferative and anti-apoptotic properties (370). Lymphoblasts 
can be recognized and eliminated by T cells (378, 379), but latency is maintained by growth 
and survival signals to infected B cells (380). Lymphoblasts enter germinal centre follicles, 
elicit latency II or the ‘default’ programme, and become memory B cells through normal 
physiological maturation (364, 366, 381-383), expressing only EBNA-1, LMP1 and 2a (353, 
384). LMP1 and 2a mimic signals from CD40 and the B cell receptor (BCR), respectively, 
enabling the B cell to mature, proliferate and survive independently of T cell help (385-393). 
Most importantly, only memory B cells have been identified as EBV-infected in peripheral 
blood so far (365, 366, 394), and infected memory B cells have been shown to evade host 
immunity (378). Memory cells can circulate peripherally in the latency I programme, with 
EBNA-1 expression within the cell nucleus (395). Latently infected B cells can return to tonsils 
and terminally differentiate into plasma cells, and/or initiate the lytic programme to produce 
and release virions from infected cells (viral “shedding”) (396) which can infect a new host 
(384, 397) or other cells of the same host (377). In established latency, EBV infection produces 
about 1-50 infected B cells per million (398). If infection occurs in early adolescence rather 
than childhood, IM can occur. Due to an increased number of latently infected memory B cells 
(399) and their elimination by the more established immune system, a massive CD8+ T cell 
expansion occurs to rapidly control infection (400) resulting in symptoms which can include a 
sore throat, swollen lymph nodes, fever and fatigue (400, 401). Following IM, viral load is 
usually controlled efficiently similar to other infected healthy carriers (402, 403).  
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Figure 1-8. Life cycle of Epstein-Barr Virus (EBV). Primary infection of epithelial and naïve 
B cells by EBV virions (1). Viral latency III program leads to proliferation and activated B 
lymphoblasts (2). Release of EBV virions in the lytic phase leads to infection of new cells (3). 
Lymphoblasts enter germinal centres and become memory B cells (4), and enter peripheral 
circulation and persist in latency 0/I (5), to become plasma cells or present themselves to T cells 
(6). These T cells can become memory T cells (7) or move to the lymphoid tissue, eliminate 
EBV infected cells (8), and monitor future reactivation. Uncontrolled infection can lead to 
disease (A, B, C). 
 
1.5.3. Immune response to EBV infection 
Only quite recently has some class I HLA (HLA-C-35T/T and HLA-Bw4) been associated with 
EBV seronegativity (404), and single nucleotide polymorphisms (SNPs) associated with 
developing IM (405). As EBV infection is common in most populations, it is possible HLA 
may not greatly influence primary EBV infection, but could affect the immune response against 
the virus over the individual’s life. Rubicz et al. (406) reviewed how HLA-DRB1 and 
HLA-DQB1 could potentially regulate EBV infection, as they linked to EBNA-1 IgG, but this 
was not seen with other viral antigens. Studies have shown the change in antibody response to 
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different EBV antigens over the course of infection (summarized in Figure 1-9). With initial 
infection, there is no cellular immunity to prevent early viral amplification (399). 
Immunoglobulin M (IgM) against viral capsid antigen (VCA) is identified early in infection 
(407), but anti-VCA IgM levels decrease by 4-6 weeks (356), switching to IgG (4) which 
continue to be produced for life. Anti-EBNA-1 IgG is not detectable until 3-6 weeks post-
infection (4), and then persists for life. Therefore, anti-VCA IgM antibodies are most helpful to 
identify current infection, whereas anti-EBNA-1 IgG indicates past infection. Memory T cells 
can later provide protection upon viral re-exposure (408), but by the time this immunity is 
formed EBV has established a permanent latent infection. 
 
 
Figure 1-9. Antibodies specific for EBV proteins after primary EBV infection. Anti-viral 
capsid antigen (VCA) IgM appears early after infection and disappear by day 120 whereas anti-
EBV nuclear antigen-1 (EBNA-1) IgG antibodies appear later and are clinically used as a 
measure of past infection. Figure unedited from (409). 
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1.5.4. Immune evasion 
Through its latency program, EBV enables lifelong persistent infection, avoiding immune 
recognition and elimination by T cells (410, 411). Understanding these underlying viral 
mechanisms can be beneficial for therapy development, as it appears the viral immune evasion 
mechanisms reduce recognition rather than provide absolute protection from host immunity 
(352). Ressing et al (412) provided a more in-depth review of the viral genes involved in 
immune evasion and their mechanisms, so only selected examples are provided here. Firstly, 
the glycine-alanine repeat (GAr) within the middle of the EBNA-1 protein largely prevents 
proteasomal degradation (413-415) and thus consequently MHC-I restricted presentation to 
CD8+ T cells (416). However, EBNA-1 peptides from lysed B cells can be autophaged (412) 
and presented through MHC-II exogenously (417) to CD4+ T cells, similarly to those observed 
for EBNA-3 and EBNA-6 epitopes (418). Experiments utilizing lymphoblastoid cell lines 
(LCLs), where B cells are infected with EBV, showed GAr deletions resulting in higher 
presentation of EBNA-1 to CD8+ T cells, with subsequent LCL inhibition (416). Additionally, 
the purine bias in EBNA-1 messenger RNA (mRNA) alters its stability, enabling immune 
evasion (419, 420) and inhibits self-synthesis (421, 422). The genes BCRF1 and BNLF2a 
encode for viral interleukin-10 (vIL10), a homologue of human IL-10 (hIL-10; 423), and are 
expressed early in EBV infection (424). While hIL-10 can act as both immune-stimulatory and 
suppressive (425), vIL-10 is only immunosuppressive. vIL-10 down-regulates MHC-I and 
reduces mRNA expression of Transporter associated with Antigen Processing (TAP)-1 and 
bli/LMP2 (412, 426-430), leading to reduced processing of endogenous antigens and reduced 
CD8+ T cell recognition of infected cells (431, 432). vIL-10 additionally inhibits monocyte 
function (433) and subsequent activation of CD4+ T cells (434), cytokine response (435-437), 
dendritic cell maturation (438), B cell growth transformation (439) and protects B cells from 
natural killer (NK) cell cytotoxicity (437). Multiple EBV genes, including BILF1, BGLF5, 
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BZLF2 and BZLF1, down regulate MHC-I and MHC-II expression (352, 412, 437, 440, 441) 
with BLZF/Zta and BZLF2 in particular reducing interferon gamma (IFNɣ)-induced T cell 
recognition (352, 412, 442). BGLF5 is additionally involved in shutting down host protein 
synthesis (443) and contributes to TLR9 down-regulation in infected B cells (444). 
Paradoxically, LMP1 is anti-apoptotic (366), but up-regulates the antigen processing pathways 
(APP) to enhance T cell presentation (445). Therefore, the virus can evade immune recognition 
long enough to establish infection, but after this point is reached, recognition of the virus 
enables the host to clear lytic infection by eliminating newly infected cells, while the latently 
infected B memory cells can escape to the periphery. 
 
1.5.5. EBV and MS 
The association between MS and EBV has been demonstrated in several studies with multiple 
reviews on EBV as a causative agent in MS (370, 446-449). Researchers have investigated 
virological factors (e.g. plasma and cell-associated levels of viral proteins, antibodies against 
different viral proteins (including quantitative measures as well as functional characteristics)), 
as well as cell-mediated immune responses specific for the virus and compared findings 
between MS patients and controls. Originally considered as part of the poliomyelitis theory 
(450), which evolved to become the “Hygiene hypothesis” (as discussed in Chapter 1.4.3), a 
recent concept is that failed regulation of EBV infection is a potential cause of MS disease 
(451). In support of this, studies and meta-analyses of IM and MS risk have demonstrated an 
association between symptomatic early infection and MS risk (384, 452-456), and recently it 
was suggested MS and IM additionally share latitudinal distribution (457). Furthermore, it has 
been reported that the presence of HLA-DRB1*15 as well as history of IM greatly increases 
MS risk (458), and HLA-DRB1*15 has been shown to be a risk factor independent of high anti-
EBV antibody titres (198, 459-461). The possibility that different EBV viral strains could 
35 
influence risk of MS has also been examined, acknowledging that strain prevalence differs 
between ethnic groups (462, 463). Strain B95-8 is most commonly used in MS in vitro 
experiments, but Lay et al. (464) identified GD-1 strain (genotype A) was significantly more 
prevalent in Australia than B95-8 (77.7% vs 16.7%). Co-infection with multiple EBV strains 
seems rare, and Yao et al. (465) reported that hosts are not re-infected with different multi-
strains, over a 15 year study period. Simon et al. (255) found that EBNA-1 N’ and C’ terminus 
as well as LMP1 variation contributed to MS risk, and Mechelli et al (466) recently reported 
that EBNA-2 variants were also associated with MS, but not HLA or MS clinical features. No 
significant difference has been identified between different EBV strains and individual MS risk 
to date (255, 464, 467, 468). 
 
1.5.5.1. Host cellular response to EBV infection 
The first indicator of EBV association with MS was by Fraser et al. (469) who reported that 
peripheral blood mononuclear cells (PBMCs) from active MS patients had an increased 
tendency to spontaneously undertake EBV-induced B cell transformation in vitro. This 
observation has subsequently been replicated (470, 471). Increased frequency of EBV-infected 
B cells has been identified in MS CSF and peripheral blood (472). Both CD4+ and CD8+ 
(Cytotoxic T lymphocytes; CTL) T cells have roles in controlling EBV infection (473-475), 
and it is possible that failure in regulation is important in development of MS. Increased EBV-
specific CD8+ and CD4+ T cells have both been identified in MS CSF (476, 477) and peripheral 
blood (478-480). In 2006, Lünemann et al. (479) identified significantly increased frequency, 
reactivity and IFNɣ production by EBNA-1 specific CD4+ T cells despite normal viral loads in 
MS patients compared to healthy controls. This significant change was not identified in T cells 
specific for other EBV antigens or cytomegalovirus targets. In 2008, the same group confirmed 
elevated IFNɣ production by EBNA-1 specific T cells in MS, and also reported EBNA-1 
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specific CD4+ T cells from MS patients were cross-reactive against myelin autoantigens 
resulting in IFNɣ production (480). In additional studies, MS CTL control of LCLs has been 
reported as impaired (481-483) as well as non-significantly increased (478), although it has 
been argued that this finding did not take into account a generalized CTL deficiency in MS 
(377, 484). Studies of CTL IFNɣ responses to synthesized EBV peptides have shown 
conflicting results with decreased (485), increased (486-488) and normal (489, 490) levels 
reported, for the same targets (EBNA-3, LMP, BMLF1 and BZLF1). It should be noted that 
endogenous EBV within LCL utilizes a patient’s APP to present lytic and latent proteins, while 
peptide experiments bypass this pathway (377). EBV-specific immune cells have also been 
found to cross-react with myelin antigens (480, 491, 492), although myelin-specific 
lymphocytes are also present in healthy individuals to a small percentage (246, 480). More 
recently, Lindsey et al. (483) found no cross-reactivity between LCL-reactive CD4+ T cells 
and brain antigens. In some of these studies, memory T cells were prominent (478, 493-495), 
and should be considered in the scheme of immune control, but are also potentially exhausted 
(377, 496). Clonally expanded B cells and B cell follicles have been detected in MS brain tissue 
and lesions (497-504) and CSF (505-509), where memory B cells and plasmablasts have also 
been identified (510). T cells have also been identified in MS brains (511, 512) but 
autoimmunity of B cells has gained focus with identification of ectopic B cell follicles within 
MS CNS (499-502). These follicles can enable viral persistence and reactivation, but structural 
differences from lymphoid follicles suggest dysfunctional B cell maturation processes, 
supported by increased B cell activating factor (BAFF) (513). Lastly, Serafini et al (500) found 
fewer numbers of CTLs in SPMS, and more B cells.  
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1.5.5.2. EBV viral load, DNA & RNA detection 
Other autoimmune diseases, like Rheumatoid Arthritis (RA) and Systemic Lupus 
Erythematosus (SLE) are correlated to increased EBV viral load compared to healthy controls 
(514, 515). However, for MS there have been conflicting results on measuring EBV viral load 
through DNA and RNA polymerase chain reaction (PCR) in peripheral blood, brain lesions and 
CSF. EBV has been detected in MS saliva (516), where it has been associated with increased 
disease activity. Significantly elevated EBV DNA has been identified in MS blood and CSF 
(329, 489), and in active relapse (517), but for the majority of cases, viral DNA levels do not 
associate with relapse/remission of MS (328, 518-520), or MS risk (479, 500, 521-530), 
including a meta-analysis undertaken by Santiago and colleagues (527). EBV (infected B cells, 
plasma cells or RNA) has been identified in post-mortem brains (324, 500, 513, 531-533) but 
this has failed to be replicated successfully (526, 534-540), while Sanders et al. (324) identified 
other herpesviruses in plaques. Pender et al (377) suggests the discrepancy in results is due to 
laboratory techniques, but overall it could mean that EBV dysregulation is a cause or effect of 
MS, and that viral load itself is not the primary cause of the disease, but instead reflects the 
humoral or cellular based pathogenesis.  
 
1.5.5.3. Host humoral response to EBV infection 
Antibodies both enable detection of immune responses against a pathogen and can functionally 
assist the immune system to detect and eliminate the pathogen. In MS, oligoclonal bands (OCB; 
IgG) are a hallmark of MS, and are present in approximately 90% of patients. Additionally, 
antibody-complement complexes have been found in CNS tissues of MS (541-543). 
Associations between EBV antibody levels and MS have been reviewed previously (384, 544). 
It has been consistently reported that later age of primary infection increases MS risk (4, 259, 
453, 545, 546), and later age of primary infection can manifest as IM, which also increases MS 
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risk (166, 263, 452-454, 547-555). Serologically, MS cases are almost 100% seropositive 
compared to 90-95% of controls (449, 517, 556-559), which is a significant observation not 
seen for other herpesviruses (259, 341, 447, 517, 545, 546, 556, 560-563). Moreover, 
prospective studies show EBV infection as a prerequisite for MS (341, 545, 563-565), and being 
EBV seronegative significantly reduces MS risk (341, 449, 563). A range of EBV proteins have 
been measured in MS studies. Anti-VCA antibodies have shown 100% seropositivity in MS 
(518, 563, 566) with evidence for elevated levels in MS cases compared to healthy controls 
(545, 556, 557, 566, 567). Additionally high titres were associated with females, HLA “DR2”, 
smokers (568) and loss of brain volume (569). Recently, Ruprecht et al (570) found elevated 
IgG against another capsid protein VP26 (BFRF3). Elevated antibodies in MS target EBNA 
complex (545, 557, 566), EBNA-2 (545), EBNA-3A,B,C (570), LMP1 (570) and lytic protein 
BRRF2 (478). The most prominent target for IgG in MS is latent protein EBNA-1. Although 
anti-EBNA-1 antibodies are common in healthy individuals (571), elevated IgG against EBNA-
1 have been shown in MS continuously (198, 341, 478, 489, 545, 566, 570, 572, 573) as well 
as already elevated years before MS onset (564, 574). Thus, anti-EBNA-1 IgG is the strongest 
humoral risk factor for MS (166, 198, 299, 341, 570, 574, 575), when compared to other EBV 
antigens (341, 479, 574). Clinically, anti-EBNA-1 IgG levels have been linked to new (Gd) 
lesions, EDSS (489, 576, 577) and lesion size (576), although there has been some difficulty in 
replicating these observations (517, 518, 578). Anti-EBNA-1 IgG has been associated with 
HLA-DRB1*1501, but also found to be independently associated with MS (269, 459, 460). A 
further breakdown of the EBNA-1 specific immune response has been investigated by 
Sundstrom et al (198) who looked at overlapping peptides within the protein for antibody 
reactivity. They found the most significant peptides reactive to antibody in MS patients were 
EBNA-1(421-440) and EBNA-1(431-450). Using EBNA-1(385-420) which had the strongest statistical 
association in logistic regression (OR 12) regardless of HLA-DRB1*1501 status, increased risk 
39 
was found in DRB1*1501 positive and “high” EBNA-1(385-420) antibody titres. This 
EBNA-1(385-420) reactivity has also been demonstrated in IM individuals (579), although in this 
context it is notable that antibody reactivity was transient and was not normally maintained over 
time. Other studies have also investigated immunogenicity of overlapping EBNA-1 fragments 
in MS cohorts (572, 580, 581), with mixed significance. It is important to identify the minimal 
epitope region to reach significance between cohorts for investigating potential cross-reactivity 
or ability for pathogenesis. A study by Mechelli et. al. (582) reported on MS-discordant 
identical twins and found significance of EBNA-1(401-411) which has yet to be tested in a larger 
population cohort. Investigation of inflammatory modification of EBV targets, such as 
citrullinated autoantibodies against EBV, show promise as diagnostic tools for rheumatoid 
arthritis (RA; 630) but has yet to be explored for MS. 
 
A hallmark of MS is the presence of OCB in the CSF (478, 500, 583-585). In MS, these CSF 
antibodies have been reported to be reactive against EBNA-1 (476, 478, 572, 583, 584, 586, 
587), BRRF2 (478), VCA (476, 557), and alpha-beta crystallin (αβC) (586) but not postulated 
autoantigens such as MBP, myelin oligodendrocyte glycoprotein (MOG) or proteolipid protein 
(508). It is argued anti-EBV IgG is only a fraction of the total intrathecally synthesized IgG, as 
other pathogen targets have been identified including measles, rubella, Varicella Zoster Virus 
(VZV), Herpes Simplex Virus (HSV) and HHV-6 (326, 342, 588-593), suggesting bystander 
reaction of a chronic inflammatory process. It is theorized that this may be due to clonally 
expanded EBV infected B/plasma cells in the CNS (353, 594). Because other viruses (like 
measles) are not present in the brain, it is possible that there is recruitment of virus-specific 
plasmablasts to the inflamed CNS (595). Jafari et al. (572) reported significantly elevated 
EBNA-1(394-451)-specific IgG in MS CSF and serum compared to non-inflammatory 
neurological disease patients. The anti-EBNA-1(394-451) IgG measurements in these two 
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compartments were significantly correlated, and when normalized by total IgG (which was 
significantly lower in MS serum and higher in MS CSF), no significant difference was seen 
between cohorts. From this it was suggested that the EBNA-1(394-451) IgG response was not 
intrathecally synthesized, instead the antibodies “leaked” into the CSF via blood-brain barrier 
(BBB) dysfunction. This theory is supported by evidence that OCB did not associate with the 
number of infected B cells in MS brain (500). 
 
1.5.6. Theories on mechanisms of MS pathogenesis 
A recent review by Pender et al. (377) summarizes the current supporting evidence for different 
theories behind MS pathology mechanisms. These encompass i) cross-reactivity, ii) bystander 
damage, iii) mistaken self hypothesis and the iv) EBV positive auto-reactive B cell hypothesis. 
The cross-reactivity theory is based upon EBV-specific T cells being cross reactive with CNS 
proteins (480, 491, 492), but being based solely on T cells, doesn’t explain the presence of EBV 
infected B cells in the brain (500, 513, 531, 532). The bystander damage theory postulates that 
the autoimmune CNS response is secondary to an EBV antigen-targeted response (500), such 
as Epstein-Barr Virus-encoded small RNA (EBER) released from EBV infected cells activate 
innate immunity (531). This is supported by the presence of EBV-infected B cells in MS brain 
(500) and CD8+ T cells found close to plasma cells (488, 500). Pender et al. argued that EBV 
should be eliminated by the immune response and that the bystander damage theory doesn’t 
explain identified autoimmunity (377, 596-598). Similar to the cross-reactivity theory, the 
mistaken-self theory or “αβC hypothesis” is based upon molecular mimicry: EBV-specific 
CD4+ T cells mistaking human homologous proteins (αβC) as foreign, inducing 
oligodendrocyte attack and resulting in demyelination (599). In support of this, EBNA-1(385-420) 
shares homology with αβC (198), EBV infection induces αβC expression in B cells (600), and 
αβC is expressed by oligodendrocytes and myelin (356, 599, 601). However, Pender et al (377) 
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said that this could only explain initial T cell mediated inflammation, with other specific T cells 
and EBV-infected B cells contributing to the persistence of inflammation (602). This could 
additionally occur through targeting MBP, as cross-reactive T cells have been identified (480, 
491, 492, 603, 604), as well as EBNA-1 sharing homology with many human proteins with 
“crucial pathway roles” (605). EBV can infect human cerebral microvascular endothelial cells 
(606), and T cells against αβC are seen in MS (607). The most recent theory, supported strongly 
by Pender et al (377), is that EBV infects autoreactive B cells, enabling evasion of immune 
recognition, elimination and apoptosis. These infected cells accumulate in target organs, secrete 
pathogenic autoantibodies and present co-stimulatory signals to autoreactive T cells (353), 
causing release of human proteins (potential new antigens) from attacked CNS, furthering 
inflammation (377). EBV infected cells can inhibit autoreactive T cell apoptosis (608-610) and 
elicit inflammatory responses, facilitating macrophage and lymphocyte infiltration (611). With 
reported 20% of human naïve B cells being autoreactive (612), the infection of that population, 
along with a genetically determined defect (such as HLA-DRB1*15) in eliminating EBV 
infected B cells by CTLs could be underlying causative factors of MS. Although this theory is 
not proven, supporting evidence includes EBV infected B cells in MS brains (500, 531, 532), 
EBV+ autoreactive B cells in IM (613), decreased CTL immunity against EBV in MS (482) 
and germinal centres in MS brains. These centres can reactivate B cells, produce autoantibodies, 
and provide an explanation for the efficacy of B-cell-specific treatment approaches such as the 
anti-CD20 monoclonal antibody Rituximab (390) and immunotherapy with EBV specific CTLs 
(496). Further research into the identification of EBV infected autoreactive B cells in MS is 
required to prove this hypothesis.  
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1.5.7. EBV targeted preventative and therapeutic strategies for MS 
Therapies for MS and EBV have targeted different aspects of the disease. General 
immunosuppressants and anti-inflammatory drugs/medications were outlined in Chapter 1.3.4. 
In light of the EBV role in MS pathogenesis, potential therapies have included anti-viral drugs 
against herpes viruses (Alacyclovir/valacyclovir), unfortunately these can’t target latently 
infected B cells or act upon antibody-producing plasma cells (614-616). However, Rituximab 
targets CD20+ B cells, including EBV infected B cells, and has clinically shown promise (106, 
617). Some B cell and BAFF targeting therapies have shown promise for other autoimmune 
disorders including RA and SLE, but are not yet used in MS (618). A vaccine against the gp350 
envelope protein of EBV has been developed, aiming to induce an immune response before 
EBV can establish a latent permanent infection. This vaccine could not prevent asymptomatic 
EBV infection (619), but has been shown to reduce the frequency of IM (620). EBV-specific T 
cells have been used successfully in treating EBV-associated lymphoproliferative disease (621-
623), and recently a similar approach was taken using autologous CTLs for a SPMS patient, 
showing substantial clinical improvement (624). If this research could be replicated and 
extended, using EBNA-1 as a target for T cell immunotherapy may emerge as an interesting 
therapeutic strategy (605, 625), although Pender et al (377) noted that CTLs could aggravate 








1.6. Summary of Background and Development of Thesis Questions 
MS is clearly a multifaceted disease, with several risk factors contributing to disease 
development. However, a conceptual understanding of the numerous influencing factors (DRB 
group alleles rather than just dichotomy of HLA-DRB1*1501 presence; specific EBV epitope 
targets rather than just history of IM) is essential to better classify and stratify risk of MS, at 
both a familial and population levels. Specific questions related to the role of EBV in the 
pathogenesis of MS were investigated using a Western Australian (WA) cohort in this thesis:  
(i) Can anti-EBNA-1 and anti-VCA IgG antibodies discriminate MS patients from healthy 
controls in the WA cohort?  
(ii) Is it possible to create an immunoassay to measure antibody reactivity against the B cell 
epitope EBNA-1(398-413), and does this aid in discriminating MS cases from healthy 
controls? 
(iii)  Does post-translational modification (citrullination) of EBNA-1(398-413) influence its 
antigenicity, compared to non-modified EBNA-1(398-413), and does this contribute to risk 
analysis? 
(iv)  Using the EBNA-1(398-413) assay, which of the IgG subclasses is most prevalent and is 
there a difference between MS cases and controls? 
(v) Are MS serum antibodies and EBNA-1(398-413) specific IgG antibodies cross-reactive to 
an array of brain proteins and how does this compare to healthy controls?  
(vi)  Does MS serum containing these potentially cross-reactive antibodies have a detrimental 





















































2.1. Universal Precautions 
To prevent any contamination between samples as well as samples to researcher, all samples 
obtained from human individuals were treated as if containing infectious agents. Each method 
was conducted following universal biosafety measures and including personal protective 
equipment (PPE) and effective hand-washing/disinfection procedures when leaving the 
laboratory. Murdoch University and the Institute for Immunology and Infectious Diseases 
(IIID) Laboratory Safety and Precautions were undertaken at all times. Preparation of PCR 
master mixes was conducted in a specially designated class II biosafety hood with laminar flow, 
and subsequent pre- and post-PCR experiments were performed in separate self-contained 
rooms. Cell lines were kept in a Physical Containment Level 2 (PC2) classification room until 
proved non-infected. Laboratory work areas and materials including benches, hoods and 
pipettes were decontaminated prior and after use with 70% ethanol or the detergent Viraclean 
(Statewide Cleaning Supplies, Australia) according to the accredited laboratory safety manual. 
 
2.2. Patient samples 
A total of 426 MS patients in the Perth (Western Australia) Demyelinating Disease Database 
(PDDD) from the cohort previously described (184) were included in the study. The control 
cohort (n=186) was established from the population of Busselton, Western Australia (626). 
Serum samples from both cohorts were collected and stored at -80°C until tested. Within the 
final year, patients who returned to clinic from the PDDD cohort had additional serum samples 
taken, and of these a subset had peripheral blood mononuclear cells (PBMCs) collected, 
additional to their clinical history. These samples were collectively named ‘PDDD-b’ (n=32), 
from which eight samples were selected for experiments, as summarized in Table 2-1. “Acute 
patients” refers to MS patients where samples were taken during a relapse of symptoms. 
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Healthy control samples were also collected from Red Cross buffy coat donations (n=34), and 
ten samples were selected based on HLA-DRB alleles. 
 
Table 2-1. Summary of PDDD-b Multiple Sclerosis (MS) and Red Cross (RC) samples. 




MS/RC Clinical Information 
1 65499 Male 03:01 15:01 MS Acute relapse 
2 65556 Female 15:01 15:01 MS CIS 
3 65514 Male 03:01 15:01 MS Acute relapse 
4 65508 Female 03:01 03:05 MS SPMS, not on treatment 
5 65672 Female 11:01 13:01 MS SPMS, fingolimod 
6 65720 Female 04:04 13:02 MS SPMS, not on treatment 
7 65726 Female 07:01 15:01 MS SPMS, interferon 
8 65715 Male 03:01 15:01 MS PPMS, not on treatment 
9 52477 Female 10:01 15:01 RC  
10 63665 Female 03:01 15:01 RC  
11 63647 Female 04:05 15:02 RC  
12 66382 Female 04:04 08:01 RC  
13 63658 Male 01:03 04:04 RC  
14 64308 Male 03:01 04:01 RC  
15 64488 Female 04:02 12:01 RC  
16 57300 Female 04:04 07:01 RC  
17 61254 Male 14:01 14:01 RC  
18 64467 Female 03:01 13:01 RC  
PDDD: Perth Demyelinating Disease Database. ID: Identifier. HLA: Human Leukocyte 
Antigen. CIS: clinically isolated symptom/s; first presentation of MS. SPMS: Secondary 
Progressive MS. PPMS: Primary Progressive MS. 
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2.3. Materials and Media 
For catalogue numbers of kits and reagents purchased, see Supplementary Table S-1. 
2.3.1. Enzyme Linked Immunosorbent Assay (ELISA) reagents 
2.3.1.1. Commercial ELISA kits 
Two different ELISA kits were purchased (DiaSorin, Australia) for detection of IgG against 
EBNA-1 and VCA. The sample diluent provided with the kits was used to dilute samples tested 
in commercial and subsequent in-house ELISAs.  
 
2.3.1.2. ELISA plates 
Streptavidin-coated 96 well plates (ThermoFisher Scientific, Australia) were used for all 
in-house ELISAs.  
 
2.3.1.3. In-house ELISA peptides 
A consensus sequence of EBNA-1 derived from individual MS patient sequences (instead of 
using the sequence of the laboratory strain of EBV B-98-5) was used to produce the B cell 
epitope: Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1(398-413)) PPPGRRPFFHPVGEAD 
(sequence selection method described in Chapter 2.4.7; amino acid sequence table in 
Supplementary Table S-2). This peptide was synthesized to 95% purity with reversed-phase 
high-performance liquid chromatography (RP-HPLC; Mimotopes Australia) with an SGSG 
sequence spacer at the N-terminus which was biotinylated to enable binding in the correct 
orientation to the streptavidin coated plates. The peptide sequence of the synthesized product 
was independently confirmed (Proteomics Node, Perth, Australia). The peptide was re-
constituted with dimethyl sulfoxide (DMSO) to 10 mg/ mL, aliquoted and stored at -20°C until 
needed. A second peptide was synthesized to identify IgG antibodies against a citrullinated 
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form of the B cell epitope. The EBNA-1(398-413) sequence was modified to contain two 
citrullinated arginine residues at aa 402-403. The peptide was reconstituted and stored 
identically to the first peptide, with the amino acid sequence confirmed by Proteomics.  
 
2.3.1.4. Phosphate Buffer Solution (PBS) 
A concentrated 10X PBS was made by dissolving 25 tablets (Sigma Aldrich, Australia) into 
500 mL autoclaved water. The buffer was subsequently filter sterilized using a Steritop filter 
unit (Merck Millipore, Australia) and stored at 4°C. Buffers requiring 1X PBS were made from 
diluting stock buffer 1:10.  
 
2.3.1.5. In-house PBS-Tween (PBST) wash buffer 
In-house wash PBST buffer was prepared by adding 0.01% Tween-20 (BDH, Australia) to 1X 
PBS buffer. 
 
2.3.1.6. In-house Coating Buffer 
Coating buffer was prepared using 1X PBS with the addition of 0.1% Bovine Serum Albumin 
(BSA; Sigma Aldrich, Australia) and 0.1% Sodium Azide (Sigma Aldrich, Australia) and used 
for all in-house ELISAs. 
 
2.3.1.7. In-house Secondary Antibody Diluent 
Secondary antibody diluent was made using 1X PBS supplemented with 2% BSA and was 
stored at 4°C, for up to a week. 
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2.3.1.8. In-house ELISA IgG detection antibodies 
Separate secondary antibodies were purchased to detect total IgG (Sigma Aldrich, Australia) 
and three IgG subclasses; IgG1, IgG2 and IgG3 (Sapphire Biosciences, Australia).  
 
2.3.1.9. Tetramethylbenzidine (TMB) 
3, 3’, 5, 5’ Tetramethylbenzidine (TMB) Liquid Substrate (supersensitive) was purchased 
(Sigma Aldrich, Australia) and stored at 4°C, and used as a colourmetric substrate for in-house 
ELISAs.  
 
2.3.1.10. In-house Stop Solution 1 N H2SO4 
1N Sulphuric acid (H2SO4) solution was prepared using deionized water in a sterile hooded 
cabinet, and stored in a dark hazardous chemicals cabinet. 
 
2.3.2. Antibody Isolation using affinity columns 
2.3.2.1. Tris-Buffered Saline (TBS) 
TBS was used for antibody capture using affinity columns (ThermoFisher Scientific, Australia) 
and prepared as per manufacturer instructions, with a final concentration of 25 mM Tris, 0.15 M 
NaCl, pH 7.2. 
 
2.3.2.2. 5M NaCl stock solution 
5M NaCl was prepared in deionized water and autoclaved, then kept at room temperature. 
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2.3.2.3. Column wash buffer 
5 M NaCl added to “acetate wash buffer” (ThermoScientific, Australia) so that final 
concentration was 0.012 M NaCl. 
 
2.3.2.4. Neutralization buffer 
1 M Tris (Sigma Aldrich, Australia) in ultrapure water and kept at 4°C. 
 
2.3.2.5. Column cleaning buffer 
Cleaning buffer was prepared by 1X TBS with 1M NaCl (from 5M NaCl stock). Stored at 4°C. 
 
2.3.3. Protein macroarray 
2.3.3.1. Macroarray 
A HexSelect Macroarray was purchased (SourceBioscience, Germany) and kept at room 
temperature until needed. 
 
2.3.3.2. 3 M HCl 
3 M HCl was prepared and stored in a hazardous cabinet.  
 
2.3.3.3. Tris-HCl, pH 7.5 
1M Tris was made in deionized water, pH adjusted to 7.5 using 3M HCl. The bottle was 
autoclaved and stored at room temperature.  
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2.3.3.4. In-house TBS Buffer 
Stock 1X TBS Buffer was made as 10mM Tris-HCl (pH7.5) with 500mM NaCl. The solution 
was autoclaved and stored at room temperature. 
 
2.3.3.5. TBS-Tween 20 (TBST) Buffer 
Final buffer was made to 20mM Tris-HCl (pH 7.5), 500mM NaCl with 0.05% Tween-20. 
 
2.3.3.6. TBS-T-Triton X100 (TBST-T) Buffer 
Final buffer was made to 20mM Tris-HCl (pH 7.5), 500mM NaCl with 0.05% Tween-20 and 
0.5% Triton-X 100 (Sigma Aldrich, Australia). 
 
2.3.3.7. Blocking Buffer 
TBS-T buffer was prepared with 3% skim milk powder (HomeBrand, Australia). 
 
2.3.3.8. Enhanced Chemiluminescence (ECL) Substrate 
ECL substrate (BioRad, Australia) was made at a 1:1 ratio with the Peroxidase substrate and 
Luminos substrate immediately before addition to the protein array. 
 
2.3.3.9. Macroarray Cleaning Buffer 
TBS-T buffer was prepared with 5% skim milk powder. 
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2.3.3.10. 1M Tris-HCl, pH 6.8 
1 M Tris buffer was made, adjusted to pH 6.8 using 3 M HCl. Bottle was autoclaved and stored 
at room temperature. 
 
2.3.3.11. Macroarray stripping Buffer 
As instructed by the manufacturer, 2% sodium dodecyl sulphate (SDS; Astral Scientific Pty 
Ltd, Australia) was prepared using 65.5 mM Tris-HCl (pH 6.8) with 100 mM beta-
mercaptoethanol (Sigma, Australia). The buffer was heated in a water bath to 70°C before use. 
 
2.3.3.12. Dot Blot Blocking Media 
1 X PBS was supplemented with 5% BSA (Sigma Aldrich, Australia).  
 
2.3.4. Cell culture 
2.3.4.1. Foetal Bovine Serum (FBS) 
FBS (Scientific Partners, Australia) was heat inactivated (56°C) for 30 minutes and aliquoted 
in 50 mL tubes and frozen at -20°C until needed. 
 
2.3.4.2. Neuroblastoma SH-SY5Y cell line 
SH-SY5Y is a human-derived cell line isolated from bone marrow of a four year old female 
with neuroblastoma. The cell line was a kind gift from Prof. Ian Mullaney’s group at Murdoch 
University. The cell line was received at passage 24 and grown in SH-SY5Y media. 
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2.3.4.3. SH-SY5Y media 
1:1 volume of DMEM High glucose (Sigma Aldrich, Australia) and Ham’s Nutrient F12 media 
(Sigma Aldrich, Australia) + 5% FBS (Serana, Australia), supplemented with 1% Penicillin-
Streptomycin-Glutamine (Invitrogen, Australia). Media was kept refrigerated at 4°C, and 
warmed to 37°C before use with cells. 
 
2.3.4.4. Oligodendrocyte MO3.13 cell line 
MO3.13 is a hybrid cell line from a mutant of human rhabdomyosarcoma with adult human 
oligodendrocytes, exhibiting markers of immature oligodendrocytes. Differentiated MO3.13 
have been shown to express MBP and MOG. This cell line was a kind gift from Prof. 
Guillemin’s group from Macquarie University with the blessing of Prof. Cashman from 
University Toronto. The cell line was received at passage 6 and grown in MO3.13 media as 
provided by Prof. Guillemin’s group. 
 
2.3.4.5. MO3.13 media 
RPMI 1640 media (Gibco, Australia) was supplemented with 10% FBS and 1% Antibiotic-
Antimycotic (Gibco, Australia). The media was kept refrigerated at 4°C, and warmed to 37°C 





2.4.1. Tracking of samples 
To ensure traceability for the large number of samples handled in this thesis, all reagents and 
samples were labelled and recorded with unique identifiers known as “Base IDs”. This process 
de-identifies personal information on patients including their name, but can be linked to the 
Universal Medical Record Number (UMRN), which is given to a single individual and can be 
used to determine if samples are from different time points of a single individual. This Base ID 
is linked to the type of sample and storage location on an in-house database system (EpiLab) 
which allows tracking of samples. To minimize risk of contamination or mistake between 
samples, a second person checked, prior to an experiment, the racking order and Base IDs of 
samples as well as locations of positive and negative controls. All reagent batch/lot numbers 
were also recorded for experiments. This can help trouble shooting in case an experiment failed.  
 
2.4.2. Blood separation and PBMC storage 
Whole blood samples from PDDD-b were collected into commercial tubes for blood separation; 
Beckton Dickinson (BD) Ethylenediaminetetraacetic acid (EDTA; BD, Australia) for plasma 
and buffy coat and serum-separating tubes (SST; BD, Australia) for serum. After registration 
of samples using IIID’s non-identifying base ID, tubes were centrifuged (1300 x g, 10 minutes) 
using Beckman Coulter Allegra X-15R. Serum was aliquoted from the SST tube, plasma and 
buffy coats were aliquoted from the EDTA tube and stored at -80°C. Frozen buffy coats were 
later used for DNA extraction with subsequent HLA typing.  
 
For Red Cross buffy coat bags, 7 mL was also allocated into a 15 mL falcon tube undiluted. 
The remaining sample was then diluted 1/3 RPMI and 30 mL of this layered over 15 mL Ficoll 
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(GE Healthcare, Australia) in 50 mL falcon tubes. All tubes were centrifuged 800 x g for 15 
minutes with the brake off. After centrifugation, the 15 mL tube was used for plasma and buffy 
coat collection, which was aliquoted and stored at -80°C.  
 
2.4.3. DNA extraction from buffy coat samples 
The PDDD MS cohort had DNA extracted using multiple commercial DNA extraction kits 
(Qiagen, Genfind & Promega, Australia). For samples from the Red Cross and newly recruited 
MS patients in PDDD-b, DNA extraction used commercial kits (Qiagen, Australia) as per 
manufacturer’s instructions and DNA was stored at 4°C.  
 
2.4.4. HLA typing 
Sequence based HLA typing of both PDDD (MS) and control cohort had been performed prior 
to project commencement as previously described (169, 184). HLA typing was additionally 
done for individuals within cohort PDDD-b but not PDDD. For both PDDD and PDDD-b, 
genotyping was performed using PCR with HLA locus specific primers followed by subsequent 
sequencing on the ABI Prism 3730 and 3730xl Genetic Analysers. Sequence editing was carried 
out using ASSIGN V4.0.1.36 (Conexio Genomics). All HLA typing results for MS and healthy 
control samples were resolved to at least the 4-digit level using heterozygous ambiguity 
resolving primers where applicable. HLA typing was carried out by the accredited staff at IIID. 
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2.4.5. Automation (and documentation) of sample preparation and ELISA 
protocol 
Samples were serially diluted using a BioMek FXP laboratory automation station (Beckman 
Coulter), and ELISA protocols were set up on a BioMek FX (Beckman Coulter) and an ELx 
405 washer (BioTek, Vermont, USA) to minimize pipetting error. Both automation processes 
required the utilization of the BioMek FX software, with user-configured experimental methods 
to optimize deck layout, required reagents, lab-ware, and liquid-handling techniques, pipetting 
and associated parameters including sample and reagent volumes, aspiration and dispensing 
speeds, heights, mixing and tip touching (adapted from (626)).  
 
2.4.6. Serum sample preparation 
MS cohort, healthy controls and internal assay control serum samples were serially diluted 
using a BioMek FXP robot to 1:1075, using sample diluent provided by the commercial 
EBNA-1 ELISA kit (DiaSorin), and refrigerated overnight. The following day, samples were 
thoroughly mixed on an orbital shaker before both commercial and in-house ELISAs were 
performed on the same day from the same sample dilutions.  
 
2.4.7. EBNA-1 B cell epitope sequencing 
EBNA-1 sequencing was carried out by Dr. Monika Tschochner prior to commencement of this 
project. Briefly, DNA of MS samples from PDDD was isolated from buffy coats with an 
automated robotic setup using DNA isolation kit (Genfind, Australia). A minority of samples 
was manually extracted using QIAamp Mini extraction kits (Qiagen, Australia) following the 
manufacturer’s instructions. A novel semi-nested PCR approach with a fully automated setup 
utilising Biomek FX robots was employed. All primers used for amplification have been 
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previously published (627-629) and have been named according to the position in the reference 
strain B95-8. First round PCR was performed using High Fidelity Taq (Roche, Australia) in a 
25µl reaction with primers EBV109111F-EBV109951R (at 25pmol/µl), resulting in an 840 
base pair (bp) fragment. A semi-nested PCR was followed using the primer combination 
EBV109111F-EBV109869R resulting in a final 749bp product. Alternatively, a shorter semi-
nested PCR was performed using the primer combinations EBV109111F-EBV109759R 
(648 bp) and EBV109111F-109459R (348bp) respectively. Successful PCR products were 
purified with AMPure (Beckman Coulter, Australia), using an automated setup and sequenced 
with the PCR primers at a concentration of 1 pmol/ul. Sequencing products were purified with 
magnetic beads using the Cleanseq (Beckman Coulter, Australia) protocol according to the 
company’s instructions at IIID’s protocol, followed by sequencing on an automated 96 capillary 
ABI 373 DNA sequencer. Sequences were edited with the ASSIGN V1.0.2.45 software 
(Connexio) and fasta files generated and aligned using Bioedit for subsequent analysis.  
 
2.4.8. In-house EBNA-1(398-413)  ELISA 
As shown in Figure 2-1, Streptavidin-coated plates were washed 3x with 300µl PBST using an 
ELx405 Microplate Washer (BioTek, Vermont, USA) and incubated at room temperature for 1 
hour with 100µl EBNA-1(398-413) or EBNA-1(398-413 CIT) biotinylated peptides (0.5µg/ mL) in in-
house coating buffer. Plates were washed (4x 300µl PBST), and incubated for 1 hour at room 
temperature on a PHMP plate shaker (Thermo Fisher Scientific) after serially diluted internal 
assay controls and either MS or healthy cohort samples were added in separate wells. Plates 
were washed (4x 300µl PBST) and incubated with 100µl anti-human IgG (Fc specific)-
Peroxidase antibody for 1 hour at room temperature. Following incubation, plates were washed 
again (4x 300µl PBST, 2x 300µl PBS only) and incubated with 100µl super-sensitive TMB 
liquid substrate for 30 minutes before stopping the reaction with 100µl H2SO4. Data was 
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recorded as optical density (OD) at 450nm on a DTX 880 Multimode detector 
spectrophotometer (Beckman Coulter), and lower cut-off was set at 3 standard deviations above 
the mean OD450nm of the negative control for all assays (ODcutoff = 0.039).  
 
 
Figure 2-1. Overview of the in-house ELISA method. Each of the steps illustrated was 
automated using the Biomek FX robot. C: Commercial. IH: In-house. 
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2.4.9. Commercial EBNA-1 and VCA ELISA 
Commercial ELISAs (DiaSorin, Australia) were used to determine IgG antibody levels against 
EBNA-1 and VCA proteins. The assays were carried out according to the manufacturer’s 
instructions with the exception that all samples were serially diluted to 1:1075 to be able to 
measure samples within the linear range of the assay (see Chapter 3). Data was recorded as 
optical density (OD) at 450nm-620nm, as described for the in-house ELISA protocol, and lower 
cut-off was set at three standard deviations above the mean OD450-620nm of the negative control 
across all plates for EBNA-1 (ODcutoff = 0.031) and VCA ELISA (ODcutoff = 0.057). In-house 
internal triplicate controls were also included, as discussed in Chapter 3.  
 
2.4.10. In-house EBNA-1(398-413) IgG subclasses ELISA 
This assay utilized the method described in 2.4.8, but following washing after sera sample 
incubation, plates were incubated with 100µl anti-human IgG1, IgG2 or IgG3-specific HRP-
conjugated secondary antibody for 1 hour at room temperature. Data were recorded as optical 
density (OD), as described previously and lower cut-off was also set at 3 standard deviations 
above the mean OD450nm of the negative control for all assays (IgG1 ODcutoff = 0.041; IgG2 
ODcutoff = 0.062; IgG3 ODcutoff = 0.043). Any plates for which triplicate or serial dilution 
controls were not within the accepted variance range were re-tested in full. 
 
2.4.11. IgG subclass antibody capture and purification 
Serum samples were chosen based upon clinical information and in-house ELISA antibody 
titres, to use with a modified spin column-based Biotinylated Protein Interaction Pull-Down Kit 
(Thermo Fisher, Australia) to collect purified anti-EBNA-1(398-413) specific antibodies. The 
columns were used according to manufacturer’s instructions, all at room temperature, and 
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centrifuged at 1250 x g for 60 seconds as mentioned. Briefly, 50µL immobilized streptavidin 
(STP) “slurry” was pipetted into a spin column and washed 5 times with TBS, centrifuging to 
remove the buffer. Next, 50µg EBNA-1(398-413) peptide in PBS was incubated with STP beads 
for 1 hour on a rocking platform (“rocker”, Ratek) at medium speed. The columns were 
centrifuged and 250µL Biotin Blocking Solution was added and incubated for 5 min before 
centrifugation three times, then washed 3 times with TBS. Following optimization to ensure the 
column was not overloaded, sera samples were diluted 1:2 and incubated with the EBNA-1(398-
413) peptide-bound beads for 1 hour on a rocker. The bead suspension was centrifuged and 
washed 4 times with column wash buffer, followed by the addition of 250µL elution buffer, 
which was incubated for 5 min and final centrifugation into a collection tube with 10µL 
Neutralization buffer. This elution procedure was repeated once to obtain sufficient antibody 
for subsequent experiment. Eluted antibodies were initially kept at 4°C. An aliquot of eluted 
antibodies was tested using EBNA-1(398-413) in-house ELISA to confirm presence of total and 
subclass IgG antibodies before use with the protein macroarray or freeze drying for subsequent 
experiments. 
 
2.4.12. Protein macroarray 
HexSelect High density protein macroarrays were purchased through Source BioScience 
(Germany). The method followed the manufacturer’s instructions, performing all steps at room 
temperature, with gloves and tweezers so as to not touch the blotted proteins on the membrane. 
Briefly, the array was rinsed with 96% ethanol and then ultra-pure H2O to remove traces of 
ethanol. In a new plastic tray, the array was washed 2 x 10min in TBST-T while on a rocker for 
gentle agitation. The array was rinsed twice in TBS, and then washed 2 x 10min in TBS on a 
rocker. The array was then incubated for 2 hours in blocking solution on the rocker (20 mL in 
sealed bag) after which primary isolated antibody (200ul each) was added to the blocking 
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solution so that each antibody was at a 1/100 dilution. The array was incubated on the rocker 
for 16 hours. The following day, the array was washed 3 x 10min in TBS-T, and incubated for 
2 hours in 20 mL secondary antibody (anti-human IgG, Sigma Aldrich) in 20 mL blocking 
buffer in a sealed bag on a rocker. After incubation, the array was washed 4 x 10min in TBS-T, 
2 x 10min in TBS and finally transferred to a new tray and incubated for 5 min with made ECL 
substrate. The array was placed between two plastic sheets and images were taken using the 
Fusion FX (Fisher Biotec, Australia) using single imaging for blot and accumulative images for 
ECL (“chemiluminescent” and “blot marker”). For the first array, the same blot was used for 
re-incubation of primary sample and blocking buffer after 3 x 10 min washes with cleaning 
buffer, before imaging. To re-use the same array for a second experiment using different 
samples, stripping the array was carried out by washing the array with heated stripping buffer 
for 30 minutes, before drying the array between blotting sheets until further use. 
 
2.4.13. Protein macroarray positive control dot blot 
To ensure optimal performance of reagents, a positive control dot blot was performed in parallel 
to each macroarray using the following method, with blocking and washing occurring on a 
PHMP shaker (Thermo Scientific, Australia). Nitrocellulose membrane (GE Healthcare, 
Germany) was blotted with EBNA-1(398-413) peptide at 1ug/ mL concentration and left to dry. 
The membrane was washed 3 x 5 min in PBST, then submerged in blocking media for 30 min 
on a shaker. After further washing steps (3 x 5 min) in PBST, pooled positive control MS serum 
was added in serial 2-fold dilution to the membrane (from 1:2 to 1:32). After 30 min room 
temperature incubation, the membrane was washed again 3 x 5 min PBST. Next the membrane 
was incubated with ELISA secondary anti-IgG HRP-conjugated antibody for 1 hour on a rocker 
at medium speed, followed by 3 x 5 min washing in PBST and 1 x 5min in PBS. Finally 
approximately 1 mL of Clarity ECL was added and incubated for 5 min before excess ECL was 
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removed and the blot was taken to the imager for immediate analysis. An example of the dot 
blot controls is seen in Supplementary Figure S-1. 
 
2.4.14. Analysis of hexSelect macroarrays 
The array was 30cm x 30cm in size, with proteins blotted in duplicate onto the membrane in a 
5 x 5 square surrounded a black ink dot. The protein array blotted proteins therefore have a 
location between X1 to X240 and Y1 to Y240. Read-out of the macroarray was time sensitive 
for signal detection, and so control blots and macroarray were imaged immediately following 
the ECL addition stage. The Fusion camera stage and height of camera did not allow a high 
resolution photo to be taken of the entire array in one image.  Therefore, an overlaying plastic 
sheet with a 3 x 3 square grid was placed on top of the array, and images were taken of each 
grid square (1 to 9) with white light (Figure 2-2A) and Chemiluminescent settings (Figure 2-
2B). This allowed the highest resolution of image while maintaining the least number of photos 
taken (due to time sensitivity). Fusion software saved the captured images as Tagged Image 
File Format (TIFF). These were converted to Bitmap Image File (BMP), and chemiluminescent 
images resolution changed to 2048 pixels x 2048 pixels to match the size of the white light 
images of the macroarray. These images were layered using Pixlr Editor to identify location of 
ECL-positive dots which appear as black on a grey background. A layering tool enabled a red 
square to identify a 5 x 5 blotted square around a black ink dot to match the chemiluminescent 
signal with X/Y location on the array, seen by the white light image. These signal locations 
were mapped by their X/Y axis location, as shown in Figure 2-2D&E where they were checked 
for duplicate matches by codes provided by the manufacturer. Only duplicate matches were 




Figure 2-2. Analysis of protein macroarray. (A) White light “dot blot” image in Pixlr 
software. (B) Chemiluminescent image in Pixlr software of equal resolution for comparison, 
with red square on additional layer. (C) Example of 5 x 5 square of dotted proteins (ink dot as 
a blue circle), with signal higher than background shown as two black dots. (D) X/Y locations 
of two dots identify matching protein codes from the manufacturer. (E) Two signals identified, 
but with mismatched protein codes, and thus excluded reactivity.  
 
2.4.15. Cell culture 
Cells were taken from an existing line (P6 for MO3.13 and P24 for SH5Y) and grown in media 
as (3.2.22 and 3.2.24 respectively) at 37°C with 5% CO2 (Sanyo Incubator, Australia). Media 
was changed every 3-5 days, and once confluence reached about 70%, cells were washed with 
PBS, then resuspended using 2ml of trypsin for no longer than 2 min (Trypsin-EDTA, Sigma 
A B 
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Aldrich) and washed with fresh media before splitting 1/5 or 1/10 into a new flask with fresh 
media. Viability and cell counts were maintained to ensure consistent growth, morphology and 
preparation for experiments. Photographs of cell cultures demonstrating cell morphology and 
count were taken using a Nikon Eclipse TS100 microscope with 40X magnification.  
 
2.4.16. Cell counts 
Cells were counted manually with a Nikon Eclipse TS100 microscope using trypan blue 
exclusion. After trypsinisation and washing of cells with media, 10ul cell media suspension was 
added to 10ul 0.4% trypan blue (Life Technologies, Australia) and mixed thoroughly before 
adding onto a Blaubrand haemocytometer (Sigma Aldrich, Australia) to calculate cell 
concentration. Trypan blue is a dye which can enter cells with disrupted cell membrane 
integrity. Dead or nonviable cells are stained by the dye, appearing dark blue and are excluded 
for the live cell count. Cells were counted in four squares of the haemocytometer according to 
the manufacturer’s instructions. Average cell count per square was calculated and multiplied 
by the dilution factors used to report cell counts per millilitre. 
 
2.4.17. Testing cell lines for Mycoplasma contamination 
Following an in-house protocol, both cell lines were tested for Mycoplasma contamination 
before use. Briefly, 2 x 106 cells were extracted after growth in antibiotic free media for two 
days. DNA was extracted using QIAamp (Qiagen, Australia) DNA extraction method followed 
by PCR using specific primers (Table 2-2) for amplification of Mycoplasma DNA (M. argini, 
M. hominis, M. hyorhinis, M. fermentans and M. pharynges) if present. Cell lines must be tested 
before use to ensure results are not influenced by metabolic products of Mycoplasma. Extracted 
DNA was diluted to 40 ng/ul for Mycoplasma PCR, and added to PCR Master Mixes 
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(Invitrogen) including the forward and reverse primers for Mycoplasma testing 
(LeedmanMyco) and positive internal controls (Human Growth Hormone; HGH) (Table 2-3). 
These underwent PCR (Biorad C1000 Thermal Cycler, Australia) with conditions as outlined 
in Table 2-4. Samples and controls were tested in duplicated, and products confirmed as 
Mycoplasma contaminated or uncontaminated by gel electrophoresis. 
 
Table 2-2. Primer sequences for PCR reactions. 
Primer Name Primer Sequence 
LeedmanMycoF 
(forward) 
5`- GGG AGC AAA CAG GAT TAG ATA CCC T-3` 
LeedmanMycoR 
(reverse) 
5`- TGC ACC ATC TGT CTC TCT GTT AAC CTC- 3’ 
HGH (forward)  5`-TAT CCC AAA GGA ACA GAA GTA TTC ATT-3` 
HGH (reverse) 5`-TGT TTG TGT TTC CTC CCT GTT GGA-3` 
 
Table 2-3. Reagent concentrations for PCR reactions 
Rxn: reaction 
 
Reagent Initial concentration Final concentration x1 rxn volumes (µL) 
PCR buffer 10x 1x 2 
MgCl2 50 mM 3 mM 1.2 
dNTP 10 mM each 0.25 mM 0.5 
Forward 
primer 
10 µM 0.25 mM 0.5 
Reverse 
primer 
10 µM 0.25 mM 0.5 
Platnium Taq 5 Units/µL 0.025 Units 0.1 
Water    13.2 
DNA 40 ng/µL 80 ng 2 
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Table 2-4. PCR temperature cycle 
Cycle  Temperature Time 
Pre-cycle 95°C 5 minutes 
 
Cycle (40x) 
95°C 15 seconds 
55°C 15 seconds 
72°C 15 seconds 
Post cycle 15°C ∞ 
 
2.4.18. Effect of MS serum on cell cultures 
Cells were cultured in 24 well Nunc plates (Thermo Scientific, Australia) with MO3.13 or SH-
SY5Y cell media, with or without acute MS pooled serum (n=3 from Table 2-1[1-3]) in 
triplicate. Plates were incubated at 37°C, 5% CO2. One of the identically cultured wells was 
analysed at 6, 24 and 48 hours. Cells were washed with PBS, trypsinized and counted. Manual 
viability was determined using the method from 2.4.16.  
 
2.5. Statistical analysis 
Comparisons between cases and controls of HLA risk groups and positivity of samples from 
the commercial and in-house ELISA were carried out using Pearson’s Chi-squared tests or 
Fisher exact tests as appropriate. ELISA OD values were analysed on the log (base 10) scale to 
normalize data, with analyses based on multiple linear regression models/ANOVA, with 
dummy group covariates as applicable. OD values exceeding the upper limit of measurement 
(OD 4.0) were incorporated via normal-based censored linear regression. Case-control logistic 
regression was used to assess the joint influence of VCA, EBNA-1, EBNA-1(398-413) IgG and 
subclasses and EBNA-1(398-413 CIT) antibody levels, as well as gender, age and HLA-DR results 
on MS disease risk. Cell viability was also analysed using a logistic regression to look for 
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interaction between time points and serum addition. Analyses were carried out using the TIBCO 
Spotfire S+ ver 8.2 statistical package (TIBCO Software Inc., Palo Alto, California) by 
Professor Ian James. 
 
2.6. Ethics statement 
The study protocol was approved by the Sir Charles Gairdner Hospital Human Research Ethics 
Committee, and informed consent was obtained from all participants in the PDDD cohort. 
Approval for use of control samples was provided by the Busselton Population Medical 
Research Institute ethics committee as well as the Red Cross. The conduction of experiments 
in this thesis using human samples was approved by the Murdoch University Ethics Committee, 


































The automation of immunological assays, PCR reactions and HLA typing has been rigorously 
developed by the Institute for Immunology & Infectious Diseases (IIID) at Murdoch University. 
Automation enables standardization of volume transfer, as well as mixing and tracking of 
samples through large batch handling of serialized protocols. Automation on robots at IIID 
utilizes the in-house developed sample tracking program EpiLab. Each sample registered is 
given a unique medical record number (UMRN) which is used instead of a patient’s name. To 
distinguish between different specimens and samples from different collection dates for the 
same patient, each sample additionally receives a unique “Base ID”, from which samples and 
their volumes can be tracked through different protocols. To optimize pipetting on Beckman 
Coulter robots, the BioMek software is used. The program gives a visual representation of the 
deck layout used on the machine and allows alterations of many different variables, including 
depth and movement of pipettes, based on lab-ware such as plates or reservoirs. Both EpiLab 
and BioMek software use comma separated values files (.csv) for tracking of samples and 
reagents as well as volume identification. Layouts of EpiLab, BioMek software and pipette 
controls are protocolled in detail in Supplementary Figures S-2, S-3 and S-4. 
 
The Enzyme-Linked Immunosorbent Assay (ELISA) is a fundamental tool in immunological 
research, and can provide quantitative information on the presence of cytokines, chemokines, 
molecules or antigen-specific proteins such as antibodies in serum, plasma or supernatant. Final 
results of the assay are dependent on a number of technical variables that may impact precision 
if not highly standardized between operators. Large studies often require performance of 
multiple manual ELISAs which is labour intensive, includes many manual handling steps and 
is subject to data and sample integrity failure as well as prone to large inter-operator variability. 
To overcome these difficulties, the ELISA work performed in this thesis, automated 
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performance of the ELISAs was chosen and included standardized plate coating, sample 




3.2.1. Determination of ideal sample dilution in the commercial EBNA-1 ELISA  
Each commercial ELISA was tested according to the manufacturer’s instructions, with provided 
calibrators (pooled human sera; 5, 20, 110 and 200 Arbitrary Units (AU)/ mL) in duplicate, 
which were used to create a linear standard curve (Figure 3-1). Averages and standard 
deviations for the calibrators of the commercial ELISAs are summarized in Table 3-1. The 
manual stated that a sample is considered ‘positive’ if the optical density (OD) reading is above 
the highest calibrator, but gives no instructions on how to determine the definitive quantity of 
antibodies in the sample. Samples can only be quantitatively measured if they fall within the 
“linear” measuring range of the assay. The standard procedure for quantitating samples above 
the linear standard curve range is to further dilute samples so the OD of the sample lies within 
the linear range. Absolute concentrations are then calculated and corrected for the dilution 
factor. However, this calculation assumes the standard curve continues to be linear above an 
OD reading of the highest calibrator in the commercial ELISA. Upon performing the suggested 
1/100 dilution of 87 MS patient serum samples, 63% and 75% MS samples had OD values too 
high and out of the linear measuring range for both the EBNA-1 and the VCA ELISAs, 
respectively.  
 
To serve as the internal control (IC) for all assays, an MS patient serum sample was aliquoted 
and stored at -80°C until further use. For each assay performed, one fresh aliquot was thawed 
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and serially diluted 1.4-fold (1/280 to 1/2108). When tested on the commercial ELISA, these 
serial dilutions resulted in OD values that were not linear, but closely fitted a power curve 
defined by the equation y=121.01x-0.881 (R2 = 0.997) (Figure 3-2; Averages and Standard 
deviations in Table 3-2). Additionally, serially diluted aliquots from other MS patients were 
also tested using the same approach, with each producing different slopes (Figure 3-3). We 
concluded that due to the differences in the power curve slopes, different dilution factors could 
not be adequately compared from one sample to another as the curves showed different 
behaviours, and thus could not be compared or expressed as a function (Table 3-3). Taking this 
into account, a plate of samples in two different dilutions was made in order to determine the 
ideal dilution for the majority of samples. Dilution at 1:1075 gave the best results within the 
linear range of the assay and the majority of samples have values above the lower cut-off 
(specific to each assay) and below the maximum OD (4.0). For subsequent statistical analysis, 
OD values were transformed (log base 10) to normalize data distribution. Furthermore, the 
serially diluted IC was additionally used to determine the inter-assay variability between 
different plates (Supplementary Table S-3) 
 
Sample dilutions were performed in a magMAX Express Microtiter 96 Deep Well Plate (Life 
Technologies) by diluting 2.8µl of  serum with 1536.6µl sample diluent (1/548), followed by 
serial 1.4-fold dilutions to reach 1/1075. The BioMek FXP had a limited pipetting volume of 
500µl, so dilutions 1/768 & 1/1075 required a two-step dilution process: 
i) 874µl (2 x 437µl) in 1223.6µl 
ii) 723µl (2 x 361.5µl) in 1012.2µl 
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Figure 3-1. Variability of linear standard curve between 12 commercial EBNA-1 ELISAs. 
Linear standard curve of the four anti-EBNA-1 ELISA calibrators (given in arbitrary units 
(AU): 5, 20, 110 & 200 AU/ mL) measured as optical density (OD) in 12 separate commercial 




Table 3-1. Optical Density (OD) Average and Standard Deviation of Commercial 
Calibrators for EBNA-1 and VCA ELISAs (n=12). 







5 0.056 0.005 0.041 0.012 
20 0.192 0.014 0.190 0.036 
110 1.266 0.053 1.611 0.122 
200 2.285 0.102 2.738 0.156 
 AU: Arbitrary units. EBNA-1: Epstein-Barr Virus. VCA: Viral capsid antigen. 
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Figure 3-2. Power curve and inter-assay variability of diluted internal control between 12 
commercial EBNA-1 ELISAs. Error bars show mean Optical Density (OD)450nm ± standard 
deviation of diluted internal control. 
 
 
Table 3-2. Optical Density (OD) Average and Standard Deviation of in-house control 
serially diluted on commercial EBNA-1 ELISA (n=12). 
Dilution Average Standard Deviation 
1/280 0.820 0.037 
1/392 0.619 0.032 
1/548.8 0.478 0.025 
1/768.32 0.372 0.024 
1/1075.648 0.262 0.012 
1/1505.907 0.190 0.011 
1/2108.27 0.139 0.010 





Figure 3-3. Three samples serially diluted tested with the commercial EBNA-1(long) 
ELISA resulting in different power curves. 1.4 fold-serial dilutions of two individual 
Multiple Sclerosis samples and the internal control sample result curves with different slopes 
when tested with the commercial EBNA-1 ELISA. 
 
 
Table 3-3. Non-linear correlation between two serially diluted MS samples (from Figure 
3-3) and the optical density (OD) values from the commercial EBNA-1 ELISA. 
 Dilution Factor 548 768 1075 1505 
MS Sample 1 OD (450nm) 0.213 0.142 0.099 0.070 
 Difference Ratio Factor - 1.50 1.44 1.41 
MS Sample 2 OD (450nm) 0.594 0.435 0.288 0.230 
 Difference Ratio Factor - 1.37 1.51 1.25 
MS: Multiple Sclerosis. OD: Optical Density. EBNA-1: Epstein-Barr Virus Nuclear Antigen-1. 
ELISA: Enzyme Linked Immunosorbent Assay. 
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3.2.2. Validation of mixing in automated samples 
To assure thorough mixing of samples during the dilution process, three aliquots of the IC in 
duplicate for consistency of results. Samples were serially diluted 1.4-fold (starting with an 
initial dilution of 1/548). Sample dilutions were mixed on an orbital shaker (30 seconds, 
1300rpm) on a BioMek FXP robot, between each dilution step. For analysis, samples were 
measured for each dilution against the in-house EBNA-1(398-413) peptide (Figure 3-4) with 
averages and standard deviations summarized in Table 3-4. The intra-assay variation of the IC 
for the in-house ELISA was determined to be low (absolute range) and lie between 4.8-23%. 
 
 
Figure 3-4. Low intra-assay variability of three individual aliquots of internal control 
diluted and measured in duplicate, using the anti-EBNA-1(398-413) in-house ELISA. Error 




Table 3-4. The Average optical density (OD450-620nm) and standard deviations of three 
aliquots of internal control, diluted and measured in duplicate, using the anti-
EBNA-1(398-413) in-house ELISA 
Dilution Average Standard Deviation %CV 
1/549 1.38 0.07 4.8 
1/768 1.00 0.12 12.17 
1/1076 0.74 0.10 12.92 
1/2108 0.56 0.08 14.97 
1/2952 0.39 0.05 12.2 
1/4132 0.28 0.04 16.02 
1/5785 0.19 0.05 23.46 
1/8099 0.15 0.01 9.91 
























The quantitation of analytes is beneficial to human health through establishing normal ranges 
and then comparing with patient cohorts. This can help identify immune environmental changes 
(such as an increase of pro-inflammatory cytokines) reflective of immune responses. ELISAs 
continue to be used in a range of immunological applications for large scale epidemiological 
studies (580) and can be a powerful tool in translational science, as shown for autoantibody 
detection in RA (630). Benefits of ELISAs include the independence of radioactive materials, 
which are required for radio-immunoassays, heightened sensitivity in antigen and antibody 
detection, when compared to older historical methods such as agglutination or 
immunoelectrophoresis, configuration for a range of different immune targets- and they are 
generally more cost effective. Ongoing improvement of the quality and utility of ELISA 
performance as high-throughput assays is increasingly important for studying large patient 
cohorts. In this chapter we presented a successful and configurable automated system for the 
performance on an ELISA, incorporating robotics for liquid handling. Limitations of this 
process include the requirement of “dead volume” of reagents to ensure adequate volume 
transfer. This means that there is slight waste for some reagents if they cannot be re-used, which 
additionally reinforces the benefit of combining multiple assays to minimize waste. Benefits of 
automation include equal reagent use estimation, minimizing the complication of high 
variability at lower reagent concentrations, reflecting inherent variability of biological assays 
(631), further compounded by small volumes of patient serum for serial dilutions. Additionally, 
standardization of assay performance and data security ensured through electronic tracking 
records of sample transfer and assay results reduced human error in reporting results. Thus, all 
samples and reagents can be tracked with quality assurance, which is particularly useful for 










4. Investigating antibody response against lytic (VCA) and latent 













MS is a multifactorial disease involving host and environmental risk factors. The strongest 
genetic contributor is HLA-DR alleles (184, 192), although genetic factors explain less than a 
third of overall variance (632). Set against this genetic background, EBV infection appears to 
be an important, and perhaps necessary, step towards the development of MS later in life (559). 
Epidemiological studies highlighted MS association with IM (456, 457), and many studies have 
investigated the MS association with serological markers of previous EBV infection in 
retrospective (567, 633) and prospective studies (341, 545, 565, 574), as well as subsequent 
meta-analysis (527, 559). Factors including genetics, smoking (269, 568), and vitamin D (580) 
have been investigated as potential additive or masking risks for EBV antibody responses, with 
varied levels of interaction reported between publications. A majority of studies, which 
measured anti-EBNA-1 responses, found significant differences between MS patients and 
healthy/control cohorts. In addition, anti-EBNA-1 antibodies have been implicated as a 
diagnostic hallmark of MS with identification of oligoclonal band formation in cerebrospinal 
fluid (CSF) samples (478, 572) and EBNA-1 specific effector CD4+ T cells capable of cross-
reacting with myelin antigens (480). Additionally, Sundström and colleagues (198) found 
significantly elevated antibodies against a short section of EBNA-1(385-420), an association that 
was not seen in other overlapping fragments of EBNA-1. This finding has been replicated in 
studies, which also examined association with HLA (166) and vitamin D levels (580). Mechelli 
et al. (582) investigated antibody responses against EBNA-1 in MS discordant identical twins, 
where they found elevated antibody responses against a B cell epitope (aa401-411 
GRRPFFHPVGE, p=0.006) in the C terminus of EBNA-1 only in affected MS individuals. This 
B cell epitope is targeted during IM (579), is not HLA restricted, and the study found no 
association of antibody response against it with smoking or IM history. Additionally, this 
epitope shares homology with αßC (RRPFF), a candidate autoantigen in MS (634). 
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Interestingly, Csuka et al. (581) found no significance when measuring IgG antibodies against 
a partially overlapping epitope EBNA-1(398-404), in MS patients (n=135), suggesting amino acids 
in position 401-411 are essential. The aim of our study presented in this chapter was to 
investigate the influence of both poly-specific and epitope-specific anti-EBNA1 and VCA 
antibodies for MS risk, in a well-characterized Western Australian MS cohort. The following 
questions were addressed in this chapter: 
1. Are there differences in antibody responses against EBNA-1, VCA or EBNA-1(398-413), 
both in terms of prevalence of detectable responses and antibody titres between MS 
patients and controls? 
2. Are these antibody responses different when grouped according to gender, age or HLA 
risk status? 
3. Do any of the values correlate with each other, specifically as epitope specific 
EBNA-1(398-413) responses are part of the polyclonal anti-EBNA-1 response? 
4. Could these factors contribute to a logistic regression model to determine factors 










4.2.1. Study cohort  
As expected, the MS cohort was enriched for females compared to the healthy cohort (p<0.001; 
Table 4-1). The cohorts were well-matched for average age within the different sexes: male 
cases 49.6 years (SD 11.3), controls 50.8 years (SD 17.7); and female cases 48.3 years (SD 
12.0), compared to controls 49.8 years (SD 17.0); overall p=0.4.  
 
Table 4-1. Demographics of study cohorts. 
 Healthy Controls MS Patients P value 
Number of individuals 186 426 - 
Gender (M/F) 95/91 100/326 p<0.001 
Average Age (mean, SD) 50 (17.5) 48.6 (11.8) 0.4 
MS= Multiple Sclerosis, M=male, F=female. 
 
4.2.2. HLA-DR allele distribution in cases and controls 
We recently determined HLA-DRB1 risk profiles in this cohort, identifying a high-risk group 
(DRB1*08/*15/*16) as well as protective group/low risk alleles (DRB1*04/*07/*09) (184). 
Accordingly, cases and controls were classified as “high-risk” if they carried any alleles from 
the high-risk group, “low-risk” if they carried any protective alleles and no high-risk alleles, or 
“neutral” if both alleles were outside these groups. Individuals with high-risk HLA-DR alleles 
were more prevalent among MS cases (odds ratio (OR) 2.40, p=0.0009), and low-risk 
individuals were less frequent (OR 0.43, p=0.0013), compared with the remaining “neutral” 
group (Figure 4-1). There was no significant difference in mean ages across the high risk (48.8), 
neutral (48.5) and low-risk (49.9) groups (p=0.5). 
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Figure 4-1. Proportion of high, neutral and low risk HLA alleles in MS and control 
cohorts. HLA: Human Leukocyte Antigen. MS: Multiple Sclerosis. ns: non-significant 
(p>0.05). 
 
4.2.3. Polyspecific EBNA-1 and VCA antibodies in cases and controls 
The commercial assays were validated using a serially diluted positive IC (see Chapter 3), 
which had a low inter-assay variability of 4.4-6.3% for EBNA-1 and 5.3-7.7% for VCA. 
Significantly more MS individuals had positive (above cut off) values for anti-EBNA-1 IgG 
antibodies (99.3% vs. 85.5% of healthy controls; p<10-11) and anti-VCA IgG antibodies (100% 
compared to 90.3% of healthy controls; p<10-10) (Figure 4-2). The three MS and 27 healthy 
control serum samples that were initially anti-EBNA-1 negative were tested at a lower dilution 
(1/100) in order to detect low positive samples. Re-testing of samples resulted in 100% EBV 
ELISA positivity of MS samples and additional positivity of 15 samples of the 27 healthy 
controls. When cohorts were combined, there was no significant difference overall in levels of 
anti-EBNA-1 IgG for males and females (mean difference (MD) 0.044 (Standard Error (SE) 
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0.041); p > 0.3). Importantly, MS cases had significantly higher mean anti-EBNA-1 levels (MD 
0.058 (SE 0.042); p < 10-15, Figure 4-3B) than healthy controls.  
 
This was also true for anti-VCA IgG titres, where the values in MS cases were higher compared 
to controls (MD 0.35 (SE 0.035); p <10-15, Figure 4-3A), but they were also higher in females 
compared to males (MD 0.13 (SE 0.034); p= 0.0001). After adjusting for case/control groups, 
EBNA-1 antibody levels were significantly increased in the “high-risk” HLA-DR group relative 
to the “low-risk” group (MD 0.17 (SE 0.045); p=0.0001, Figure 4-3E). Levels in the “neutral” 
group were marginally higher than the “low-risk” group (MD 0.11 (SE 0.055); p=0.05). There 
was also no significant difference between antibody levels in the “high-risk” and “neutral” 
groups (p=0.22). Differences between cases and controls remained highly significant after 
adjustment for the influence of HLA-DR effects (MD 0.54 (SE 0.042); p<10-15, Figure 4-3E), 
with again no significant difference in EBNA-1 titres in males and females (p=0.24). This was 
in contrast to observations of anti-VCA antibody levels, with no significant difference between 
the low and high risk groups (p=0.09), but values were slightly lower in the neutral group 
compared to the high and low HLA-DR risk groups (Figure 4-3D).  
 
Interestingly, higher EBNA-1 antibody levels were associated with younger age among females 
(p=0.0009) while values were higher among older males (p=0.02), as illustrated in Figure 4-4. 
For VCA there was no significant change over age for females (p=0.56), while again for males, 
values increased with age (p=0.0001). There was no significant difference in the linear slopes 
among cases and controls (p>0.3). 
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4.2.4. Epitope-specific EBNA-1(398-413) antibodies in cases and controls 
We developed and optimised a novel in-house ELISA assay to detect IgG antibodies directed 
against a previously identified EBNA-1 epitope (166, 480). To confirm the relevance of this 
epitope sequence in vivo, 45 MS samples were successfully amplified and sequenced covering 
the 16 amino acids of the EBNA-1 epitope PPPGRRPFFHPVGEAD (amino acid code in 
Supplementary Table S-2). Of these, 40 sequences were completely conserved with a further 
five samples showing variation at amino acid positions G13 A/V and E14 Q/D/G of EBNA-1. 
 
MS serum samples showed 97.9% positivity against this short peptide, compared with 77.4% 
healthy controls (p<10-14), and as shown in Figure 4-2, with ELISA titres significantly higher 
among MS cases compared with controls (Figure 4-3C, p<10-15). There was no detectable 
influence of HLA-DR profiles on epitope-specific EBNA-1(398-413) antibody levels in controls 
(p=0.98, Figure 4-3F), although levels were slightly higher among the high risk group for the 
MS cases (p=0.0008). For IgG reactivity against EBNA-1(398-413), there was no significant 
influence of gender (p=0.25, Figure 4-3C) or age (p=0.22, Figure 4-4). Examining correlations 
between these two anti-EBNA-1 antibody assays, we observed consistently higher epitope-
specific antibody levels in cases compared to controls across all anti-EBNA-1 values (p<10-15) 
as shown in Figure 4-5. There were no significant differences in the slopes between cases and 
controls (p=0.3) nor between sexes (p=0.9). Inter-assay variability of serially diluted IC for this 
assay was 21.4-25.4%. Additionally, all ELISAs were compared for number of cases and 
controls that reached maximum optical density (OD 4.0), and while no healthy control samples 
reached the maximum on any assay, less than 1% of MS cases measured OD 4.0 for EBNA-1 
or VCA, but 6.8%  of cases reached maximum OD for EBNA-1(398-413)
 (Table 4-2). 
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Figure 4-2. Proportions of positive samples tested by ELISA in Multiple Sclerosis (MS) 
and healthy control cohorts. VCA: viral capsid antigen. EBNA-1: Epstein-Barr Virus Nuclear 
Antigen-1. The MS cohort had significantly more positive anti-EBV antibodies tested by all 
three assays. Dotted lines above the bars for EBNA-1 show the percentage of samples which 
tested positive at a lower dilution, showing MS patients were universally EBV positive. 
 
 
Table 4-2. Number of samples that reached maximum saturation optical density (OD) for 
anti-EBV ELISAs. 
 Number of samples with maximum OD (4.0) 
Assays Healthy Controls 
(n=186) 
MS cases (n=426) 
EBNA-1 0 2 
VCA 0 4 
EBNA-1(398-413) 0 29 
 
87 
Figure 4-3.  ELISA results for two cohorts stratified by gender and according to HLA-
DRB1 allele variation. Serum levels (log10 optical density (OD)) of anti-VCA, anti-EBNA-1 
and anti-EBNA-1(398-413) IgG from Multiple Sclerosis (MS; red) cases and healthy controls 
(Cont; blue) compared by gender (A-C) and HLA-DRB1 risk alleles (D-F). M: male; F: female. 
VCA: viral capsid antigen. EBNA-1: Epstein-Barr Virus Nuclear Antigen-1. MS: Multiple 
Sclerosis. 
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Figure 4-4. Gender separated correlations of ELISA values and age for Multiple Sclerosis 
(MS) and Busselton controls. Correlations between age and serum levels (log10 OD) of anti-
VCA, anti-EBNA-1 and anti-EBNA-1(398-413) IgG from MS cases (A-C) and Busselton controls 
(D-F), plotted by gender. There was no difference in slopes between cases and controls 
(p>0.05). Higher EBNA-1 IgG were associated with younger age in females (p=0.0009) while 
values were higher among older males (p=0.02). No change in VCA levels over age for females 
(p=0.56), while increased in age for males (p=0.0001). No association was seen for age and 
anti-EBNA-1(398-413) IgG. Overall, there was no significant difference in the linear slopes among 







Figure 4-5. Correlation of two anti-EBNA-1 antibody assays: EBNA-1 and EBNA-1(398-413) 
targeting polyclonal versus epitope-specific antibodies. Correlation between anti-EBNA-1 









4.2.5. Logistic regression and receiver-operating characteristic (ROC) curve 
analyses using predictive models for MS risk 
Beginning with a predictive model based on our previous study (184), case-control logistic 
regression analyses described in Table 4-3 demonstrate the independent effects of high-risk 
HLA-DR alleles (adjusted OR 2.40, p=0.0009) and protective HLA-DR alleles (adjusted OR 
0.43, p=0.0013) as well as female gender (adjusted OR 3.57, p=1.7×10-10). Following 
incorporation of the significant and independent influences of anti-EBNA-1 values (adjusted 
OR 6.76 per unit log increase, p=1.8×10-14) and anti-VCA values (adjusted OR 4.96 per unit 
log increase, p=6.3×10-7) in a second model, the influence of high-risk HLA-DR alleles was no 
longer significant (adjusted OR 1.40, p=0.26) although the effects of protective HLA-DR alleles 
(adjusted OR 0.42, p=0.0061) and female gender (adjusted OR 2.63, p=3.5×10-5) were 
preserved. Finally, in a third model which included the addition of significant EBNA-1(398-413) 
values (adjusted OR 3.47 per unit log increase, p=1.7×10-9) significance of anti-EBNA-1 values 
(OR 3.17, p=3.0×10-5), anti-VCA values (OR 4.30, p=2.3×10-5) as well as protective HLA-DR 
alleles (OR 0.38, p=0.003) were maintained, but the effect of the high-risk HLA-DR group (OR 
1.26, p=0.47) had decreased further. The improvements in predictive ability of the successive 
models are evident from the receiver-operating characteristic (ROC) curves shown in Figure 4-
6 based on the linear-logistic model scores. The final model here is defined by: 2.62 - 
0.975(HLA-DRlow-risk) + 0.23(HLA-DRhigh-risk) - 1.0(Male) + 1.46×logVCA + 1.15×logEBNA-
1 + 1.24×logEBNA-1(398-413). For this model the area under the curve (C-statistic) is 0.885 (95% 
confidence interval 0.853-0.911), providing a sensitivity of 394/426=92% and specificity of 
119/186=64% at a cut-off logistic value of 0 (OR 21.9). These results identify that including 
commercial anti-EBNA-1 and anti-VCA ELISA values abrogate high risk HLA-DRB1 alleles 
as a risk factor, as does the addition of in-house anti-EBNA-1(398-413) ELISA values. 
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Table 4-3. Analysis of genetic and serological MS risk factors using progressive logistic 
regressions. 
 Model 1 Model 2 Model 3 
 Odds 
Ratio 
P value Odds 
Ratio 





2.40 0.0009 1.40 0.26 1.26 0.47 
HLA-DR Low 
risk group 
0.43 0.0013 0.42 0.0061 0.38 0.003 
Gender (Female) 3.57 1.7×10-10 2.63 3.5×10-5 2.73 4.0×10-5 
EBNA-1 
(commercial) 
OD values (log) 
  6.76 1.8×10-14 3.17 3.0×10-5 
VCA 
(commercial) 
OD values (log) 
  4.96 6.3 x 10-7 4.30 2.3 x 10-5 
EBNA-1(398-413) 
OD values (log) 
    3.47 1.7 x 10-9 
Logistic regressions for significance of MS risk factors identified previously by this group (184) 





Figure 4-6. Receiver operating characteristic curve for logistic scores including HLA-
DRB1 risk alleles, gender and ELISA values. Receiver operating characteristic curves 
demonstrate the additional predictive power of including results from the commercial anti-
EBNA-1, anti-VCA and additionally the in-house EBNA-1(398-413) ELISA compared to the 






This is the first EBV-specific serological examination performed using a Western Australian 
MS cohort as well as using population-based controls, and indeed one of the few based in 
Australia, with the majority of MS research in the past years coming from Tasmanian groups 
(259) and Queensland (496). It is also the first population-based study to confirm the specific 
association between antibody responses directed against a putative B-cell epitope 
EBNA-1(398-413) and MS risk (166, 582). Both cohorts are largely of European descent, so 
epidemiological and serological studies may provide insight into the environmental component 
of MS risk and development in a Southern Hemisphere environment. The MS cohort here was 
significantly enriched for females at an approximately 3:1 ratio, similar to the global prevalence 
by gender, however the underlying causative factor for higher risk of MS in females remains 
unknown.  
 
Utilizing EBNA-1 and VCA specific ELISAs differentiates between latent (past) and lytic 
(recurrent) infection. Seropositivity for VCA was higher than expected, with almost universal 
detectable titres in both cohorts, suggesting recurrent lytic infection or a very strong humoural 
response against VCA in primary infection. The universal seropositivity for EBNA-1 was 
expected for MS, and seropositivity in 90% of controls fits well within the range reported in 
other serological studies (449), postulating that EBV infection may be a requirement of MS 
development. Investigating how many MS patients had IM would be interesting, in particular 
whether associations seen in American and European studies are also relevant for an Australian 
cohort. A significant difference for positivity between MS and controls was also detected for 
EBNA-1(398-413), despite the fact that serological responses were not universally positive among 
MS cases. Higher antibody titres against EBNA-1, VCA and EBNA-1(398-413) support an EBV-
responsive immune environment in MS patients.  This study also showed greater statistical 
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significance against the EBNA-1(398-413) epitope than that seen in previous MS studies 
investigating antibodies specific for other EBNA-1 regions, such as EBNA-1(385-420) (198), 
EBNA-1(402-502) (198, 580) and EBNA-1(398-404) (581). Although most of these studies (shown 
in Figure 4-7) were significant, this study aimed to identify the minimal epitope necessary to 
reach significance in a large cohort. The significance found suggests that the B cell epitope 
EBNA-1(398-413), and not just partial regions, is important in MS immune responses.  
 
Figure 4-7. Review of published studies using overlapping epitopes for EBNA-1 (C’ 
terminus) ELISAs. aThis study of EBNA-1(398-413) (blue line) compared to other published 
studies. bRed indicates non-significant IgG reactivity (581), while black had significant findings 
c(198), d(198, 580), e(572). EBNA-1: Epstein Barr Virus Nuclear Antigen-1.  
 
Multiple trends were identified when grouping cases and controls by HLA, gender and age. 
Elevated anti-EBNA-1 and anti-VCA IgG titres were shown in the “high-risk” HLA group and 
MS patient compared to controls. Antibody levels against VCA were higher in females (also 
reported by Mouhieddine et al (301)) and older men, and while no significant difference was 
detected for anti-EBNA-1 IgG between genders, higher levels were found in younger women 
and older men. It is interesting that we found highly significant influences of age and gender 
on both EBNA-1 and VCA IgG antibody levels in this study, which would indicate that both 
values have increased among females relative to males over calendar time – among both cases 
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and controls. This is intriguing in light of epidemiological evidence that the ratio of females to 
males with MS has steadily increased in recent decades (111), although any causal association 
is speculative at present. Unlike anti-EBNA-1 antibodies, anti-EBNA-1(398-413) antibodies were 
not influenced by HLA-DR genotypes, gender or age – which may in part explain why they 
remain significantly associated with MS risk even when comparing identical twins (582). This 
also supports the contention that this EBNA-1 domain is a true B-cell epitope, in keeping with 
previous studies that demonstrated prominent although transient epitope-specific responses 
during acute IM (580) as well as dominant epitope-specific anti-EBNA-1 IgG antibodies in 
healthy controls as well as patients with EBV associated nasopharyngeal carcinoma (635). As 
observed in previous studies (480, 528, 559, 565, 636), polyclonal anti-EBNA-1 antibody levels 
that can be measured using commercial ELISA techniques are significantly higher and are 
highly significantly associated with MS risk. This appears to reflect disease predisposition, 
given evidence that higher anti-EBNA-1 antibody levels can be observed years before disease 
onset (565), and remain stably elevated both before and after the onset of clinically isolated 
demyelinating syndromes (636). Higher anti-EBNA-1 antibody levels have also been 
associated with increased clinical and radiological features of disease activity beyond the initial 
demyelinating event (489, 576), although longitudinal anti-EBNA-1 serological profiles have 
not been assessed in relation to MS disease progression. In this context, it is notable that a recent 
genome-wide study of determinants of quantitative anti-EBNA-1 antibody levels (406) has 
identified a large heritable component (~43%) with a much smaller influence of local 
environment (~4%). Moreover, significant genetic associations were located almost exclusively 
within the HLA region (406), in keeping with our observations that anti-EBNA-1 antibody 
levels were associated with HLA-DR alleles in both cases and controls.  
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There was a significant correlation between polyclonal antibody titres against EBNA-1 and the 
shorter version of anti-EBNA-1(398-413), with significant, consistently higher EBNA-1(398-413) 
antibody levels in cases to controls across all anti-EBNA-1 values. When comparing the 
correlated values, there was no significant difference between cohorts or gender, suggesting 
lack of preferential targeting. However, the consistently “higher titres” of EBNA-1(398-413) in 
both cohorts (comparative to EBNA-1) was surprising as it may be reasonable to expect that 
antibody levels against a small epitope within EBNA-1 would be lower than the polyclonal 
response against EBNA-1. Accordingly, this may be due to the sensitivity and/or target of the 
commercial and in-house ELISAs. The commercial ELISA company could not disclose which 
EBNA-1 targets were used in their antigen pre-coated plates, or how the antigens were 
produced. Commercially available EBNA-1 proteins often remove the glycine-alanine repeat 
from the protein due to cross-reactivity, and if used in the commercial ELISA, could exclude 
the beginning section of EBNA-1(398-413), explaining differences in reactivity. Several factors 
including post-translational modifications and whether the EBV targets were produced in cell 
lines could affect antibody reactivity through epitope conformation. Additionally, the 
commercial assays used different reagents to the in-house ELISA, which may contribute to 
different sensitivities, as well as polyclonal antibodies possibly competing for the same target 
epitope rather than accumulating in their response. 
 
This study extends our previous observation that groups of HLA-DR alleles provide both high-
risk and protective influences on MS risk (184), with evidence that the ability to discriminate 
MS cases and controls can be substantially enhanced by the inclusion of quantitative measures 
of serological responses specific for Epstein-Barr virus infection. The association of MS and 
EBNA-1(398-413) was statistically highly significant, and independent of the broader influence of 
anti-EBNA-1 antibodies, so that in our final logistic regression model each of these serological 
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measures contributed greater than 3-fold increased adjusted OR per unit increase in log10 OD 
value (Table 4-2). Incorporating the combined effects of HLA-DR genotyping and quantitative 
anti-Epstein-Barr virus antibody levels provides for a final logistic score that performs 
remarkably well in terms of diagnostic sensitivity and specificity, as shown in Figure 4-6, given 
that neither of these parameters has any direct association with the neurological features of MS. 
Previous studies have identified statistical interactions between HLA-DRB1*15 and anti-
EBNA-1 antibody levels (166) or history of EBV-associated IM (458, 637), suggesting that 
these risk factors may share a common pathway in disease susceptibility. Our data would 
support this view, particularly the finding that the strong independent effect of high-risk HLA-
DR alleles (model 1, p=0.0009) on MS risk (Table 4-4) was substantially abrogated after 
incorporation of the influence of anti-EBNA-1 antibody levels (model 2, (EBNA-1(long), 
p=1.8×10-14; high-risk HLA-DR alleles, p=0.26). These results require cautious interpretation 
when considering that this cohort has served a ‘discovery’ dataset, and it is clear from other 
studies that have estimated the influence of genetic risk factors in MS (632) that the 
classification sensitivity and specificity will typically be lower when examined in a validation 
dataset. Ideally, to test the robustness of the risk model analysis, the in-house ELISA would be 
validated on a separate MS cohort, either from Australia or the Northern Hemisphere. This 
could be of use for other studies of MS cohorts to utilize grouping of HLA-DR risk alleles and 
to incorporate anti-EBNA-1 antibody responses. Nevertheless, it is interesting that our own 
estimates of the influence of HLA-DR genotypes closely match those identified by another 
study (632). The discriminatory capacity of our final model, with a sensitivity of 92%, 
specificity of 64% and an overall odds ratio of 21.9 for a logistic score greater than zero, 
certainly argues for the relevance of Epstein-Barr virus-specific immunity in MS pathogenesis, 
as well as for the potential development of diagnostic and treatment strategies that specifically 
target this aspect of disease susceptibility. Limitations of this study include the commercial 
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assays providing arbitrary calibrators for quantifying antibody levels. Additionally, the 
manufacturer suggestion of diluting all samples 1/100 results in a majority of samples reaching 
maximum OD and requiring re-testing. This study combated the limitation by finding the 
dilution 1/1075 for most samples to fall within the linear range of the assay (Figure 4-2 and 
Table 4-2), where few samples reach maximum OD (Table 4-2) and re-testing of negative 
samples showed a minor increase of seropositivity (Figure 4-2). Our anti-EBNA-1(398-413) 
ELISA had the highest number of cases reaching maximum OD, however this should reflect 
the sensitivity of the in-house assay.  
 
4.4. Summary 
Results from this study suggest that in addition to the significant role of HLA-DR risk alleles, 
the ability to discriminate MS cases from controls can be substantially enhanced by the 
inclusion of quantitative measures of the serological response to Epstein-Barr Virus infection. 
Specifically, MS patients had significantly higher IgG antibody responses against both EBNA-1 
and VCA. When further investigating IgG antibody responses against EBNA-1, epitope 
responses against a short EBNA-1(398-413) epitope were additionally elevated in MS patients 
compared to controls. Importantly, the MS cohort proved to be universally positive for previous 
EBV infection compared to 90% of controls. Unlike antibody response against EBNA-1, the 
anti-EBNA-1(398-413) antibodies were not influenced by HLA-DR genotypes, gender or age, 
which may in part explain why they remain significantly associated with MS risk even when 
comparing identical twins (582). Incorporating the combined effects of HLA-DR genotyping 
and quantitative anti-EBV IgG antibody levels provides a final logistic score that performs 
remarkably well in terms of diagnostic sensitivity and specificity, given that neither of these 









5. Citrullination in MS pathogenesis: antibody responses against a 













5.1.1. Chemical process of citrullination 
Citrullination is a post-translational process in which arginine is converted to the non-standard 
amino acid citrulline (638). This deimination is facilitated by the enzyme family 
peptidylarginine deiminase (PAD) (639) as shown in Figure 5-1. It has been shown that the 
change in charge alters the secondary and tertiary structure of the protein (640, 641) and is 
implicated in controlling and altering gene expression (642, 643), but the openness of protein 
structure can make it more susceptible to enzymatic proteolysis. 
 
 
Figure 5-1. Process of citrullination. Unedited from (644). 
 
5.1.2. Citrullination in autoimmune diseases 
Citrullination has been documented in other neurological disorders including Alzheimer’s and 
Creutzfeldt–Jakob disease (645, 646) but most prominently in RA, where anti-citrullinated 
autoantibodies have provided strong diagnostic value and are commonly used in clinical 
practice (647). In RA, antibodies specific for citrullinated EBNA-1(35-85) showed diagnostic 
specificity of 98.5% and correlated with other disease-specific antibodies against fibrinogen in 
a recent study (648). Elevated antibodies against EBNA-1 have also been reported (649), and 
protein citrullination alters the protein presentation by HLA-DR molecules (650, 651) and 
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subsequent T cell responses (170, 179, 652, 653). Also in RA, single nucleotide polymorphisms 
(SNPs) have been reported that can cause increased expression of PAD genes, causing more 
citrullination (654).  
 
5.1.3. Citrullination in MS 
Citrullination can target multiple proteins including MBP, glial fibrillary acidic protein 
(GFAP), nuclear proteins and members of the CXC chemokine family (655-658), which play a 
role in immune cell recruitment and migration into the CNS. MBP is a component of myelin 
that sheaths and protects nerves in the brain and spinal cord, is heavily citrullinated in children, 
but decreases over years of brain development. The enrichment of citrullinated MBP and GFAP 
(659) in MS brain lesions raises the possibility that this modified autoantigen could be a 
candidate target. Citrullination of MBP causes its open structure to be degraded more easily by 
Cathepsin D (639, 660, 661), which can be produced by macrophages and reactive astrocytes 
(498, 662). Susceptibility to degradation is correlated to the amount of citrulline within the 
MBP (641, 660, 661). Citrullination causes partial unfolding, leading to less tight packing of 
myelin sheaths and therefore to destabilization (663-665). This could potentially lead to 
exposure of additional epitopes, subsequently targeted by cross-reactive immune cells (641, 
666). Bradford et al. (659) suggested citrullination could occur by cell death (extracellularly) 
or during myelin degradation from phagocytosis (intracellularly). Numerous studies have 
investigated citrullination of myelin and neural proteins in humans and mouse models (Table 
5-1), but no reports to date have investigated correlation of citrullination levels or immune 
responses to citrulline and MS HLA risk markers. In MS cases, levels of citrullination and 
antibodies against citrullinated MBP are elevated (667). It is currently under debate whether 
immune responses to these citrullinated MBP epitopes could explain Th1 polarization 
(increased inflammatory cytokine production) in MS patients (668) or whether the 
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modifications of a usually identified ‘self-peptide’ allows presentation of new epitopes to the 
immune system (667). These concepts need to incorporate the fact that citrulline and antibodies 
targeting modified proteins occur naturally within a healthy immune repertoire (669), as do 
MBP-reactive T cells (246, 670). However, the gradual and consistent change in auto-reactivity 
regulation could develop into an immune reactivity leading to pathologic conditions (671, 672). 
 
 
Table 5-1. Summary of investigations on citrullination in human and Experimental 
Autoimmune Encephalomyelitis (EAE) models of MS. 
Human Mouse (EAE) model 
↑ Citrulline protein in brain matter (673-
680) 
↑ Citrullinated MBP in brain matter (673, 
674, 677, 678) 
↑ PAD4 (675, 677) 
↑ PAD2 (674) 
↑ Nuclear histone citrullination (675) 
↑ Citrullinated GFAP in SPMS than other 
neurological disorders (OND) (681, 682) 
↑ Proteinases  in MS CSF (683) 
↑IgG, IgM & IgA against MBP, MOG 
and/or αß-C. Adding these antibodies to 
lymphocytes caused blast formation and 
pro-inflammatory cytokines. (684) 
Anti-citrullinated MBP antibody response 
predicts CIS conversion to MS (667, 685) 
↑ Citrullination in post mortem brain  (675, 
676, 680) 
↑ PAD2 and PAD4 in synovial and brain tissue 
(642, 675) 
↑ Citrullinated GFAP in EAE than OND (681, 
682) 
MBP and GFAP citrullinated in MOG-induced 
EAE (681) 
PAD2 K/O mice citrullinated MBP with PAD4 
(686) 
Hypercitrullination of CNS proteins, 
correlating to demyelination in EAE (680) 
Citrulline proteins highest in relapse phase of 
EAE, compared to acute-phase; increased 
citrulline associated with myelination during 
development of CNS (660) 
↑ PAD2 expression had more severe course 
(687)  
MBP: myelin basic protein. PAD: peptidylarginine deiminase. K/O: knockout. GFAP: glial 
fibrillary protein. SPMS: secondary progressive MS. OND: other neurological disorders. MOG: 
myelin oligodendrocytic protein. CIS: clinically isolated symptoms. 
 
5.1.4. Viral target citrullination and role in MS 
The diagnostic value of antibodies against citrullinated proteins has demonstrated importance 
and value in RA (688). Although understanding the role of citrullination of MBP and its 
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consequences in disease pathogenesis is important, our work is focused on the persistent and 
potentially damaging immune responses to latent EBV infection. Notably, the B cell epitope 
EBNA-1(398-413) discussed in Chapter 4 shares homology (aa 405-9) with alpha beta crystalline 
(αß-C; Table 5-2), a small heat shock protein which is also an autoantigen candidate for MS.  
 
Table 5-2. Amino acid sequence comparison of ELISA peptides. 
Peptide Amino acid sequences 
EBNA-1(398-413) 
aa398PPPGRRPFFHPVGEADaa413 
EBNA-1(398-413 CIT)       PPPGCitCitPFFHPVGEAD 
Alpha Beta Crystallin (ɑßC)                 RRPFF 
Homology shared between EBNA-1 epitope and ɑßC underlined. 
 
Antibodies against αß-C are part of a healthy immune repertoire but have also been shown to 
accumulate in the oligodendrocyte-myelin unit in early MS lesions (689). αß-C protein has been 
identified in MS CSF (690), and associated with other neurological disorders (691-693). αß-C 
was originally detected in optical lenses but has since been also identified in kidneys, heart, 
skeletal tissue and CNS (600, 690, 691, 694-697), but not in spleen, liver or lymphoid tissue 
(600, 691, 695-697). However, Bruno et al (698) did report αß-C in lymphoid tissue, and this 
tissue has also been reported to contain MBP (699). Stoevring et al (690) suggested αß-C 
produced by oligodendrocytes is incorporated extracellularly into myelin sheaths, accessible to 
be presented by the MHC class II pathway, leading to an inflammatory CD4+ T cell response.  
So far it is unclear whether this pathway is MS-specific as the protein and antibodies are present 
in healthy individuals also without causing comparable symptoms. Our study aims to identify 
whether antibody responses can be measured against a citrullinated form of the EBNA-1(398-413) 
peptide, and if so how this contributes to the MS risk model described in Chapter 4.   
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In order to address the influence of citrullination of EBNA-1(398-413) as a risk factor in MS, the 
study described in this chapter used the same serum samples from diagnosed MS patients from 
the Perth Demyelinating Disease Database (PDDD) and control cohort from the Busselton 
Study as described in Chapter 4. The following questions were addressed in this chapter: 
1. Are there any differences for antibody responses, in terms of positivity and titres, for 
EBNA-1(398-413 CIT) seen between MS cases and healthy controls? 
2. Do these values differ according to gender, age or HLA risk status? 
3. What is the correlation between anti-EBNA-1(398-413) and its citrullinated version 
EBNA-1(398-413 CIT)? 
4. Could incorporation of antibody levels against the citrullinated version of 












5.2.1. Epitope-specific anti-EBNA-1(398-413 CIT) antibodies in cases and controls 
Among MS serum samples, 82.8% were found to have positive antibody responses against 
EBNA-1(398-413 CIT), compared with 40.3% of healthy controls (p<0.00005), and as shown in 
Figure 5-2, ELISA titres were significantly higher among MS cases compared with controls 
(p<0.00005). There was no detectable influence of HLA-DR profiles (Figure 5-3), gender or 
age on epitope-specific EBNA-1 antibody levels in controls or MS samples (p>0.3). Seven MS 
samples and no healthy controls reached the maximum optical density (OD 4.0) using the 
EBNA-1(398-413 CIT) ELISA (Table 5-3). A correlation can be seen for IgG antibodies against 
citrullinated and uncitrullinated targets in both cohorts (Figure 5-4), but a trend is more apparent 
through reviewing IgG levels as a ratio of EBNA-1(398-413 CIT)/EBNA-1(398-413) compared with 
EBNA-1(398-413) (Figure 5-5). Here, both cohorts show EBNA-1(398-413 CIT) antibody levels 
proportional to anti-EBNA-1(398-413), with EBNA-1(398-413 CIT) values rarely being higher than 
antibodies against the uncitrullinated epitope. For the few samples that had comparatively 
higher EBNA-1(398-413 CIT) values, the proportion of these samples were significantly higher in 
the MS cohort (Table 5-4, p<0.05). Inter-assay variability of serially diluted IC for this 
citrullinated target ELISA assay was comparable to the uncitrullinated ELISA ranging from 
20.9 to 28.1%. 
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Figure 5-2. Seropositivity of samples against EBNA-1(398-413 CIT), compared to past 
ELISAs. VCA: viral capsid antigen. EBNA-1: Epstein-Barr Virus Nuclear Antigen-1. MS: 
Multiple Sclerosis. The MS cohort had significantly more positive anti-EBV antibodies tested 




Figure 5-3.  Anti-EBNA-1(398-413 CIT) IgG levels between cohorts stratified by HLA-DRB1 
allele variation. Serum levels (log10 OD) from MS (red) cases and healthy controls (blue). MS 
anti-EBNA-1(398-413 CIT) IgG are significantly higher compared to controls for each HLA risk 
group (low, neutral and high), but no significant difference was seen between the HLA risk 
groups for either cohort.  
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Table 5-3. Number of samples that reached maximum saturation optical density (OD) for 
anti-EBNA-1 in-house ELISAs. 
 Number of samples with maximum OD (4.0) 
Assays Healthy Controls 
(n=186) 
MS cases (n=426) 
EBNA-1(398-413 ) 0 29 
EBNA-1(398-413 CIT) 0 7 
The seven MS samples that measured maximum OD for EBNA-1(398-413 CIT)
 were also maximum 






Figure 5-4. Correlation of optical density (OD) reflecting EBNA-1(398-413) and 
EBNA-1(398-413 CIT) specific IgG levels. Both MS cases (red) and healthy controls (blue) show 
moderate correlation between assays. Anti-EBNA-1(398-413 CIT)
 IgG levels in all samples appear 
to consistently have a smaller OD than anti-EBNA-1(398-413) IgG, with increased variability of 




Figure 5-5. Ratio of EBNA-1(398-413 CIT)/EBNA-1(398-413) to EBNA-1(398-413) from epitope-
specific antibody assays. MS cases (red) and healthy controls (blue) show a maintained ratio 
between cases and controls for comparing antibody levels on the two assays. Both cohorts show 
a majority of samples have EBNA-1(398-413 CIT) levels proportional to EBNA-1(398-413).   
 
Table 5-4. Number of samples with higher antibodies against EBNA-1(398-413 CIT) than 
EBNA-1(398-413). 
Number of samples with EBNA-1(398-413 CIT) > EBNA-1(398-413) 
Healthy Controls (n=186) MS cases (n=426)  
p<0.05 2 (1%) 20 (4.7%) 
A larger proportion of MS samples had higher EBNA-1(398-413 CIT)
 values compared to 
EBNA-1(398-413) ELISA. 
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5.2.2. Logistic regression and receiver-operating characteristic curve analyses 
As previously described within Chapter 4, measurement of EBNA-1-specific IgG antibody 
levels significantly improved the ROC curve in case-control logistic regression. Model 4 (Table 
5-5) included the addition of significant EBNA-1(398-413 CIT) values (adjusted OR 1.74 per unit 
log increase, p=1.59×10-3) which slightly reduced but maintained the significant influence of 
anti-EBNA-1(long) values (OR 2.92, p=1.42 x 10
-4), anti-VCA values (OR 4.26, p=3.19×10-5) as 
well as protective HLA-DR alleles (OR 0.40, p=5.60×10-3). However, as with the inclusion of 
EBNA-1(398-413) in Model 3, the high-risk HLA-DR group remained non-significant (OR 1.42, 
p=0.47). The inclusion of EBNA-1(398-413 CIT) significantly contributed to the model, however 
the addition was shown to decrease the significance of EBNA-1(398-413). Therefore, the addition 
of this anti-EBNA-1(398-413 CIT) assay shows minimal contribution to improving the overall 
logistic regression model, as evident from the ROC curves shown in Figure 5-6 based on the 
linear-logistic model scores. With the addition of the citrullinated EBNA-1 peptide ELISA, the 
final model is defined by 2.90 - 0.922(HLA-DRlow-risk) + 0.35(HLA-DR(high-risk) – 0.99(Male) + 
1.45×logVCA + 1.07×logEBNA(long) + 0.79×logEBNA(398-413) + 0.55×logEBNA(398-413 CIT).  
This model provides a sensitivity of 391/426=92% and specificity of 121/186=65% at a cut-off 
logistic value of 0 (OR 20.8). This, in fact, reduces the discrimination capability in model 3 







Table 5-5. Analysis of genetic and serological Multiple Sclerosis risk factors using 
progressive logistic regression models. 
 Model 2 Model 3 Model 4 
 Odds 
Ratio 
P value Odds 
Ratio 





1.40 0.26 1.26 0.47 1.42 0.29 
HLA-DR Low 
risk group 
0.42 0.0061 0.38 0.003 0.40 5.60 x 10-3 
Gender (Female) 2.63 3.5×10-5 2.73 4.0×10-5 0.37 6.04 x 10-5 
EBNA-1(long) 
OD values (log) 
6.76 1.8×10-14 3.17 3.0×10-5 2.92 1.42 x 10-4 
VCA OD values 
(log) 
4.96 6.3 x 10-7 4.30 2.3 x 10-5 4.26 3.19 x 10-5 
EBNA-1(398-413) 
OD values (log) 
  3.47 1.7 x 10-9 2.20 1.62 x 10-3 
EBNA-1(398-413 CIT) 
OD values (log) 
    1.74 6.4 x 10-3 
Logistic regression models for MS risk factors identified previously by this group including 




Figure 5-6. Receiver operating characteristic (ROC) curve for logistic scores including 
HLA-DRB1 risk alleles, gender and ELISA values. Receiver operating characteristic curves 
demonstrate the additional predictive power of including results from the commercial anti-
EBNA-1(long), anti-VCA and additionally the in-house EBNA-1(398-413) and EBNA-1(398-413 CIT) 





The recognition of citrullinated proteins by autoantibodies has been well-documented as a 
diagnostic utility in RA, and although some studies have reported citrullinated MBP as a target 
in MS (673, 674, 677, 678), there are currently no reports in regard to an antibody response to 
a citrullinated target, as utilized diagnostically in RA. This study is the first to review a 
citrullinated version of a latent EBV epitope as a target for immune response in MS. As 
described previously, serological studies on Australian MS cohorts have been limited over the 
past decades, in comparison to the research occurring across Europe and North America.  
 
This study determined that serological measures of IgG antibodies specific for 
EBNA-1(398-413 CIT) peptide were independently associated with MS risk, with seropositivity and 
antibody titres significantly increased in cases to controls. However, despite MS cases having 
higher mean antibody levels, there was no association with gender, HLA risk groups or age, as 
seen for uncitrullinated EBNA-1(398-413). Correlations of citrullinated and uncitrullinated 
EBNA-1(398-413) IgG levels (if not titrated to define an endpoint) suggest that both MS cases and 
healthy control individuals have antibodies against the citrullinated epitope at an equal or higher 
level than against the non-citrullinated form. This was surprising as the logged EBNA-1(398-413 
CIT) IgG levels were significantly higher in the MS cohort, and literature suggests an increased 
citrullinated response in MS. The citrullinated response may also reflect a pro-inflammatory 
environment of the individual. Additionally, in the logistic regression model, inclusion of the 
EBNA-1(398-413 CIT) values reduced the significance of the EBNA-1(398-413) antibody levels in MS 
risk. If this immune response is independent of these factors, it may be reflective of a more pro-
inflammatory environment in MS patients, rather than a specific targeted immune response, as 
seen in EBNA-1.  
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It has been identified that PAD is able to localize to the nucleus, making citrullination of the 
EBNA-1 protein possible (675). However, past studies focusing on immune responses to αß-C 
(700), found increased responses to this protein in MS cases. Sundqvist and colleagues (166) 
suggested from data by Steinmann et al (701) showed that MS patients have a strong T cell 
mediated autoimmunity towards αß-C, and that it could be possible that high anti-EBNA1 
antibody levels might lead to increased autoimmunity against αβC, thereby increasing 
inflammation. A further question is whether the antibodies measured were specific for what 
could be a citrullinated version of EBNA-1, or a citrullinated version of the αβC protein, as a 
form of cross-reactivity, which could imply autoantibodies produced in the CNS later circulate 
in the periphery. Vossenaar et al (702) postulated that attributes of citrullinated proteins 
contribute to immune responses in multiple ways including increased PAD expression, more 
successful presentation of citrullinated protein by dendritic cells, plasma cells making 
antibodies against the citrullinated protein and the citrullinated protein-bound IgG antibodies 
potentially binding with higher affinity to Fcϒ receptors of macrophages.  
 
Despite the less significant results for citrullinated-targeted antibody responses compared to the 
uncitrullinated form of EBNA-1(398-413), further research into citrullination is warranted. 
Potential studies could include modelling citrullinated forms of the epitopes to see if high-risk 
HLA alleles present the citrullinated forms more efficiently than the non-citrullinated epitopes, 
as seen in RA (650), measuring PAD enzyme expression in blood, brain and CSF, and 
identifying whether anti-EBNA-1(398-413 CIT) antibodies increase or decrease over time in relation 
to disease progression. It has been shown that patients with more progressive MS forms have 
increased citrulline residues in the brain, and higher citrullination of MBP could occur by 
increased PAD2 synthesis, which could be affected by promoter methylation (674).  Identifying 
these citrullinated targets and their mechanisms of control, could help elucidate whether 
114 
citrullination is a cause, by-product or result of MS pathogenesis, which may lead to more 
targeted therapeutic strategies.   
 
5.4. Summary 
Results from this study suggest that MS patients have higher antibody levels specific for EBNA-
1(398-413 CIT). A strong correlation was also seen between EBNA-1(398-413)
 and EBNA-1(398-413 CIT). 
Targeting citrullinated forms of the epitope may only be seen in a subset of patients, and an 
elevated IgG antibody response to the citrullinated form is not seen unless there is an equally 
high EBNA-1(398-413) IgG antibody response. Including EBNA-1(398-413 CIT) into a logistic 
regression is statistically significant, but when reviewed with other demographic and 
serological values, these values don’t provide a significant improvement of the risk model, as 
seen in the ROC curve. The regression model suggests that the measurement of antibodies 
directed against citrullinated EBNA-1 does not have the same diagnostic values as seen in RA. 
However, citrullination is still an important process which occurs in MS and seems to be 































6.1.1. Immunoglobulin gamma subclasses and their role in immunity 
Sixty percent of total immunoglobulins in plasma are immunoglobulin gamma (IgG). These 
antibodies are most important in secondary antibody responses against infection, as part of 
immunologic memory, and the adaptive immune system. While IgM antibodies are the first to 
appear following viral infection (Figure 1-9), maturation of early IgM antibody responses is 
driven by repeated contact of B cells with a cognate antigen and cytokine stimulation of the 
immunoglobulin. This results in switching of the heavy chain, producing different antibody 
isotypes and subclasses (703), including IgG. IgG against EBV are detectable 3-6 weeks post-
infection, and persists at relatively constant levels for life. Following antigen-binding, IgG has 
three major effector functions: activation of the complement cascade, opsonisation and fixation 
(Figure 6-1). Their main role is not to destroy foreign bodies or infected cells, but rather to ‘tag’ 
them for destruction by other immune cells. This communication is elicited by the pathogen-
bound IgG antibodies binding to Fcɣ receptors, which are present on surfaces of macrophages, 
neutrophils and NK cells. The combination of antibody-mediated immunity show that IgG is 
often the first line in defence against an influx of antigen or infected cells, such as the lytic 
phase or ‘reactivation’ in which replication of EBV takes place. 
 
IgG is composed of four subclasses (IgG1, 2, 3 and 4) which exist in different quantities in a 
healthy adult immune system (Table 6-1) dependent on the B cell environment (704) and 
differentiate by structure of the hinge region. Each subclass can be increased by stimulation 
from certain antigens, with IgG1 and IgG3 predominantly targeting presented viral antigens, 
IgG2 targeting mostly lipid polysaccharides while IgG4 has been suggested to have a role in 
tolerance to allergens and responses to certain infectious agents (705, 706). IgG binding of 
antigen often induces an effector cell response such as phagocytosis, degranulation, antibody-
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dependent cell-mediated cytotoxicity (ADCC), inflammatory cytokine production and mediates 
activation of mast cells, monocytes and macrophages (707-709). This can in part be attributed 
to high and low affinity Fcɣ receptors present on immune cells which can bind to IgG subclasses 
with different strength (710). As IgG antibody subclasses differ in these abilities (Table 6-1), 
their biological functions are subclass-specific and can be associated with disease outcome 




Figure 6-1. The multi-functional effector role of IgG antibodies. Adapted from (713). IgG 
antibodies act to identify foreign targets (antigens) and elicit an immune response through 
complement or by effector cells (aNatural killer cells/ neutrophils). mAb: monoclonal 









Table 6-1. Summary of Immunoglobulin gamma (IgG) subclass contribution to total IgG 
and comparative function. 
 IgG1 IgG2 IgG3 IgG4 
Mean adult serum level 
(g/l) 
6.98 3.8 0.51 0.56 
Relative Abundance (%) 60 32 4 4 
Complement activation ++ + +++ - 
Opsonization +++ +/- ++ + 
Phagocyte binding + - + +/- 
Sensitization for killing by 
NK cells (ADCC) 
+ - + - 
Adapted from (714, 715). ADCC: Antibody-Dependent Cell-mediated Cytotoxicity. 
 
6.1.2. EBV IgG subclass prevalence in MS 
The presence of IgG antibodies within OCB in CSF is a hallmark of MS diagnosis, and IgG as 
well as complement have been found in MS lesions (542). The IgG OCB have been found to 
be reactive against EBNA-1 (478). The abnormal presence of antibodies and B cell clones in 
CSF and lesions, respectively, may suggest a pathogenic role in the disease (707). Past studies 
have investigated IgG subclasses of OCB, to help identify the microenvironment within the 
CNS. IgG1 and IgG3 have been reported as elevated in MS CSF  (716, 717), and Grimaldi et 
al. (718) identified that six of ten MS patients with IgG1 OCBs showed additional reactivity 
against IgG3 or IgG4, suggesting a “microheterogeneous” composition. Greve et al (704) and 
Di Pauli et al. (707) reported higher IgG1 in CSF of MS patients compared to healthy controls 
and other neurological disorders, respectively. Neither study reported any difference in total 
IgG, IgG1, IgG2 or IgG3 in serum. However, both studies supported that elevated IgG1 and 
IgG3 reflect “type 1 immunity”, a response caused by IFNɣ-induced antibody isotype switching 
for IgG subclasses (719). Additionally, Torkildsen et al reviewed that increased expression of 
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IgG-binding Fcɣ receptors has been identified in MS lesions (540) and reported Fcɣ receptor 
polymorphisms associated with MS, but this has not been confirmed in other studies so far 
(720-723).  
 
One of the theories behind MS pathogenesis is molecular mimicry between viral (such as EBV) 
and self-peptides, and so levels of IgG subclasses specific for autoantigen or viral targets have 
also been investigated. Egg et al. (724) reported that MS relapse patients were more often anti-
myelin oligodendrocyte glycoprotein (MOG) and anti-MBP IgG3 positive than those in 
remission, and identified reduced anti-MOG IgG3 titres in patients treated with intravenous 
immunoglobulin (Ig) or interferon-beta. They found IgG1>IgG2>IgG3 but no IgG4 against 
MOG, with IgG1 significantly associated with IgG3. The group did suggest that IgG2 responds, 
in a T cell independent manner, to carbohydrates, which could be targeted during myelin 
destruction, but levels would be higher in lesions than in circulation.  Wakiguchi et al (725) 
found only elevated EBV-specific IgG1 in the serum of chronic EBV infection paediatric cases, 
whereas in MS adult cases, Lünemann et al. (480) reported non-significant differences for anti-
EBV lysate IgG1 compared to healthy controls. However, Lünemann’s group did identify 
elevated EBNA-1(458-641)-specific IgG1 in MS CSF compared to controls, with no significance 
for IgG2 or IgG4. They did not detect any anti-EBNA-1 IgG3 in MS cases or controls. More 
recently, Cepok et al. (478) found that the oligoclonal IgG in MS CSF were cross-reactive for 
EBNA-1 protein, a potential molecular mimicry target. Obtaining CSF samples is difficult, but 
measuring circulating antibodies could contribute to understanding ongoing demyelination due 
to MS OCB in CSF being potentially attributed to a dysfunctional BBB (572). To date, anti-
EBV subclass data has only been collected from small cohorts. The importance of IgG 
subclasses is that in addition to measuring antibody response against a viral target, subclass 
specificity can characterize the immune response. 
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To examine the IgG subclass responses in MS, the study described in this chapter used samples 
from the previously identified cohorts of MS patients and healthy controls (Busselton Study). 
Given the available samples, the following questions were addressed in this chapter: 
1. Are there differences in antibody response, positivity and titres, against EBNA-1(398-413) 
specific IgG1, IgG2 and/or IgG3 subclasses between the two cohorts? 
2. Are results influences by gender, age or HLA risk status? 
3. What is the correlation of subclass antibodies and EBNA-1(398-413) IgGTotal from Chapter 
4? 












6.2.1. Anti-EBNA-1(398-413) IgG1, IgG2 and IgG3 in cases and controls 
In contrast to previous studies measuring mainly IgG subclasses against entire EBV proteins, 
we focused with our analysis on IgG subclasses against a very small section of EBNA-1. A 
surprisingly small proportion of samples had detectable anti-EBNA-1(398-413) IgG subclass 
levels by our in-house ELISAs (Figure 6-2), with the highest positive proportion being IgG1 
(42% for MS, 28% controls; p<0.01). IgG2 was only positive in very few samples from either 
cohort, but significantly more samples were above the lower cut off in the MS group (8% MS, 
3% controls; p<0.05) and no significant differences were observed for IgG3 positivity between 
cohorts (3% MS, 5% controls, p>0.05). Only 25 of the 426 MS patients were positive for more 
than one subclass against EBNA-1(398-413), with the majority of those positive for IgG1+2 
(n=19), next to IgG1+IgG3 (n=2), IgG2+IgG3 (n=1) and IgG1+IgG2+IgG3 (n=2). Although 
numbers were small, MS samples had a significantly higher mean titre for IgG1 (p<0.05) and 
IgG3 (p<0.05), but not for IgG2 (p=0.3). Furthermore, there was no detectable influence of 
HLA-DR profiles, gender or age on subclass epitope-specific EBNA-1 antibody levels in 
controls or MS samples (p>0.3). After adjusting for MS/control effects, log10 (IgGTotal levels) 
were positively associated with IgG1 (p=0.0002), IgG2 (p=7.8 x 10-16) and IgG3 (p=0.035). 
When considered jointly, IgG3 lost significance after adjusting for IgG1 and IgG2 (p=0.2), 
while IgG1 (p=0.01) and IgG2 (p=1.3 x 10-14) were independently associated with IgGTotal. 
Therefore, IgG2 appears to have the dominant association, while IgG1 is still strongly 




Figure 6-2. Seropositivity of anti-EBNA-1(398-413) IgG subclasses in MS and control 
cohorts. Percentage of positive samples between MS (n=427; red) and controls (n=186; blue) 
for EBNA-1(398-413) IgG subclass ELISAs. MS had significantly more positive samples for both 










Figure 6-3.  ELISA results for both cohorts split by IgG subclass. Serum anti-
EBNA-1(398-413) IgG1, IgG2 and IgG3 OD450nm from MS (red) and healthy controls (HC; blue). 
MS is significantly higher than controls for IgG1 and IgG2 (**p<0.05), but no significant 







Figure 6-4. Correlation of anti-EBNA-1(398-413) total IgG and EBNA-1(398-413) IgG1. MS 
(red) had consistently higher IgG1 values than healthy controls (blue). Samples can only reach 
















6.2.2. Logistic regression and receiver-operating characteristic curve analyses 
Adjusting for risk factors (HLA, previous commercial and in-house ELISA data) and gender, 
anti-EBNA-1(398-413) IgG1 (p=0.005), IgG2 (0.027) and IgG3 (p=0.029) were independently 
significant risk factors. IgG1 and IgG2 were positively associated with MS cases while IgG3 
was negatively associated. As demonstrated in Table 6-2 (Model 5), inclusion of EBNA-1, 
VCA and EBNA-1(398-413) resulted in abrogated IgG1 and IgG2 effects (p=0.8, p=0.53 
respectively), while IgG3 remained significant (p=0.008) for reducing risk. Inclusion of the IgG 
subclass values did not abrogate effects of VCA, EBNA-1 or EBNA-1(398-413). Similar results 
were seen when results for EBNA-1(398-413) were omitted, with EBNA-1 and VCA values 
abrogating IgG1 and IgG2. This model shows significance for protective (low risk) HLA-DR 
alleles (OR 0.39, p=0.0043) but there was no significant association for high risk HLA-DR 
alleles (p=0.31), similar to the inclusion of EBV-specific ELISA results described in Chapter 
4. Despite significance of IgG3, addition of the assay results show minimal contribution to 
improving the logistic regression, as evident from the ROC curves shown in Figure 6-5 based 
on the linear-logistic model scores. With the addition of values for anti-EBNA-1(398-413) IgG 
subclasses, the final model was defined by 1.90 - 0.942(HLA-DRlow-risk) + 0.34(HLA-DR(high-
risk) – 0.96(Male) + 1.54×logVCA + 1.25×logEBNA(long) + 1.24×logEBNA(398-413) – 
0.05×logEBNA(IgG1) – 0.58×logEBNA(IgG2) –0.1.83×logEBNA(IgG3).  This model provided a 
sensitivity of 391/426=92% and specificity of 121/186=65% at a cut-off logistic value of 0 
(OR 20.8). However, this, in fact, reduces the discrimination capability in model 3, previously 






Table 6-2. Analysis of genetic and serological MS risk factors using progressive logistic 
regressions. 
 Model 2 Model 3 Model 5 
 Odds 
Ratio 
P value Odds 
Ratio 





1.40 0.26 1.26 0.47 1.39 0.31 
HLA-DR Low 
risk group 
0.42 0.0061 0.38 0.003 0.39 0.0043 
Gender 
(Female) 
2.63 3.5×10-5 2.73 4.0×10-5 2.62 9.5×10-5 
EBNA-1(long) 
OD (log) 
6.76 1.8×10-14 3.17 3.0×10-5 3.49 1.2×10-5 
VCA 
OD values (log) 
4.96 6.3×10-7 4.30 2.3×10-5 4.69 1.2×10-5 
EBNA-1(398-413) 
OD (log) 
  3.47 1.7×10-9 3.46 4.8×10-9 
EBNA-1(398-413) 
IgG1 OD (log) 
    0.95 0.79 
EBNA-1(398-413) 
IgG2 OD (log) 
    0.55 0.53 
EBNA-1(398-413) 
IgG3 OD (log) 
    0.16 0.0078 
Logistic regressions for significance of MS risk factors identified previously by this group 
including commercial ELISA values (Model 2), EBNA-1(398-413) results (Model 3) and EBNA-
1(398-413)-specific IgG subclasses (Model 5). EBNA-1(398-413)-specific IgG1 and IgG2 did not 




Figure 6-5. Receiver operating characteristic curve for logistic scores including HLA-
DRB1 risk alleles, gender and ELISA values. ROC curves demonstrate the additional 
predictive power of including results from the commercial anti-EBNA-1(long), anti-VCA and 
additionally the in-house EBNA-1(398-413) and EBNA-1(398-413) subclass ELISA, compared to the 











Defining levels of total and antigen-specific IgG subclasses is important due to their different 
affinities for antigen targets and biological functions. This chapter reviewed an in-house assay 
to quantitate the amount of EBNA-1(398-413)-specific antibodies within the subclasses of IgG1, 
IgG2 and IgG3 using the automated ELISA protocol from Chapters 3 and 4. It was originally 
expected that anti-EBNA-1(398-413) IgG1 would be the most prevalent in all samples positive for 
IgGTotal against this epitope, but this was not seen. A majority of patients and controls had non-
detectable IgG subclass levels, which was unexpected considering almost all individuals were 
positive for EBNA-1(398-413) IgGTotal. It was also surprising that more than one subclass was only 
detected in a minority of “positive” samples. It is possible that the secondary IgG subclass 
antibodies, which were purchases from a different company, were less sensitive than the total 
IgG secondary antibody, which would mean more individuals were positive for anti-
EBNA-1(398-413) subclasses, but were below the detection limit of the assay. On the other hand, 
it cannot be excluded that quantitative differences in detection occurred due to different 
chemical binding specificities of the IgG2 antibodies, such as IgGTotal and IgG2 targeted the Fc 
portion of patient antibodies, while IgG1 and IgG3 targeted the hinge region (Figure 6-1).  
 
To date, the only MS-associated EBV-specific subclass research that has been reported is from 
Lünemann et al. (480) who measured all four subclasses against EBNA-1 protein excluding the 
glycine-alanine region. His group found significantly higher anti-EBNA-1 IgG1 in MS patients 
compared to controls, and detected no IgG3 in MS or control cohorts and also detected anti-
EBNA-1 IgG4 in a subset of patients. Our own study did not measure IgG4 due the lack of 
evidence in the literature that would indicate diagnostic or pathogenic role for IgG4 antibodies 
in MS. Nonetheless, our study did find significant differences in IgG3 levels between cohorts, 
which was not identified in the Lünemann study (480), despite their EBNA-1 protein being a 
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larger target and identifying polyclonal antibodies compared to our short EBNA-1(398-413) 
peptide. However, Lünemann’s cohorts were small- with only 20 MS patients and 16 EBV-
positive controls. We could show for the first time that IgG3 against EBNA-1(398-413) is 
detectable, but may require larger cohorts as less than 10% of either group in our study had 
detectable anti-EBNA-1(398-413) IgG3 levels. This conclusion could also be drawn regarding 
significant differences in positivity but not titre for anti-EBNA-1(398-413) IgG2 in this study. Our 
study supports Lünemann’s findings of elevated IgG1 against EBNA-1, with significantly 
higher titres and more IgG1-positive individuals in the MS cohort. This is important because 
IgG1 significance is maintained despite using a much smaller portion of EBNA-1 as a target. 
Overall, IgG1 elevation could indicate a ‘type 1 immunity’ response in MS patients. The most 
interesting finding from this study was that IgG3 elevated levels were detected more often in 
healthy controls, and indeed proved statistically significant in reducing MS predisposition in 
our risk model. This is surprising as IgG3 and IgG1 were both previously associated with the 
“type 1 immunity” (704). Vidarsson et al. reviewed that IgG3 and IgG1 are both expected in 
response to viral infections, and IgG3 is expected first in the course of infection (714). It may 
be possible that IgG3 reflects early detection and control of EBV, while IgG1 is elevated in 
individuals with sustained EBV reactivation.  
 
Similar to the total IgG against EBNA-1(398-413) in chapter 4, none of the subclass IgG data was 
significantly associated with HLA risk status, gender or age. This would support the earlier 
conclusions that the peptide is a true B-cell-epitope, but considering the small number of 
positive samples, a control cohort should be tested to validate this finding. IgG1 and IgG2 were 
independently associated with IgGTotal, but it should again be noted that these associations are 
made with quite small sample sizes for the IgG subclass data. In a risk model, each subclass 
was independently significant as a risk factor, and interestingly IgG3 had a negative association 
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with MS risk. When commercial and IgGTotal against EBNA-1(398-413) values were included, only 
IgG3 remained significant, and subclass data had no effect on the other ELISA findings. 
Addition of IgG subclasses in the model resulted in the logistic regression reducing 
discrimination capability. Therefore, these results do not support significant benefit from 
including anti-EBNA-1(398-413) IgG subclass ELISAs in a validation cohort due to the large 
proportion of samples with no detectable levels, and instead focus on the functional properties 
of these antibodies would appear more beneficial. Additionally, for future research it would be 
interesting to investigate Fcɣ receptor expression in this cohort to compare with subclass data, 
despite conflicting literature, as identifying a functional link between IgG antibodies and Fcɣ 
receptor expressing cells in MS CNS would be beneficial to understanding the significance of 
these elevated anti-EBNA-1 antibodies in MS. Lastly, the large cohort could be utilized to study 
as Wuhrer et al. (726) suggested glycosylation of IgG subclass changes are associated with 
inducing antigen-specific immune responses (727). 
 
6.4. Summary 
Results from this study suggest that MS patients have higher IgG1 and IgG2 levels specific for 
EBNA-1(398-413), however a majority of samples were seronegative for each IgG subclass tested. 
IgG1, IgG2 and IgG3 were positively and independently associated with IgGTotal against 
EBNA-1(398-413), but when combined, only IgG1 and IgG2 remained significant. No association 
could be observed for any of the subclasses with HLA risk alleles, gender or age. Including 
these factors into a logistic regression model showed that IgG1 and IgG2 were not significant, 
but IgG3 was statistically significant, contributing a lower risk for MS, yet not improving the 
risk model, as seen in the ROC curve. Our results presented in this chapter suggest a mainly 









7. Whole serum and anti-EBNA-1(398-413) IgG cross-reactivity with 
brain antigens tested by protein macroarray, and in vitro effect 











7.1. Introduction  
7.1.1. Cross reactivity of EBV-specific antibodies with autoantigens 
EBV is known to share homology and functions with a range of protein sequences in humans, 
which is a vital contribution to the virus’ ability to evade the immune system. EBV remains 
latent within B cells over decades of an individual’s life, however phases of lytic replication 
enable the host to detect and target the virus. Studies have identified that in MS, EBV-specific 
immune cells are cross-reactive with myelin antigens (480, 491, 492), and Elliott et al. (728) 
identified MS patients with antibodies reactive against myelin. However, anti-MBP (729) and 
anti-MOG (730) antibodies are also common in people with a healthy immune system so just 
the presence of autoantibodies does not seem sufficient to cause disease. One of the prominent 
theories behind MS pathology is the trigger of immune T cell cross-reactivity, where immune 
cells specific for EBV erroneously recognize self peptides as foreign and mounting a response 
(483). Further to the implications of cross-reactive T cells, anti-EBNA-1 antibodies have also 
been reported in MS CSF (476, 478, 572). Our short targeted EBNA-1(398-413) peptide shares 
amino acid sequence homology with ɑßC, which raises the question whether the antibodies 
against this region themselves, like the EBV-specific T cells, can cross react and target myelin 
or the ɑßC component (480). Testing for such antibody cross-reactivity in autopsied tissue 
would be most relevant, but limited access to human samples makes this difficult. There has 
been considerable research utilizing mouse models, but many difficulties are needed to be 
overcome translation of findings (731). In vitro models do have some limitations but are a good 
alternative of investigating cellular and molecular mechanisms of disease pathogenesis. The 
hexSelect macroarray was chosen as it consists of a variety of expressed recombinant human 
brain proteins. It can serve as a very useful method for detection of autoantibodies utilised as 
part of a screening process to identify proteins of interest for further experimentation.  
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7.1.2. Use of hexSelect array for MS and other autoimmune diseases 
The hexSelect array (Source BioScience, USA) has been used in multiple publications, 
including cardiac disease (732), colorectal cancer (733) and mRNA processing bodies in 
autoimmune disease (734). The array can help identify cross-reactivity of antibodies to 37,000 
expressed recombinant proteins (including a large spectrum of brain proteins), spotted in 
duplicate onto a 30cm x 30cm membrane. The array can help in screening for new antibody 
targets, identifying disease autoantibody signatures and could be used to understand disease 
pathogenesis and potential targets for therapeutic strategies. Cepok et al. (478) used the array 
to identify antibody reactivity of 12 MS CSF and 5 control samples, and identified and 
confirmed 0-10 “expression clones” specifically stained above background in each patient. 
Strongest CSF reactivity against two peptides: EBNA1 (302-641) and BRRF2, which are both 
derived from EBV proteins, was found in 3 patients. However, the arrays used by Cepok’s 
group were blotted on two separate membranes and proteins codes were different from the 
hexSelect array used in our study. Understanding the potential-cross reactivity of antibodies 
may assist in understanding disease pathogenesis, help with diagnosis and aid in developing 
new treatments.  
 
7.1.3. In vivo and in vitro models for MS pathogenesis 
There are currently multiple animal models for MS available, mainly used to test safety and 
efficacy of drug treatments, and pathological changes including citrullination as outlined in 
Table 5-1. Experimental Autoimmune Encephalomyelitis (EAE) animal models (including 
mice, guinea pigs, rats and primates) induce monophasic CNS damage following immunization 
with myelin antigens and therefore only reflect part of the underlying MS mechanism. These 
models can contribute to the understanding of the diseases pathogenesis and limitations in their 
application have been reviewed in detail before (735-738), including the difficulty of translating 
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treatments into clinical trials (739). From a cellular point of view, the mature CNS is a complex 
matrix of multiple different cell types (740). As the pathogenesis of MS is not fully understood, 
determining a cellular model including all relevant cell types for the disease is difficult. A range 
of different cell types have been shown to be involved in disease pathogenesis including: 
neuronal, glial, astrocytes and oligodendrocytes and combinations thereof have all been 
reviewed in MS studies (741). Multiple groups have worked towards in vitro models for MS, 
with focus on the BBB endothelium (742) and it’s disruption by EBV infection (606). Others 
have focused on serum and antibody effects in cell cultures and their influence on binding 
abilities and degradation of immunogenic targets. Lily et al. (743) reported no significant 
difference in surface binding of MS autoantibodies to oligodendrocyte and neuronal cell lines 
compared with controls, but when stratifying by RRMS and SPMS they found higher binding 
of serum antibodies from RRMS compared to SPMS patients. Elliot et al. (728) added MS-
derived immunoglobulin to rat spinal cord-derived astrocyte cell culture, reporting complement 
dependent demyelination in 30% of MS patients, with mediated axonal loss with two MS 
patient sera. The neuronal cell line SH-SY5Y has not been utilized in MS studies as it is 
obtained from the peripheral nervous system rather than CNS, and is therefore a good control 
cell line. In order to test out potential autoantibodies functionally, we chose two cell lines for 
our in vitro experiments. The oligodendrocytic cell line MO3.13, which has been used to test 
cell-penetrating peptides for the potential of re-establishing myelination (744) as well as 
identifying anti-MOG antibodies on demyelination (745). The neuronal cell line SH-SY5Y on 
the other hand was chosen as a control cell line. The cell line is obtained from the peripheral 
nervous system rather than CNS, and is therefore an ideal candidate to measure target effects. 
Both cell lines can also be differentiated further when stimulated with chemicals. This gives us 
the unique possibility to measure both effect to immature cells and to cells more accurately 
representing the mature cell type in vivo (744, 746). 
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The study described in this chapter used a subset of diagnosed MS patients from the PDDD-b 
and a control group from the Red Cross (RC) cohort. All samples had been tested on 
commercial and in-house ELISAs. The following questions were addressed in this chapter: 
1. Does healthy control plasma contain IgG antibodies which target brain proteins? 
2. Does MS serum have IgG antibodies which target brain proteins, and do these targets 
differ from healthy controls and between clinical courses for MS groups? 
3. Can isolated anti-EBNA-1(398-413) IgG antibodies bind and target brain proteins, and if 
so are the proteins the same as from whole serum reactivity as expected? 
4. What is the possible role of identified brain proteins targeted in MS in particular with 
regards to inflammation, and do they have common roles or co-localization in human 
tissue? 










7.2.1. Study Cohort 
For screening of potential autoantibodies, samples were pooled. The groups used in the 
macroarray were chosen from clinical information for MS and HLA-DRB alleles for Red Cross 
controls (Table 2-1). There was a 2:1 male to female ratio for the MS acute/relapse patients. 
Additionally, all SPMS patients were female, and the single PPMS patient was male. Red Cross 
controls (7 female, 3 male) were chosen for either having high risk, moderate or low risk/ 
“protective” HLA-DRB1 alleles. All three CIS patients had HLA-DRB1*1501, and one patient 
was homozygous.  
 
7.2.2. Protein array binding whole serum and anti-EBNA-1(398-413) isolated IgG  
As expected, whole serum had a higher background on the array than isolated IgG. One 
difficulty encountered in the experiment was that isolated antibodies which showed initially 
positive results (duplicate dots for one protein), tended to become negative due to fading within 
10 minutes of ECL reagent addition. This finding raised questions regarding the durability and 
avidity of the isolated antibodies, as control dot blots performed with pooled MS serum did not 
fade as quickly as the macroarrays, using the same secondary antibody and ECL reagents 
(Figure S-4). However, several CIS MS antibodies were isolated, and when tested on ELISA 
were above the negative cut-off value. For photos of the protein arrays, positive spots above the 
background level were identified, and matched to the manufacturer’s list of dotted proteins 
identified by their (X,Y) locations. Dots which were not identified in duplicate were not 
included, as per the manufacturer’s instructions. Confirmed proteins (detected in duplicate) for 
each sample group are summarized in Table 7-1, with images of duplicates shown in Figure 
7-1. 
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Table 7-1. Proteins identified as reactive with MS and healthy serum IgG.  
Healthy control plasma (2) was tested after reusing the stripped membrane. Numbers indicate 














STMN4 Stathmin-4 4   1 3 
HDAC5 Histone deacetylase 5 1   1 2 
MBD3 Methyl-CpG binding 
domain protein 3 
1     
PIM3 Serine/threonin-protein 
kinase Pim-3 
1     
EPN1 Epsin-1 1     
JMJD8 Jumonji domain-
containing protein 8 
1     
SHB2 SH2 domain-containing 
adapter protein B 
1     
HBA2  Haemoglobin subunit 
alpha  
 1    
EEF1A2 Elongation factor 1-alpha 
2 (Statin S1)  
 1    
TROVE2 60 kDa SS-A/Ro 
ribonucleoprotein 
  2   
NFKBIL2 NF-kappa B inhibitor 
like protein 2 
  1   
KAT2A Histone acetyltransferase    1  
CENPB Major centromere 
autoantigen B 
   1 2 
AMPD2 AMP deaminase 2    1  
MAP1LC3A Microtubule-associated 
protein 1A/1B light chain 
3A precursor 
    3 
UFC1 Ubiquitin-fold modifier-
conjugating enzyme 1 
    1 
AZGP1 Zinc-alpha-2-
glycoprotein  
    1 
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Proteins reactive with acute MS Serum 
 X136Y9/X139Y8 STMN4                X91Y214/X94Y213 STMN4      
 X116Y199/X119Y198 STMN4        X210Y46/X209Y49 STMN4          
 X143Y87/X144Y90 HDAC5          X88Y182/X89Y185 MBD3            
 X137Y209/X140Y210 PIM3       X51Y12/X51Y15 EPN1 
 X128Y22/X129Y25 JMJD8                  X81Y91/X84Y91 SHB2 
 
Proteins reactive with acute MS isolated anti-EBNA-1(398-413) antibodies 
 X16Y66/X19Y66 HBA2                     X111Y11/X114Y11 EEF1A2           
 
Proteins reactive with progressive MS serum 
 X62Y190/X65Y189 TROVE2    X87Y207/X90Y208 TROVE2 
X36Y184/X39Y183 NKFBIL2      
 
 
Figure 7-1. Raw images of duplicates tested with the macroarray for each sample group. 




Proteins reactive with healthy plasma 
X97Y35/ X100Y34 KAT2A      X210Y46/X209Y49 STMN4   





Proteins reactive with Healthy plasma [2] [post stripping membrane] 
X210Y46/X209Y49 STMN4           X136Y9/X139Y8 STMN4    
 X91Y214/X94Y213 STMN4          X143Y87/X144Y90 HDAC5 
X198Y87/X199Y90 HDAC5          X67Y175/X70/Y174 CENPB 
X1Y222/X1Y225 CENPB              X33Y72/X34Y75 MAP1LC3A      
X202Y196/X202Y198 MAP1LC3A   X96Y204/X99Y203 MAP1LC3A 
X57Y214/X60Y215 UFC1  X231Y231/X234Y231 AZGP1 
Figure 7-1. Raw images of duplicates tested with the macroarray for each sample group. 
Full names of protein codes are in Table 7-1 and Supplementary Table S-4. 
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7.2.3. Cell culture 
The cell lines, SH-SY5Y (neuronal) and MO3.13 (oligodendrocytic), were tested for 
mycoplasma contamination before experiments were conducted and both cell lines were found 
to be negative using the PCR technique (Figure 7-2).  They were grown in flasks until 70% 
confluent (Figure 7-3) and kept between passages 7-14 for MO3.13 and 14-33 for SY5Y. The 
cell line MO3.13 was tested for its ability to differentiate using phorbol myristate acetate 
(PMA). Differentiation was successful as determined by morphological changes like elongation 









Figure 7-2. Gel electrophoresis of Mycoplasma PCR testing of cell lines. Row A is products 
from the positive HGH control, row B was products using the Leedman Mycoplasma PCR. 1kb 
ladder (1, 12), negative control (2), uninfected cell control (3), and positive Mycoplasma 
infected cell controls (B4-B8: M. arginine; M. hominis; M. hyorhinis; M. fermentans; M. 
pharyngis). DNA extraction negative control (B9) shows MO3.13 (B10) and SY5Y (B11) cell 
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Figure 7-3. Cell lines SY5Y undifferentiated (A), MO3.13 undifferentiated (B) and 












7.2.4. MS serum effect on cell lines 
Cell lines were tested in triplicate wells for viability after incubation with MS serum for 6 hours, 
24 hours and 48 hours at two different concentrations by diluting 1:100 and 1:1000. A summary 
of averaged viability counts is shown in Table 7-2 (raw data in Supplementary Table S-5), and 
displayed in Figure 7-4. Logistic regression was used to identify any significant changes over 
time with and without serum due to relatively low number of cell counts. For oligodendrocytic 
MO3.13, there was a significant effect of time on viability (p=0.005), due to decreased viability 
at 48 hours, but no significance of either serum addition (p=0.21). For neuronal SHY-5Y, serum 
1/1000 had a very different viability trend over time compared to no serum and serum 1/100 
(p=6.6x10-6). For this, serum 1/1000 had a lower viability at 6 hours which increased by 48 
hours, whereas ‘no serum’ and ‘serum 1/100’ had initial high viability which decreased by 48 













Table 7-2. Averaged percentages of cell viability from triplicates of cell lines. 
  Viability (%) 
Time point Serum dilution MO3.13 SY5Y 
6 hours No serum 95.7 97.6 
  serum 1/100 95.2 97.8 
  serum 1/1000 84.4 83.9 
24 hours No serum 96.0 96.7 
  serum 1/100 93.3 97.2 
  serum 1/1000 92.3 82.5 
48 hours No serum 93.7 77.2 
  serum 1/100 90.3 77.0 





Figure 7-4. Average viability of MO3.13 and SH-SY5Y cell lines with and without MS 
serum over 48 hours. Overall, there are no significant changes in viability between no serum 
(blue), serum diluted 1/100 (green) and 1/1000 (red) for either cell type. 
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7.3. Discussion  
7.3.1. Functions of proteins identified by hexSelect macroarray 
From our previous studies presented in past chapters, we identified that MS patients have more 
antibodies (IgG) against the EBNA-1(398-413) peptide of EBV. Here we aimed to improve our 
knowledge of antibody-mediated MS pathogenesis based upon the possible cross-reactive and 
functional capabilities of those antibodies. Furthermore, we wanted to identify whether the 
isolated antibodies that independently contribute to a risk model can target any human brain 
proteins identified by macroarray. Both MS patient sera and control plasma reacted against 
multiple proteins of the array, confirmed in duplicate reactivity against the same protein. A 
summary of the known functions of the identified reactive proteins is given in Table 7-3. The 
fact that reactive proteins were identified with control plasma is not surprising, as it is well 
established that a healthy immune system contains antibodies against MBP and ɑßC, and 
possibly other brain proteins. Pooled serum from acute and progressive MS individuals did bind 
in part to the same proteins as seen for healthy controls, but additionally showed binding to 
different proteins. Progressive MS cases only showed reactivity to two targets, whereas acute 
cases showed reactivity to seven targets (with STMN4 having four separate duplicates). 
However, it is not known whether these are exactly the same target or different sections of the 
whole protein. It was unexpected that there were not more shared targets between the different 








Table 7-3. Function of identified proteins confirmed by macroarray. 
Functions from  as summarized in (747). ▲Role as reported by (748). A-MS: acute MS. P-MS: 
progressive MS. HC: healthy controls. 
 
Role Protein Name Function in humans A-MS P-MS HC 
DNA/ 
transcription 
CENPB Interacts with heterochromatin, believe to assist 
organization of DNA structure and centromere 
formation. 
  ✓ 
 MBD3 Transcriptional repressor, role in gene silencing, 
although doesn’t bind to DNA by itself. 
✓   
 JMJD8 Hydroxylating/demethylates proteins▲ ✓  ✓ 
 SHB2 Regulates signal transduction cascades by 
linking activated receptors to downstream 
signalling components. May play a role in 
angiogenesis, regulating insulin-producing cells, 
TCR & IL-2 signalling, apoptosis and neuronal 
cell differentiation. 
✓   
 EEF1A2 Promotes the GTP-dependent binding of 
aminoacyl-tRNA to the A-site of ribosomes 
during protein biosynthesis 
✓   
 HDAC5 Deacetylates lysine residues of core histones, 
which relates to transcriptional regulation. 
✓  ✓ 
 TROVE2 Binds to misfolded non-coding RNA, stabilizing 
and protecting them from degradation. 
 ✓  
 NFKBIL2 Also known as TONSL, “tonsoku like protein”, 
part of complex which maintains genome 
integrity during DNA replication. 
 ✓  
 KAT2A “General control of amino acid synthesis 
protein-5 like 2.” Promotes transcriptional 
activation. 
  ✓ 
Growth control PIM3 Prevents apoptosis, promote cell survival and 
protein translation. Involved in control of energy 
metabolism and regulation of cell growth. 
✓   
Metabolism/ 
Energy 
AMPD2 Critical role in energy metabolism, part of 
purine nucleotide cycle. 
  ✓ 
 AZGP1 Stimulates lipid degradation in adipocytes, may 
bind polyunsaturated fatty acids. 
  ✓ 
Blood HBA2 Role/importance not known, but haemoglobin 
carries oxygen for red blood cells. 
✓   
Autophagy MAP1LC3A Involved in formation of autophagosomal 
vacuoles (autophagosomes). 
  ✓ 
Endocytosis EPN1 Regulates receptor-mediated endocytosis. ✓   
Microtubule STMN4 Microtubule destabilizing activity. ✓  ✓ 
Unknown UFC1 Forms intermediate with UFM1, which role is 
not yet known. 
  ✓ 
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The most surprising result from this experiment was that targets for isolated anti-
EBNA-1(398-413) antibodies were not also seen for pooled MS serum from the same patients, and 
that repeating the array with the same pooled plasmas of healthy controls showed additional 
results with only partial confirmation of targets identified when used the first time. Possibilities 
for these results could be attributed to either (i) specificity, in that non-specific binding is 
occurring between antibodies and proteins and so the duplicate results are “false positive”, or 
(ii) sensitivity of the array is not allowing detection of “true” binding of antibodies to the 
proteins, which would explain the lack of confirmation in replication (Healthy plasma [2]). 
Either rationale could be confirmed by western blot. In western blots either isolated antibodies 
or serum are tested for reactivity against a single candidate protein. Interestingly, no antibodies 
were identified as cross-reactive to myelin or ɑßC, as expected for anti-EBNA-1(398-413) 
antibodies due to sequence homology (as reviewed in Chapter 5). The protein array did contain 
several similar proteins (beta-crystallin B2, sphingomyelin phosphodiesterase, myelin 
transcription factor 1, myelin expression factor 2, myelin protein zero-like protein 1 & 3 
precursor and myelin transcription factor 1-like protein), but reactivity was not identified using 
our assay. However, the exact protein sequences of proteins used for the array are not known, 
and so homology with anti-EBNA-1(398-413) is speculative and cannot be more closely evaluated. 
Some proteins were identified to show reactivity within healthy controls and MS patients 
(STMN4 and HDAC), which have transcriptional and structural roles.  
 
Interestingly, only acute MS samples reacted to HBA2 and EPN1, related to blood regulation 
and endocytosis respectively, and PIM3, related to cell growth control. Only healthy control 
samples reacted with targets associated with metabolism (AMPD2 and AZGP1). The healthy 
controls did show more reactivity, but also had more individuals included in the pooled samples 
than MS (ten compared to three). The protein macroarray did not result in the anticipated large 
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number of reactivities. Therefore, the reported reactive proteins should be individually 
confirmed by western blot, separating the samples per patient or single control. This is also 
important as the proteins expressed on the macroarray cannot be confirmed by the company to 
have human post-translational modification, and so may miss some cross reactive targets due 
to conformational differences to the in vivo situation. Western blot confirmation is of particular 
importance for proteins not included on the macroarray such as αßC, which is known to have 
sequence homology with the EBNA-1(398-413) epitope. The differences in reactivity between 
progressive and acute MS could represent the deterioration of the immune system with disease 
progression, although cellular experiments on these patients would additionally shed light on 
the involvement of immune dysregulation. 
 
7.3.2. Effect of patient sera on cell culture viability  
The key limitation on in vitro models for MS has been the heterogeneity and complexity of the 
adult human CNS, which has multiple interacting cell types. Elliott et al (728) overcame this 
limitation by using a rat brain model, which although impressive through its combination of 
homologous growth factors and modelling structure, still leaves a gap of translation between 
the animal model and humans in vivo. The cell lines we obtained are both human derived, and 
the use of the SH-SY5Y cell line in itself acts as a good control as it is sourced from neurons 
of the peripheral nervous system, compared to MO3.13 which is derived from oligodendrocytes 
from the CNS, which are more readily targeted in disease pathogenesis. Ideally, a cell culture 
model using oligodendrocytes, astrocytes, neurons and glial cells of mature human brain would 
be used. As cells are dependent on neighbouring cells and their produced molecules, a 3D model 
would be highly advantageous. Some groups are working towards this, however complications 
arise from the competitive growth rates of some cells impeding expansion of others, and so 
accomplishing the physiological ratio similar to in vivo is difficult.  
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In this study, we were able to create differentiated oligodendrocyte cell lines, although defining 
them as terminated would be premature, as more than a single chemical agent is needed for 
differentiation in vivo. Both cell lines were confirmed as Mycoplasma negative as infection can 
alter the cell’s metabolism and could lead to misleading results. Preliminary evaluation of the 
cell lines showed that no effect of serum was seen in the MO3.13 cell line over time. The 
decreased viability at 48 hours may have been due to the cells’ immature state and rapid growth, 
limiting nutrients and causing a higher death rate. As for SH-SY5Y, there is no clear reasoning 
for why serum 1/1000 did not follow the same decreased viability at 48 hours, although it could 
be possible that there were beneficial components in diluted patient serum, in opposition to the 
postulated hypothesis. For both cell lines, it is plausible that the serum was too dilute to achieve 
any antibody-dependent cytotoxicity without cells or additional complement added to the cells. 
Pooling serum could address this issue, as well as investigating mature cell forms where the 
growth rate isn’t as rapid. These cell cultures will be useful for future studies which could test 
patient derived antibodies in combination with patient derived immune cells, even isolated 
EBV-infected B cells, to review their in vitro capabilities as representative of the in vivo 
microenvironment. With antibodies contributing to ADCC, opsonisation, complement 
activation and activation of effector cells (749), the true benefit of the antibodies may need to 








Immune cross-reactivity has long been proposed as an important component in MS 
pathogenesis, whether as a trigger or contributing factor. With a large amount of evidence 
supporting IgG antibodies against EBV as a necessary prerequisite to developing MS, in 
particularly EBNA-1, finding cross-reactive targets of these elevated antibodies is of great 
interest. Results from this study showed that healthy control and MS serum contained IgG 
antibodies which bound to a range of different brain proteins involved in several signalling 
pathways with a range of functional roles. Some proteins were common between healthy 
controls and MS samples, but most were unique to either group. A higher background was seen 
when testing serum rather than isolated antibodies on the hexSelect macroarray, however 
isolated antibodies were cross reactive to a short epitope within EBNA-1 and human brain 
proteins. Healthy control samples contained more reactive proteins compared to MS samples 
and protein reactivity was different within different clinical patterns of MS.  Cell cultures were 
successfully grown in the laboratory and proven negative for Mycoplasma. Both cell lines 
showed an overall non-significant influence of serum on viability, however this could be due 
to their immature state or the level of serum. Further experiments could include binding 
potential of anti-EBNA-1(398-413) antibodies to these cell cultures which could be checked with 
confocal microscopy, as well as the influence of patient-derived EBV-specific or EBV infected 




























MS is a multifaceted disease, with several risk factors. Therefore treatment of the cause for 
inflammation and demyelination is challenging. The role of EBV infection in MS as a 
contributing risk factor is not yet fully understood. The focus of this project was to identify how 
adaptive immune responses against EBV differ between MS patients and healthy controls, with 
particular focus on a known B cell epitope within EBNA-1. To the author’s knowledge, this is 
the first study of EBV serology using these two well-established Western Australian cohorts. 
The MS cohort in our study reflects the global gender bias, with a 3:1 prevalence of females, 
while the ratio of gender in the healthy cohort was approximately 1:1. Additionally, over half 
of the individuals in the MS cohort carried “high-risk” HLA-DR alleles, according to grouping 
by Nolan et al (184), while just over half of participants in the control group carried “low-risk” 
HLAs. This is in line with the concept that there is a genetic predisposition for development of 
MS, upon which environmental factors further increase the risk, and perhaps ‘trigger’ MS. 
 
Associations between EBV-specific immunity and MS pathogenesis can be grouped into two 
schools of thought; (i) naturally occurring autoreactive B cells are latently infected with EBV, 
evade elimination due to the viral immune evasion and/or inadequate immunological control, 
and consequently expand, or (ii) autoreactive T (and maybe B) cells develop through persistent 
targeting of EBV-specific proteins, potentially through HLA-restricted antigen presentation and 
antibody-dependent mechanisms, leading to viral-host cross-reactivity. Both theories have 
supporting evidence as discussed by Pender et al. (377) and outlined in Chapter 1.5.6, but one 
should consider that these theories might not be mutually exclusive. They have evolved with 
new knowledge of MS pathogenesis, and should continue to do so. Figure 8-1, created by the 
author of this thesis, depicts how MS pathogenesis can be caused by multi-faceted immune 
responses against EBV and particularly EBNA-1, with primary focus on the virus’ role in 
causing inflammation in the CNS through cross-reactivity. This model integrates novel aspects 
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into past theories of MS mechanisms such as T cell only cross-reactivity as the model also 
includes the important role of B cells in the pathogenesis, and incorporates the ideas of 
bystander-damage. Additionally, it supports the hypothesis that EBV-specific cross-reactivity 
with αβC results in inflammation within the CNS (steps 18 and 19 in Figure 8-1). The model 
also includes considerations of the role of autoreactive T cells in MS pathogenesis as outlined 
in steps 1, 5 and 15b and that EBV and EBV-infected B cells have been identified in post-
mortem CNS tissue (324, 500, 513, 531-533) as shown in step 2. The data presented in this 
thesis includes a targeted investigation of EBV-specific antibodies, produced by specialized 
plasma cells in response to EBV infection. In particular, experimental results of this thesis add 
to the current understanding of MS pathogenesis in steps 8, 11, 12 and 17. Primarily, EBNA-1 
specific plasma cells produce anti-EBNA-1 IgG antibodies with the potential to cross-react with 












Figure 8-1. Model of MS pathogenesis involving EBV infection. [EBV: Epstein-Barr Virus. EBNA-1: Epstein-Barr Virus Nuclear Antigen. IgG: 
Immunoglobulin G. TCR: T cell receptor. HLA: Human Leukocyte Antigen. NK: Natural killer cell. aa: amino acids.] (1) EBV infected B cells 
(autoreactive or EBV specific) evade immune recognition and enter the CNS. (2) EBV infected B cells can reactivate within ectopic follicles in the 
CNS and produce EBV, which can infect other B cells and possibly other cell types (e.g. epithelial, NK and T cells). (3a) EBV infected B cell 
presents EBNA-1 peptide to immune system. (3b) Citrullinated EBNA-1 (dark green) peptide is presented to the immune system. (4) EBNA-1 
presenting B cells are recognized by CD8+ T cell specific for EBV through TCR; recognizing EBV peptide (8-10aa) presented through class I 
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HLA. (5) These CD8+ T cells become memory T cells. (6) Memory T cells can be re-stimulated by new EBV presenting B cells, as EBV goes 
through stages of replication to infect more cells. (7) B cells are eliminated by CD8+ T cell recognition, cells break apart and release EBV peptides. 
(8) Peptides are taken up by dendritic cells which independently present or assist presentation of EBNA-1 peptide (approx. 15aa) through B cells 
to CD4+ T cells, through class II HLA. (9) Following B cell activation by CD4+ T cells, B cells can mature into memory B cells. (10) These 
memory B cells can enter circulation. (11) B cells can also mature to become plasma cells, which enter the peripheral system. (12) Plasma cells 
release antibodies specific for the antigen presented by the B cell, which with environmental triggers, class switch into IgG. (13) These antibodies 
can cross the disrupted blood brain barrier (BBB) and enter the cerebrospinal fluid, as identified in oligoclonal bands. (14a) CD8+ and CD4+ T 
cells as well as plasma cells can cross the disrupted BBB and enter the CNS. (14b) Within the CNS, cells release cytokines and chemokines, 
affecting surrounding cells, promoting more inflammation and recruitment of more immune cells. (15a) EBNA-1 specific T cells attack myelin 
and/or oligodendrocytes through cross-reactivity. (15b) These T cells could also be autoreactive, primed by EBV-infected autoreactive B cells, and 
thus attack myelin and oligodendrocytes. (16) Regulatory T cells release anti-inflammatory cytokines to limit demyelination. (17) EBNA-1-specific 
plasma cells produce EBNA-1-specific antibodies, which cross react with brain proteins. (18) Fc of cross-reactive anti-EBV IgG antibodies are 
recognized by Fc receptor of macrophages and initiate damage of self (e.g. myelin and oligodendrocytes). (19) Macrophages demyelinate neurons, 






This thesis used optimized automation for all immunoassays to ensure accurate quantitation of 
anti-EBV antibodies for subsequent analysis. Using ELISA techniques, is was shown that the 
MS cohort was universally positive for EBV infection, whereas only 90% of the controls were 
EBV seropositive. This is in line with the literature (341, 449, 563), and EBV infection is a 
prerequisite for our model in Figure 8-1, as EBV infection is necessary for autoreactive B cells 
to evade immune elimination, and for EBV-specific B cells to continually stimulate the EBV-
specific T cell population (step 5 of Figure 8-1), with both cell populations being able to trigger 
cross-reactivity in the CNS (steps 15 and 17). Our MS cohort had significantly higher IgG 
antibody titres against VCA and EBNA-1 in concordance with the vast majority of studies (545, 
573). These elevated antibody levels could indicate a higher risk of cross-reactivity with self 
peptides by sheer titre of antibodies, as well as indicating that T cells might not be providing 
adequate control of EBV reactivation. Gender and age were seen to influence immune response 
to EBNA-1 and VCA, however the association of HLA and antibody titres is most intriguing. 
In logistic regression analysis, high-risk HLA significance was abrogated by inclusion of 
EBNA-1 and VCA ELISA data, suggesting a common pathway. This genetic association with 
EBV infection warrants further research, potentially through the modelling of EBNA-1 and 
VCA peptides and presentation by “high-risk” HLA compared to “low-risk” HLA alleles. 
 
Extrapolating from the publication by Mechelli et al. (582) which studied MS-discordant 
identical twins, a novel in-house ELISA was developed and optimized to investigate IgG 
antibodies against a short B cell epitope within the EBNA-1 protein: EBNA-1(398-413). 
Significantly more samples were seropositive in the MS cohort and had higher antibody titres 
against EBNA-1(398-413) than healthy controls. This reflects that EBV is a requirement for 
developing MS as well as the possibility that EBV-specific plasma cells are higher in number 
and/or reactivity in MS patients. It is notable that another study targeting an epitope within 
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EBNA-1(398-404) (581) did not find significant differences between MS and healthy controls 
(Figure 4-7). Their epitope was only six amino acids long, thus highlighting the importance of 
optimal peptide length to present a real antibody target as well as emphasizing the 
immunogenicity of the EBNA-1(398-413) peptide used in this thesis, and its significance in 
immune responses in relation to MS risk. Although not associated with HLA-DR, gender or 
age, this novel experiment adds to existing understanding of EBNA-1 peptide immunogenicity 
with antibodies against this peptide significantly improving the logistic regression model 
(Figure 4-6), increasing the discrimination between MS cases and controls, in addition to the 
commercial anti-EBNA-1 ELISA results. As mentioned in Chapter 4.3, validation of this model 
with another cohort would be most beneficial, either with another Australian cohort, a cohort 
from the Northern Hemisphere, or from a population with different HLA MS risk alleles (162, 
163). Our antibody findings indicate presence of EBNA-1(398-413) reactive B cells in patients 
that mature into plasma cells as shown in steps 8 and 11 in Figure 8-1, which could reflect poor 
control of EBV infection and the ability to restimulate T cells responses. This should be 
examined further through characterizing EBV-specific T cell populations, which our group is 
currently investigating. Additionally, the EBNA-1(398-413) peptide shares homology with ɑßC, 
which is present in the CNS and could be evidence of molecular mimicry as a cause of cross-
reactivity, similar to Lünemann’s finding of EBNA-1 specific T cells cross-reacting with 
myelin (480), as described in step 15a of Figure 8-1.  
 
Data on the anti-EBNA-1(398-413) IgG antibody subclasses was the first of its kind, following 
from observations of enriched EBV-specific IgG1 antibodies in MS cases previously published 
by  Lünemann et al. (480) from a small set of patients and controls. Surprisingly, anti-
EBNA-1(398-413) IgG1 antibodies were detected in less than half of each cohort, and anti-
EBNA-1(398-413) IgG2 and IgG3 in less than 10%. This path of research may therefore offer 
158 
value in terms of revealing the functional characteristics of EBNA-1-specific antibodies in the 
context of MS pathogenesis as part of our MS model, such as opsonisation or recruitment of 
other cells. Importantly, we were able to detect anti-EBNA-1(398-413) IgG3 antibodies using our 
in-house ELISA, which had never been published before. These antibodies contributed to a 
reduced MS risk in the logistic regression model and are of high importance. Indeed, the anti-
EBNA-1(398-413) IgG1 and IgG2 elevation in MS cases did not remain significant in the logistic 
regression while IgG3 did. This could reflect that in response to a sustained pro-inflammatory 
environment, more IgG antibody subclass switching from IgG3 to IgG1 occurs in MS patients.  
 
EBV specific antibodies within oligoclonal bands in the CSF have been identified previously 
(476, 478, 572, 583, 584, 586, 587). Following the significance of anti-EBV antibody 
quantitation, this thesis showed that anti-EBNA-1(398-413) antibodies which are present in MS 
and healthy controls have the ability to cross-react with brain proteins involved in a range of 
functions. This experiment was the first of its kind. The potential pathogenic role of these 
antibodies is shown in step 17 of Figure 8-1: presence of anti-EBNA-1 antibodies in blood and 
CSF as well the ability of some antibodies to cross-react with proteins within the CNS, causing 
antibody-dependent cytotoxicity, in addition to damage from T cells. Autoreactive antibodies 
were identified in both MS patients and healthy controls for a range of proteins. There was little 
overlap of common targets (Table 7-3), with only MS serum showing reactivity for proteins 
involved in endocytosis (EPN1) and growth control (PIM3) while only healthy controls showed 
reactivity for proteins associated with metabolism (AMPD2 and AZGP1). This shows that 
autoreactive antibodies are common in healthy controls, potentially from EBV-infected 
autoreactive B cells but quantity of antibodies may differ between cohorts. There were shared 
targets for different proteins involved in the DNA/transcription pathway. The crucial difference 
is that in MS patients, these autoreactive antibodies have the ability to cross the disrupted blood-
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brain barrier into the CSF and CNS, identify targets not presented in the periphery and 
contribute to inflammation. This is supported by the presence of anti-EBNA-1 reactive IgG in 
MS CSF (572). When testing isolated anti-EBNA-1(398-413) antibodies, we detected two novel 
cross-reactive targets: haemoglobin subunit alpha (HBA2) and elongation factor 1-alpha2 
(EEF1A2) which have roles in blood and DNA/transcription pathways, respectively. These 
might be additionally involved in MS pathogenesis through their pathways to inhibit new 
myelin production (steps 19 and 20 of Figure 8-1) and affect oxygen delivery to the 
microenvironment. Surprisingly, isolated antibodies and matched serum did not detect the same 
targets on the macroarray. This could be due to a range of factors including (i) different binding 
affinity of antibodies, (ii) the presence of inhibiting co-factors within the serum or (iii) relatively 
lower levels of epitope specific antibodies to other autoreactive antibodies in serum. By 
utilizing anti-EBNA-1(398-413) antibody isolation, autoreactive antibodies were further enriched 
and so protein targets could be identified that were masked by using whole serum. This should 
be considered in future serum and/or CSF testing of MS samples for cross-reactivity. The 
benefit of the protein macroarray is that it allows a multitude of potential targets to be screened, 
and we next plan to confirm the cross-reactivity of identified targets by Western blot. For future 
cross-reactivity testing of anti-EBNA-1(398-413) antibodies, inclusion of MBP, GFAP and ɑßC 
proteins which were not present on the commercial macroarray (listed in Chapter 7.4) should 
be included due to their advocated immunogenicity in MS. In particular, cross-reactivity with 
ɑßC should be further investigated as it shares sequence homology with our EBNA-1 peptide. 
This cross-reactivity of isolated anti-EBNA-1(398-413) IgG support our model of EBV-specific 
immune cross-reactivity contributing to inflammation and neuronal degradation as shown in 
step 17 of Figure 8-1.  
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Citrullinated autoantibodies have a prominent role in RA diagnostics, therefore we also 
examined the role of citrullination of the EBNA-1(398-413) peptide. No literature to date has 
investigated whether anti-EBV responses are altered by this pro-inflammatory modification in 
MS, or in relation to different HLA alleles. The model in Figure 8-1 incorporates this, showing 
the processing of citrullinated epitopes through B and T cell interactions, resulting in anti-
citrullinated EBNA-1 antibodies. In this study, MS cases had significantly higher 
EBNA-1(398-413 CIT) seropositivity and elevated antibody titres compared to controls, although 
no influence by HLA-DR, gender or age was found. Although anti-EBNA-1(398-413 CIT) IgG 
levels in MS were not as discriminatory as citrullinated autoantibodies in RA, they did 
independently contribute to the risk model in Chapter 5, and likely reflect a larger sustained 
pro-inflammatory environment in MS patients. It would be intriguing to investigate whether 
MS CSF oligoclonal bands are reactive to citrullinated EBNA-1 peptide as has also been shown 
for non-citrullinated forms (584). Immunofluorescence experiments on post-mortem brain 
samples could further establish if these antibodies are present in the CNS. For future study, 
cross-reactivity of EBNA-1(398-413 CIT) IgG and brain proteins would be of high interest as MBP 
and homologous ɑßC are both known to become citrullinated. A study by Svendsen et al 
suggested a genetic component to autoantibodies in RA-discordant twins (750), which could be 
investigated in our MS cohort to identify whether MS citrullinated antibodies reflect an 
autoreactive or a modified anti-EBV immune response through cross-reactivity (steps 12 and 
13 of Figure 8-1). Additionally, the effect of citrullinated EBV antibodies could be explored 
using a mouse model such as EAE (described in Chapter 7.1.3). In EAE, immunization with 
myelin antigen induces neurological damage in a short time frame, and allows for identifying 
T cell-mediated mechanisms following immunization. However, the role of herpesviruses in 
mouse EAE pathogenesis has been only recently investigated (751). Primate studies would be 
even more informative as recent studies have highlighted the role of EBV-infected B cells in 
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disease progression, and myelin immunization to cause MS-like symptoms might be triggered 
through different pathways (752). Despite not having mouse or primate models, this thesis did 
functionally investigate the potential effect of these antibodies on oligodendrocytic and 
neuronal cell lines in vitro. Whole serum of MS patients did not show a pathogenic effect on 
viability for either cell line in preliminary experiments, but this does not mean the antibodies 
are ineffective. These results could be explained by high serum dilution levels, the replicative 
ability of cells in undifferentiated forms. Furthermore, these high antibodies could have a long-
term cytotoxic effect, or inclusion of other cellular components such as T cells, B cells and/or 
macrophages are needed to reproduce MS pathogenesis in vitro as shown in step 18 and 19 in 
Figure 8-1. Additionally, other than causing direct apoptosis, EBV specific antibodies could 
lead to damage of brain proteins by recruiting other cells, changing the chemokine environment 
and up/down regulating pathways involved in cell signalling.  
 
Future aims of MS research should focus on the importance of EBV, and include investigations 
of the cellular response and control of the virus, to contribute a better understanding to the 
model shown in Figure 8-1, and extend from epidemiological studies to functional aspects of 
the pathology. This important concept could recently be shown in a proof of principle study by 
Pender et al.(624). The group isolated patient-derived EBV-specific T cells and saw a beneficial 
clinical outcome when reintroducing these cells into a SPMS patient after enrichment. To 
further investigate this, our group plans to immunophentoype EBNA-1 specific CD4+ and 
CD8+ T cell subpopulations and to investigate their cytokine profiles in MS patients. 
Additionally our group is planning to study the role of regulatory T cells, as depicted in step 16 
of Figure 8-1, as they represent the ability to suppress inflammation and low regulatory T cells 
could be an additional mechanism by which MS pathogenesis occurs. It would also be very 
interesting to further investigate this MS study population, with regard to when EBV infection 
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occurred or if they had IM, as IM has been associated with MS risk (384, 452-456) in addition 
to HLA-DRB1*15 (458) and latitudinal distribution (457). How IM is associated with MS is 
not yet fully understood, but it is possible that primary infection with EBV later in life results 
in a more mature immune response, and this increases MS risk by how well the virus is 
controlled. Lastly, the influence of UVB and vitamin D should not be underestimated in their 
roles in the promotion of autoimmune diseases (outlined in chapter 1.4.3), and of MS more 
specifically. In this regard, it would be interesting to investigate whether individuals within the 
MS cohort migrated to Australia, and if it was early or later in life. This could benefit through 
identifying additional factors such as early-life or cumulative sunlight exposure as risk factors 
for MS, and to assess how these factors relate to our existing statistical model.  
 
The epidemiological study presented in this thesis offers new insights into the contribution of 
EBV to MS, showing anti-VCA and particularly anti-EBNA-1 IgG as well as combined HLA-
DR alleles and gender can be integrated into a significant risk model. This study is the first of 
its kind to identify significantly elevated antibodies in MS specific for EBNA-1(398-413) IgG, and 
identified a subclass bias towards IgG1 in MS using this target. Antibodies specific for 
citrullinated EBNA-1(398-413) were not as common as uncitrullinated targets, but significantly 
contributed to MS risk, suggesting this modification may be involved in separate mechanisms 
for causing damage. Lastly, this study identified novel cross-reactive brain protein targets for 
EBNA-1(398-413) specific antibodies. This provides the conceptual framework for functionality 
of these antibodies, from which we can further investigate cell populations and signalling 
pathways to elucidate other mechanisms behind triggering and progression of MS. These 
findings support the pathogenic importance of EBV in MS development, and its potential for 
diagnostic and therapeutic targeting that can be applied in clinical practice in order to improve 
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Supplementary Table S-1. All Reagents and Kits Catalogue Reference Numbers.  
Reagent Company Catalogue Number 
10X PCR buffer Invitrogen Y02028 
1Kb Plus DNA Ladder Invitrogen 10787-018  
24 well Tissue Culture Plate with lid Becton Dickinson 353047 
3, 3’, 5, 5’ Tetramethylbenzidine (TMB)  Sigma Aldrich T4444 
Ampure Purification Kit Beckman Coulter A63882 
Antibiotic-Antimycotic (100X) Invitrogen 15240-096 
beta-mercaptoethanol  Sigma Aldrich M7522 
Bovine Serum Albumin (BSA) Sigma Aldrich A7906 
CleanSeq Purification Kit Beckman Coulter A29154 
DMEM High glucose Sigma Aldrich D6429 
DNA Isolation Kit Genfind A41497 
DNA Extraction Kit (Maxwell 16 Blood) Promega AS1010 
dNTP Invitrogen 10297-117 
EBNA-1 IgG ELISA Kit DiaSorin P001607 
ECL substrate BioRad 170-5061 
Ethylenediaminetetraacetic Acid Becton Dickinson 367873 
Ficoll VWR International 17-1440-03 
Foetal Bovine Serum (FBS) Scientific Partners (Serana) S-FBS AU-015 
Ham's Nutrient F12 Media Sigma Aldrich 51651C 
magMAX Express 96 Deep Well Plate Life Technologies 4388476 
MgCl2 Invitrogen Y02016 
Penicillin-Streptomycin-Glutamine (100X) Invitrogen 10378-016 
Phosphate Buffer Saline (PBS) Tablets Sigma Aldrich P4417 
Platinum Taq DNA polymerase Invitrogen 10966034 
Protein-interaction Pull-Down Kit ThermoFisher Scientific 21115 
Protran Supported 0.45um membrane GE Healthcare 10600016 
QIAamp DNA Extraction Kit Qiagen 51106 
RPMI 1640 Invitrogen 21870092 
239 
SDS Astral Scientific Pty Ltd 227 
Secondary Antibody- IgG1 Sapphire Biosciences ab99774 
Secondary Antibody- IgG2 Sapphire Biosciences ab99779 
Secondary Antibody- IgG3 Sapphire Biosciences ab99829 
Secondary Antibody- Total IgG  Sigma Aldrich A0170 
Skim Milk powder Diploma N/A 
Sodium Azide (Naxx) Sigma Aldrich S2002 
Sodium Chloride (NaCl) Sigma Aldrich S7653 
Serum Separating Tubes (SST) Becton Dickinson 367958 
Steritop filter unit Merck Millipore SCGPT05RE 
Streptavidin-coated 96 well plates ThermoFisher Scientific 436014 
Taq (Expand High Fidelity for HLA) Roche  11732641001 
Tris (Trizma Base) Sigma Aldrich T6066 
Tris-Buffered Saline (TBS)  ThermoFisher Scientific 28376 
Triton X100 Sigma Aldrich X100-1L 
Tween 20 BDH 663684B 
VCA IgG ELISA Kit DiaSorin P001606 












Supplementary Table S-2. Abbreviations for amino acids. 
Amino Acid Three letter abbreviation One letter symbol 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Asparagine or aspartic acid Asx B 
Cysteine Cys C 
Glutamine Gln Q 
Glutamic acid Glu E 
Glutamine or glutamic acid Glx Z 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 




Supplementary Figure S-1. Positive control dot blot (right) for macroarray (left). Image is 
merged, as where white signal on dot blot is positive ECL signal. Serum was serially diluted 
neat, 1:2, 1:4, 1:8, 1:16, negative (no serum) and 1:32. This example shows that the positive dot 
























Supplementary Figure S-2. Layout of EpiLab sample tracking program, where samples from 























Supplementary Figure S-3. ELISA protocol steps robot layout on BioMek. Coating plates 
(A), sample addition (B) and secondary antibody addition (C) using appropriate reagent storage, 






Supplementary Figure S-4. BioMek FXP control of pipetting accuracy and precision. 
Pressurized volume control for Span 8 (8 head pipette which can be control independent 












































18 Mean StDev %CV 
280.0 0.847 0.861 0.836 0.814 0.826 0.800 0.840 0.816 0.751 0.775 0.791 0.880 0.779 0.813 0.807 0.855 0.892 0.813 0.822 0.037 4.490 
392.0 0.640 0.628 0.671 0.629 0.592 0.597 0.660 0.631 0.559 0.581 0.612 0.624 0.610 0.654 0.601 0.649 0.607 0.574 0.618 0.031 4.990 
548.8 0.466 0.489 0.492 0.485 0.498 0.461 0.474 0.507 0.416 0.459 0.508 0.481 0.449 0.497 0.476 0.497 0.486 0.442 0.477 0.024 5.089 
768.3 0.330 0.367 0.398 0.407 0.375 0.363 0.383 0.387 0.337 0.349 0.384 0.381 0.368 0.384 0.398 0.389 0.383 0.331 0.373 0.023 6.152 
1075.6 0.246 0.254 0.268 0.263 0.271 0.251 0.276 0.282 0.245 0.256 0.261 0.267 0.249 0.283 0.271 0.276 0.262 0.260 0.263 0.012 4.476 
1505.9 0.190 0.209 0.203 0.191 0.193 0.184 0.196 0.199 0.168 0.181 0.186 0.180 0.193 0.200 0.191 0.184 0.196 0.182 0.190 0.010 5.070 
2108.3 0.149 0.129 0.152 0.145 0.143 0.118 0.143 0.133 0.125 0.140 0.145 0.141 0.134 0.145 0.143 0.147 0.140 0.133 0.139 0.009 6.377 






































18 Mean StDev %CV 
280.0 2.340 2.349 2.208 1.968 2.171 2.378 2.172 2.354 2.085 2.257 2.239 2.147 2.0184 2.227 2.236 2.163 2.352 2.521 2.232 0.137 6.115 
392.0 1.874 1.917 1.839 1.665 1.659 1.906 1.822 1.987 1.690 2.043 1.892 1.684 1.8375 1.770 1.785 1.791 1.865 1.646 1.815 0.115 6.339 
548.8 1.636 1.561 1.584 1.466 1.548 1.737 1.575 1.708 1.522 1.685 1.538 1.468 1.5456 1.602 1.559 1.471 1.651 1.364 1.568 0.094 5.992 
768.3 1.298 1.286 1.321 1.085 1.301 1.433 1.259 1.461 1.254 1.422 1.309 1.206 1.3568 1.349 1.287 1.238 1.374 1.129 1.298 0.098 7.534 
1075.6 1.054 0.931 0.929 0.808 0.889 0.994 0.949 1.025 0.872 0.925 0.966 0.855 0.9161 0.946 0.913 0.894 0.994 1.030 0.938 0.064 6.858 
1505.9 0.780 0.720 0.706 0.628 0.679 0.794 0.712 0.778 0.620 0.754 0.758 0.657 0.7274 0.765 0.688 0.641 0.764 0.676 0.714 0.055 7.741 
2108.3 0.597 0.544 0.563 0.508 0.506 0.594 0.536 0.585 0.555 0.548 0.538 0.511 0.5578 0.559 0.530 0.505 0.574 0.563 0.549 0.029 5.308 












































768.3 1.478 1.637 0.632 0.726 1.169 1.287 1.610 1.394 0.880 1.138 1.440 0.974 0.796 0.885 0.881 1.001 1.341 0.959 
1075.6 1.103 0.950 0.500 0.545 0.871 1.085 1.210 0.753 0.793 0.768 1.000 0.870 0.624 0.702 0.810 0.969 0.898 0.977 
1505.9 0.805 0.928 0.375 0.354 0.620 0.665 0.733 0.866 0.614 0.786 0.770 0.539 0.385 0.520 0.652 0.771 0.699 0.692 
2108.3 0.532 0.611 0.347 0.302 0.557 0.540 0.509 0.487 0.411 0.569 0.592 0.595 0.418 0.395 0.488 0.584 0.570 0.539 
2951.6 0.368 0.318 0.201 0.201 0.358 0.322 0.355 0.335 0.400 0.308 0.339 0.308 0.345 0.266 0.345 0.433 0.446 0.419 
4132.2 0.212 0.243 0.161 0.143 0.260 0.248 0.238 0.235 0.223 0.228 0.327 0.223 0.171 0.262 0.172 0.301 0.322 0.316 






































36 Mean StDev %CV 
768.3 0.949 0.980 0.799 0.795 0.842 0.902 1.370 1.377 1.277 1.054 0.916 1.379 1.106 1.140 1.155 0.846 0.750 0.766 1.073 0.269 25.06 
1075.6 0.995 1.056 0.600 0.597 0.636 0.640 0.646 1.027 0.993 0.651 0.892 0.988 0.960 0.808 0.920 0.789 0.755 0.552 0.831 0.182 21.94 
1505.9 0.504 0.604 0.480 0.433 0.472 0.578 0.496 0.797 0.599 0.479 0.729 0.852 0.853 0.571 0.611 0.555 0.463 0.421 0.619 0.155 25.08 
2108.3 0.422 0.409 0.487 0.324 0.481 0.431 0.598 0.553 0.586 0.547 0.516 0.503 0.610 0.449 0.351 0.821 0.408 0.318 0.496 0.107 21.47 
2951.6 0.419 0.335 0.318 0.254 0.252 0.302 0.503 0.311 0.318 0.496 0.391 0.430 0.355 0.377 0.417 0.196 0.233 0.340 0.342 0.076 22.34 
4132.2 0.215 0.236 0.204 0.176 0.225 0.220 0.330 0.339 0.316 0.348 0.281 0.312 0.240 0.250 0.282 0.156 0.231 0.240 0.247 0.055 22.45 
5785.1 0.145 0.172 0.146 0.115 0.170 0.139 0.239 0.242 0.139 0.255 0.209 0.222 0.247 0.192 0.205 0.135 0.124 0.186 0.181 0.044 24.35 
Blank 0.030 0.032 0.034 0.033 0.031 0.031 0.029 0.032 0.034 0.029 0.030 0.030 0.032 0.033 0.029 0.032 0.031 0.032 0.031 0.002 7.37 













































768.3 0.814 0.850 0.587 0.819 0.902 0.931 1.219 0.875 0.801 0.779 1.015 1.009 0.631 1.014 0.916 0.754 0.741 1.267 
1075.6 0.677 0.611 0.405 0.473 0.694 0.630 0.662 0.673 0.687 0.564 0.773 0.756 0.690 0.500 0.611 0.536 0.908 0.688 
1505.9 0.541 0.451 0.335 0.236 0.520 0.611 0.622 0.614 0.423 0.424 0.466 0.456 0.537 0.392 0.537 0.528 0.415 0.688 
2108.3 0.359 0.328 0.230 0.312 0.387 0.327 0.362 0.356 0.374 0.372 0.329 0.309 0.358 0.277 0.224 0.468 0.296 0.348 
2951.6 0.273 0.210 0.130 0.210 0.337 0.248 0.354 0.317 0.297 0.224 0.256 0.335 0.151 0.203 0.195 0.341 0.198 0.353 
4132.2 0.186 0.140 0.102 0.164 0.205 0.161 0.175 0.168 0.230 0.162 0.240 0.151 0.129 0.139 0.099 0.128 0.149 0.198 






































36 Mean StDev %CV 
768.3 0.920 0.737 1.050 0.684 0.696 0.719 1.284 1.281 1.372 0.923 1.115 1.190 1.206 0.913 1.045 0.724 0.712 0.925 0.928 0.207 22.33 
1075.6 0.778 0.556 0.558 0.784 0.547 0.549 0.989 0.683 0.928 0.636 0.458 0.879 0.825 0.616 0.675 0.469 0.552 0.720 0.659 0.138 20.98 
1505.9 0.704 0.370 0.390 0.478 0.415 0.429 0.631 0.677 0.776 0.680 0.674 0.630 0.589 0.415 0.334 0.309 0.375 0.506 0.505 0.131 25.85 
2108.3 0.352 0.298 0.394 0.303 0.304 0.369 0.358 0.538 0.381 0.320 0.318 0.460 0.328 0.324 0.451 0.557 0.256 0.273 0.350 0.073 20.96 
2951.6 0.241 0.191 0.250 0.280 0.191 0.207 0.212 0.242 0.264 0.387 0.311 0.348 0.260 0.235 0.220 0.158 0.208 0.185 0.251 0.065 25.84 
4132.2 0.229 0.143 0.159 0.203 0.148 0.147 0.137 0.285 0.236 0.247 0.193 0.160 0.174 0.155 0.162 0.100 0.125 0.134 0.168 0.044 25.93 
5785.1 0.187 0.106 0.117 0.115 0.104 0.124 0.184 0.191 0.202 0.206 0.116 0.158 0.140 0.114 0.095 0.074 0.102 0.100 0.129 0.036 28.10 







v) EBNA-1(398-413) IgG Subclasses 
 
 1   2   3   4   5   
Dilution IgG1 IgG2 IgG3 IgG1 IgG2 IgG3 IgG1 IgG2 IgG3 IgG1 IgG2 IgG3 IgG1 IgG2 IgG3 
768.32 0.833 0.995 0.982 0.715 0.732 0.863 0.672 0.652 1.012 0.970 0.724 1.038 0.708 0.952 0.698 
1075.648 0.580 0.726 0.664 0.454 0.508 0.452 0.483 0.498 0.659 0.680 0.574 0.733 0.589 0.615 0.517 
1505.907 0.529 0.483 0.508 0.337 0.362 0.315 0.339 0.390 0.496 0.580 0.436 0.487 0.334 0.449 0.446 
2108.27 0.323 0.340 0.406 0.241 0.280 0.255 0.270 0.260 0.373 0.399 0.331 0.342 0.319 0.341 0.283 
2951.578 0.229 0.261 0.259 0.186 0.212 0.192 0.194 0.182 0.204 0.317 0.239 0.259 0.268 0.248 0.211 
4132.209 0.224 0.249 0.273 0.142 0.158 0.137 0.145 0.144 0.206 0.236 0.190 0.199 0.182 0.183 0.162 
5785.093 0.215 0.174 0.199 0.116 0.125 0.160 0.119 0.153 0.133 0.184 0.155 0.155 0.153 0.141 0.133 
 
 6   7   8       
Dilution IgG1 IgG2 IgG3 IgG1 IgG2 IgG3 IgG1 IgG2 IgG3 Average StDev %CV 
768.32 1.068 0.941 1.079 0.894 1.001 0.881 0.578 0.784 0.624 0.869 0.151 17.4 
1075.648 0.818 0.638 0.796 0.651 0.830 0.662 0.418 0.591 0.474 0.610 0.113 18.5 
1505.907 0.497 0.474 0.548 0.403 0.667 0.442 0.327 0.338 0.310 0.445 0.081 18.2 
2108.27 0.384 0.347 0.424 0.326 0.479 0.340 0.264 0.208 0.284 0.329 0.055 16.8 
2951.578 0.282 0.263 0.316 0.261 0.380 0.292 0.160 0.210 0.220 0.240 0.042 17.5 
4132.209 0.241 0.213 0.238 0.197 0.234 0.266 0.125 0.118 0.178 0.196 0.042 21.5 




































Protein Code Protein Name 
STMN4 Stathmin-4 
HDAC5 Histone deacetylase 5 
MBD3 Methyl-CpG binding domain protein 3 
PIM3 Serine/threonin-protein kinase Pim-3 
EPN1 Epsin-1 
JMJD8 Jumonji domain-containing protein 8 
SHB2 SH2 domain-containing adapter protein B 
HBA2  Haemoglobin subunit alpha  
EEF1A2 Elongation factor 1-alpha 2 (Statin S1)  
TROVE2 60 kDa SS-A/Ro ribonucleoprotein 
NFKBIL2 NF-kappa B inhibitor like protein 2 
KAT2A Histone acetyltransferase 
CENPB Major centromere autoantigen B 
AMPD2 AMP deaminase 2 
MAP1LC3A Microtubule-associated protein 1A/1B light chain 3A precursor 
UFC1 Ubiquitin-fold modifier-conjugating enzyme 1 
AZGP1 Zinc-alpha-2-glycoprotein  
250 
Supplementary Table S-5. Raw data of cell viability counts of MO3.13 and SH-SY5Y with 
MS serum. 
  MO3.13  SH-SY5Y  
Time 
point 
 Conditions Alive Dead % Viability Alive Dead % Viability 
6 hours No serum 45 2 95.7 5 0 100.0 
    42 4 91.3 13 1 92.9 
    39 0 100.0 10 0 100.0 
  serum 1/100 21 1 95.5 28 2 93.3 
    39 1 97.5 33 0 100.0 
    37 3 92.5 9 0 100.0 
  serum 1/1000 10 4 71.4 20 5 80.0 
    17 2 89.5 27 0 100.0 
    61 5 92.4 28 11 71.8 
24 hours No serum 58 4 93.5 101 2 98.1 
    39 1 97.5 45 3 93.8 
    80 3 96.4 62 1 98.4 
  serum 1/100 38 1 97.4 48 2 96.0 
    60 3 95.2 41 0 100.0 
    66 4 94.3 45 2 95.7 
  serum 1/1000 17 3 85.0 27 11 71.1 
    99 3 97.1 30 2 93.8 
    77 4 95.1 24 5 82.8 
48 hours No serum 60 4 93.8 11 7 61.1 
    52 3 94.5 23 4 85.2 
    66 6 91.7 23 4 85.2 
  serum 1/100 61 4 93.8 42 12 77.8 
    71 7 91.0 36 6 85.7 
    62 10 86.1 25 12 67.6 
  serum 1/1000 23 4 85.2 31 2 93.9 
    66 5 93.0 22 4 84.6 
    88 10 89.8 40 8 83.3 
1/100: dilution of serum in total cell media volume.  
 
